<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[News]]></title>
    <link>https://www.cytoskeleton.com/blog/</link>
    <description><![CDATA[News]]></description>
    <pubDate>Thu, 12 Mar 2020 14:34:37 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Spring Special is Active]]></title>
      <link>https://www.cytoskeleton.com/blog/spring2020/</link>
      <description><![CDATA[<div class="page-title" style="text-align: center;"><img alt="spring special header" src="https://www.cytoskeleton.com/media/wysiwyg/Final-1_2.gif" title="Spring Special Header" width="100%" /></div>
<p>&nbsp;</p>
<p>Terms and Conditions: 20% off the purchase of any 2 or more items. Must use coupon code SPRING20 when placing your order. Offer only valid on direct orders in the United States and Canada. Offer cannot be combined with any other discount offer. Offer expires March 31st, 2020.</p>
<div class="page-title" style="text-align: center;"></div>
<div class="page-title" style="text-align: center;">&nbsp;</div>]]></description>
      <pubDate>Tue, 03 Mar 2020 08:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[February 2020 Newsletter : MAPping Tau's Future]]></title>
      <link>https://www.cytoskeleton.com/blog/mapping-taus-future/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://cytoskeleton.com/mapping-taus-future" title="February Newsletter" target="_blank"><img alt="February Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Mapping_Tau_s_Future_Page_1.jpg" style="margin-left: 30px; margin-right: 30px;" title="February Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://cytoskeleton.com/mapping-taus-future" title="February Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Tau is a structural microtubule-associated protein (MAP) predominantly (but not exclusively) localized to microtubules (MTs) within neuronal axons. Tau is arguably the most studied MAP, primarily due to its central role in neurodegenerative tauopathies (e.g., Alzheimer&rsquo;s Disease, corticobasal degeneration, frontotemporal dementia)<sup>1,2</sup>. Importantly, tau is as essential in normal cellular physiology as in neurodegeneration. First described as a MAP which promotes assembly of MTs<sup>3-5</sup>, tau&rsquo;s roles now also include MT stabilization, MT bundling, modulation of MT-dependent axonal transport, and regulation of neurite outgrowth<sup>1,2,6-10</sup>. However, the complete physiological understanding of how tau regulates MT functional organization remains unknown. Four recent studies of novel means by which tau interacts with MTs and other MAPs are discussed below.</p>
<p class="Standard">Technological advances, especially in microscopy, provide unparalleled direct, single molecule insights into how tau binds MTs<sup>9-11</sup>. A recent cryo-electron microscopy study<sup>12</sup> reveals that tau&rsquo;s repeat MT binding regions adopt extended structures and bind to the MT surface along a protofilament to stabilize interactions between tubulin heterodimers (Fig. 1). The extended conformation of each repeat region spans intra- and interdimer interfaces, allowing connections between tubulin heterodimers<sup>12 </sup>(Fig. 1). These analyses at the near-atomic level have led some researchers<sup>10</sup> to suggest that tau is ideally situated to promote MT assembly, perhaps in the absence of any stabilization given tau&rsquo;s rapid on-off rate<sup>13</sup>. Tau&rsquo;s rate was determined through fast single molecule tracking experiments. These findings contrast with the dogma that structural MAPs adhere to the MT surface in a static fashion to prevent disassembly. In living neuronally-derived cells and primary neurons, tau dynamically binds, dissociates, and binds neighboring MTs rapidly (termed &ldquo;kiss and hop&rdquo;) with an on-off rate of 40 milliseconds<sup>13</sup>. Despite this unexpectedly rapid MT dwell time (shorter by two orders of magnitude than previously reported<sup>14</sup>), tau was still a potent promoter of tubulin polymerization in neurites.&nbsp;</p>
<p class="Standard"></p>
<p style="text-align: justify;"><a href="https://cytoskeleton.com/mapping-taus-future" title="February Newsletter" target="_blank"><strong>Click to read more</strong></a></p>
<p style="text-align: justify;"></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Fri, 14 Feb 2020 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: RhoA and NLRP3 inflammasome activation in in vivo and in vitro models of sepsis-induced intestinal dysfunction]]></title>
      <link>https://www.cytoskeleton.com/blog/rhoa-and-nlrp-inflammasome/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/cn03" title="CN03" target="_blank"><img alt="Legend: Swiss 3T3 fibroblasts were plated on glass coverslips, grown to 30% confluency in DMEM plus 10% FBS and serum starved for  24 h in media containing 1% FBS followed by 24 h in serum free media.  Cells were treated with a buffer control (A) or 1 &micro;g/ml CN03 for 2 h at 37&deg;C/5% CO2 (B).  Cells were then fixed, stained with Acti-stainTM 488 phalloidin (Cat.# PHDG1), and visualized by fluorescence microscopy.  Images were taken at a magnification of 40x.  The control cells (A) exhibited very few stress fibers, whereas treatment with CN03 (B) resulted in the development of abundant stress fibers. Under similar conditions, RhoA was activated ~10-fold as determined using the RhoA G-LISA&reg; activation assay (Cat.# BK124) (See Fig. 2).  " src="https://www.cytoskeleton.com/media/wysiwyg/CN03-Fibroblasts.jpg" style="float: right;" title="Legend: Swiss 3T3 fibroblasts were plated on glass coverslips, grown to 30% confluency in DMEM plus 10% FBS and serum starved for  24 h in media containing 1% FBS followed by 24 h in serum free media.  Cells were treated with a buffer control (A) or 1 &micro;g/ml CN03 for 2 h at 37&deg;C/5% CO2 (B).  Cells were then fixed, stained with Acti-stainTM 488 phalloidin (Cat.# PHDG1), and visualized by fluorescence microscopy.  Images were taken at a magnification of 40x.  The control cells (A) exhibited very few stress fibers, whereas treatment with CN03 (B) resulted in the development of abundant stress fibers. Under similar conditions, RhoA was activated ~10-fold as determined using the RhoA G-LISA&reg; activation assay (Cat.# BK124) (See Fig. 2).  " width="275" /></a></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p><span style="font-size: x-small;">Legend: Swiss 3T3 fibroblasts were plated on glass coverslips, grown to 30% confluency in DMEM plus 10% FBS and serum starved for&nbsp; 24 h in media containing 1% FBS followed by 24 h in serum free media.&nbsp; Cells were treated with a buffer control (A) or 1 &micro;g/ml CN03 for 2 h at 37&deg;C/5% CO2 (B).&nbsp; Cells were then fixed, stained with Acti-stainTM 488 phalloidin (Cat.# PHDG1), and visualized by fluorescence microscopy.&nbsp; Images were taken at a magnification of 40x.&nbsp; The control cells (A) exhibited very few stress fibers, whereas treatment with CN03 (B) resulted in the development of abundant stress fibers. Under similar conditions, RhoA was activated ~10-fold as determined using the RhoA G-LISA&reg; activation assay (Cat.# BK124)</span>&nbsp;</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard"><span>Sepsis and the accompanying systemic inflammatory response are an over-reaction of an organism&rsquo;s immune system in response to infection or injury which results in organ dysfunction/failure if untreated. A healthy intestinal barrier is a primary defense against these pathogenic processes. Here, the authors investigate how </span>NLRP3 inflammasome and RhoA participate in sepsis-induced intestinal barrier dysfunction and their functional status after treatment with astragaloside IV (AS-IV), a bioactive compound from <em>Astragalus membranaceus</em><span>. In <em>in vivo</em> (cecal ligation and puncture mice) and <em>in vitro</em> (Caco-2 cells treated with lipopolysaccharide [LPS]) models of sepsis, AS-IV alleviated barrier dysfunction (e.g., decreased mouse mortality, cytokine release, and barrier permeability and increased tight junction expression in vivo; reduced cytokine levels, improved gut barrier function absent cytotoxicity in vitro). NLRP3 inflammasome and RhoA activities were elevated in intestinal tissues and Caco-2 cells and correspondingly reduced after AS-IV administration. Furthermore, a cell-permeable Rho activator prevented the effects of AS-IV, while a cell-permeable Rho inhibitor antagonized LPS-induced NLRP3 inflammasome activation. </span>Cytoskeleton&rsquo;s RhoA G-LISA activation assay kit, cell-permeable Rho activator, and Rho inhibitor (Cat. # <a href="https://www.cytoskeleton.com/bk124" title="BK124" target="_blank">BK124</a>, <a href="https://www.cytoskeleton.com/cn03" title="CN03" target="_blank">CN03</a>, <a href="https://www.cytoskeleton.com/ct04" title="CT04" target="_blank">CT04</a>, respectively) were essential in identifying RhoA (and NLRP3 inflammasome) as the molecular targets of AS-IV in the alleviation of sepsis-induced barrier dysfunction.&nbsp;&nbsp;</p>
<p class="Standard">&nbsp;&nbsp;</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p class="Standard"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31835087" title="Xie S. et al" target="_blank">Xie S. et al. 2020. Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling. <em>Int. Immunopharmacol</em>. <strong>78</strong>, 106066.</a></p>
</div>
</div>
</div>
</div>
</div>
<p></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<p style="padding-left: 30px;"></p>
<p style="padding-left: 30px;"></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk124" title="BK124" target="_blank">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/cn03" title="CN03" target="_blank">Rho Activator II (Cat. # CN03)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/ct04" title="CT04" target="_blank">Rho Inhibitor I (Cat. # CT04)</a></p>
</div>
</div>
<div class="product-essential"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9jbjAz/product/501/form_key/RqIvNF0HPXtvKsAF/" enctype="multipart/form-data" id="product_addtocart_form" method="post"><span></span>
<div class="product-shop">
<div class="product-options" id="product-options-wrapper"></div>
</div>
</form></div>
</div>
<p style="padding-left: 30px;"></p>
<div class="product-essential"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9iazEyNA,,/product/476/form_key/RqIvNF0HPXtvKsAF/" enctype="multipart/form-data" id="product_addtocart_form" method="post"><span></span>
<div class="product-shop">
<div class="product-options" id="product-options-wrapper"></div>
</div>
</form></div>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/acd03" title="ACD03" target="_blank">&nbsp;</a></p>
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view"></div>
<div class="product-essential" style="padding-left: 30px;"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9ydDAy/product/563/form_key/Nc9dqAbuQWzFcjM3/" enctype="multipart/form-data" id="product_addtocart_form" method="post" style="padding-left: 30px;">
<p style="padding-left: 30px;"></p>
<div class="product-shop" style="padding-left: 30px;"></div>
</form></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Thu, 06 Feb 2020 08:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[January 2020 Newsletter : Rho GTPases Control Cell Migration]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-gtpases-control-cell-migration/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://cytoskeleton.com/rho-gtpases-control-cell-migration" title="January Newsletter" target="_blank"><img alt="January Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Rho_GTPases_and_Cell_Migation_v2_Page_1.jpg" style="margin-left: 30px; margin-right: 30px;" title="January Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://cytoskeleton.com/rho-gtpases-control-cell-migration" title="January Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Directed cell migration depends upon integrin-containing focal adhesions connecting the cell&rsquo;s actin cytoskeleton with the extracellular matrix (ECM) and transmitting mechanical force. Focal adhesion formation and subsequent migration require dynamic re-organization of actin-based contractile fibers and protrusions at a cell&rsquo;s trailing and leading edge, respectively, in response to extracellular guidance cues. Migration is essential for healthy cell (and organism) development, growth, maturation, and physiological responses to diseases, injuries, and/or immune system challenges. Various pathophysiological conditions (e.g., cancer, fibrosis, infections, chronic inflammation) usurp and/or compromise the dynamic physiological processes underlying migration<sup>1-5</sup>.</p>
<p class="Standard">Rho-family GTPases (e.g., RhoA, Rac1, Cdc42, and RhoJ) act as molecular switches, cycling between a GTP-bound &ldquo;on&rdquo; state and a GDP-bound &ldquo;off&rdquo; state. Activation is mediated by guanine nucleotide exchange factors (GEFs) and intrinsic GTPase activity is amplified/activated by GTP-activating proteins (GAPs). Rho-family GTPases regulate the dynamic assembly and disassembly of actin filaments which are necessary for the formation, extension, withdrawal, and disassembly of the cellular protrusions (i.e., filopodia and lamellipodia; regulated by Rac and Cdc42, respectively) at the front of the cell and of contractile actomyosin fibers (regulated by RhoA) at the rear of the cell<sup>1-8</sup> (Fig. 1). Interestingly, recent research clearly demonstrates that RhoA is also active at the leading edge<sup>1,9-12</sup>. Of particular interest is how these GTPases regulate cell migration and force generation through the dynamic re-organization of the actin cytoskeleton<sup>1-3,13,14 </sup>(Fig. 1). This newsletter discusses the roles of Rho-family GTPases in establishing and regulating cell-ECM adhesions and cellular directionality during cell migration.</p>
<p style="text-align: justify;"><a href="https://cytoskeleton.com/rho-gtpases-control-cell-migration" title="January Newsletter" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 07 Jan 2020 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Arp2/3 regulates RhoA activity and protein levels through cortactin/p190RhoGAP and CCM2/Smurf1, respectively]]></title>
      <link>https://www.cytoskeleton.com/blog/Arp-regulates-RhoA/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/acd03" title="ACD03" target="_blank"><img alt="Schematic diagram of cortactin&rsquo;s primary structure with key post-translational modifications and binding domains highlighted." src="https://www.cytoskeleton.com/media/wysiwyg/Coractin-100.jpg" style="float: right;" title="Schematic diagram of cortactin&rsquo;s primary structure with key post-translational modifications and binding domains highlighted." width="275" /></a></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p>Schematic diagram of cortactin&rsquo;s primary structure with key post-translational modifications and binding domains highlighted.</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Recently, the potential for the actin cytoskeleton (e.g., actin-binding protein complex Arp2/3) to regulate the activity and protein expression of upstream Rho-family GTPases (e.g., RhoA, Rac1, Cdc42) was evaluated. Genetic or pharmacological inactivation of Arp2/3, which controls actin filament branching, reduced contractility and correlated with decreased myosin II and RhoA (but not Rac1 or Cdc42) activation. The GTPase-activating protein p190RhoGAP reduced RhoA activity through increased physical interactions between the two proteins. P190RhoGAP is normally inhibited via direct cortactin binding, but following Arp2/3 inhibition,<span> cortactin dissociated from p190RhoGAP. Surprisingly, RhoA (but not Rac1, Cdc42, or p190RhoGAP) protein levels increased due to reduced RhoA ubiquitination mediated by the adaptor protein CCM2 (cerebral cavernous malformation 2) and the E3 ubiquitin ligase Smurf1 and subsequent proteasomal degradation. Furthermore, Arp2/3 inhibition and concomitant reduction in active RhoA/increase in total RhoA resulted in defects in cytokinesis which were rescued with a cell-permeable Rho activator. </span>Cytoskeleton&rsquo;s RhoA, Rac1, and Cdc42 antibodies; rhotekin-RBD and PAK-PBD beads; Acti-stain phalloidins; and Rho activator II (Cat.# <a href="https://www.cytoskeleton.com/arh04" title="ARH04" target="_blank">ARH04</a>, <a href="https://www.cytoskeleton.com/arc03" title="ARC03" target="_blank">ARC03</a>, <a href="https://www.cytoskeleton.com/acd03" title="ACD03" target="_blank">ACD03</a>, <a href="https://www.cytoskeleton.com/rt02" title="RT02" target="_blank">RT02</a>, <a href="https://www.cytoskeleton.com/pak02" title="PAK02" target="_blank">PAK02</a>, <a href="https://www.cytoskeleton.com/phdg1" title="PHDG1" target="_blank">PHDG1</a>, <a href="https://www.cytoskeleton.com/phdr1" title="PHDR1" target="_blank">PHDR1</a>, and <a href="https://www.cytoskeleton.com/cn03" title="CN03" target="_blank">CN03</a>, respectively) were essential in identifying a specific feedback loop between Arp2/3 and RhoA that reveals a previously unknown actin-based regulatory role in RhoA GTPase-mediated signal transduction.&nbsp;&nbsp;</p>
<p class="Standard">&nbsp;&nbsp;</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;">
<p class="Standard"></p>
<p class="Standard"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830327/" title="Huang" target="_blank">Huang Y. et al. 2019. Arp2/3-branched actin maintains an active pool of GTP-RhoA and controls RhoA abundance. <em>Cells</em>. <strong>8</strong>, 1264.</a></p>
</div>
</div>
</div>
</div>
</div>
<p></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<p style="padding-left: 30px;"></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/acd03" title="ACD03" target="_blank">Anti-Cdc42: mouse Mab - (Cat. # ACD03)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/arh04" title="ARH04" target="_blank">Anti-RhoA: mouse Mab - (Cat. # ARH04)</a>&nbsp;-&nbsp;Replaced by ARH05 - available <a href="https://www.cytoskeleton.com/arh05" title="ARH05" target="_blank">here</a></p>
</div>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/arc03" title="ARC03" target="_blank">Anti-Rac1: mouse Mab - (Cat. # ARC03)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/cn03" title="CN03" target="_blank">Rho Activator II - (Cat. # CN03)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/pak02" title="PAK02" target="_blank">PAK-PBD beads (binds active Rac/Cdc42 proteins) - (Cat. # PAK02)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/phdg1" title="PHDG1" target="_blank">Acti-stain 488 phalloidin - (Cat. # PHDG1)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/phdr1" title="PHDR1" target="_blank">Rhodamine Phalloidin - (Cat. # PHDR1)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/rt02" title="RT02" target="_blank">Rhotekin-RBD beads (binds active Rho proteins) - (Cat. # RT02)</a></p>
</div>
<div class="product-essential" style="padding-left: 30px;"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9ydDAy/product/563/form_key/Nc9dqAbuQWzFcjM3/" enctype="multipart/form-data" id="product_addtocart_form" method="post" style="padding-left: 30px;">
<p style="padding-left: 30px;"></p>
<div class="product-shop" style="padding-left: 30px;"></div>
</form></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Wed, 25 Dec 2019 08:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Xenopus Egg Cytoplasm Self-assembles into Spatially Organized, Cell-like Compartments De Novo]]></title>
      <link>https://www.cytoskeleton.com/blog/xenopus-egg-cytoplasm/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/sir-tubulin" title="CY-SC002" target="_blank"><img alt="HeLa cell undergoing mitosis that has its microtubules labeled with SiR-tubulin" src="https://www.cytoskeleton.com/media/wysiwyg/7_min.JPG" style="float: right;" title="HeLa cell undergoing mitosis that has its microtubules labeled with SiR-tubulin" width="275" /></a></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p><span>HeLa cell expressing mcherry-H2B (red) stained with SiR-tubulin (green). Data collected by confocal imaging. Courtesy of Daniel Gerlich and Claudia Blaukopf, Institute of Molecular Biotechnology, Vienna. </span></p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Recently, <em>Xenopus laevis </em>eggs were used to study if homogenized egg cytoplasm can support spontaneous cellular re-assembly with restored macromolecular structures and functionality<span>. Bright-field and fluorescent microscopy demonstrated that the cytoplasm of eggs arrested at interphase and homogenized can undergo self-assembly into sheets of 300-400 micron long, cell-like compartments in ~30 minutes. Successful self-assembly required formation of microtubules (MTs), but not F-actin, minus-end-directed cytoplasmic dynein motor activity, and adenosine triphosphate. MTs in the cell-like compartments appeared similar to the MTs of intact <em>Xenopus</em> embryos. Neither nuclei (chromatin) nor centrosomes were needed for self-assembly initiation. Genomic input was minimized, if not fully precluded, by inhibition of protein translation with cycloheximide. Introduction of demembranated sperm nuclei as a source of centrosomes and DNA enabled the cell-like compartments to undergo multiple cycles of mitosis if cycloheximide was excluded. </span>Cytoskeleton&rsquo;s SiR-actin and SiR-tubulin live cell imaging probes, along with green and far-red fluorescently-labeled tubulins (Cat.# <a href="https://www.cytoskeleton.com/live-cell-reagents/spirochrome/sir-actin" title="CY-SC001" target="_blank">CY-SC001</a>, <a href="https://www.cytoskeleton.com/sir-tubulin" title="CY-SC002" target="_blank">CY-SC002</a>, <a href="https://www.cytoskeleton.com/tl488m" title="TL488M" target="_blank">TL488M</a>, <a href="https://www.cytoskeleton.com/tl670m" title="TL670M" target="_blank">TL670M</a>, respectively), revealed the dynamic re-organization, subcellular localization, and functional roles of MTs and F-actin in the formation of the cell-like compartments. The study confirms that cytoplasmic components of <em>Xenopus</em> egg extracts provide the necessary macromolecular complexes, spatial organization, and cell cycle function to initiate self-organization.&nbsp;&nbsp;</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;">
<p class="Standard"></p>
<p class="Standard"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31672897" title="Dec Citation" target="_blank">Cheng X. and Ferrell Jr. J.E. 2019. Spontaneous emergence of cell-like organization in <em>Xenopus</em> egg extracts. <em>Science</em>. <strong>366</strong>, 631-637.</a></p>
</div>
</div>
</div>
</div>
</div>
<p></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p></p>
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/live-cell-reagents/spirochrome/sir-actin" title="CY-SC001" target="_blank">SiR-Actin Kit -&nbsp;<span>50 nmol SiR-Actin and 1 umol verapamil - (Cat. # CY-SC001)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/sir-tubulin" title="CY-SC002" target="_blank"><span><span>SiR-Tubulin Kit - 50 nmol SiR-Tubulin and 1 umol verapamil - (Cat. #CY-SC002)</span></span></a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/tl488m" title="TL488M" target="_blank">Tubulin protein (fluorescent HiLyte 488): porcine brain - (Cat. #TL488M)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/tl670m" title="TL670M" target="_blank">Tubulin protein (fluorescent HiLyte 647): porcine brain - (Cat. #TL670M)</a></p>
</div>
<div class="product-essential"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS90bDY3MG0,/product/572/form_key/FsxTGA9PT6X17dlB/" enctype="multipart/form-data" id="product_addtocart_form" method="post">
<p></p>
<div class="product-shop"></div>
</form></div>
</div>
</div>
<div class="product-essential" style="padding-left: 30px;"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9saXZlLWNlbGwtcmVhZ2VudHMvc3Bpcm9jaHJvbWUvc2lyLWFjdGlu/product/632/form_key/rmRJEvHjGEod3coX/" enctype="multipart/form-data" id="product_addtocart_form" method="post" style="padding-left: 30px;"><span></span>
<div class="product-shop" style="padding-left: 30px;">
<div class="product-options" id="product-options-wrapper" style="padding-left: 30px;"></div>
</div>
</form></div>
<div class="product-name-view"></div>
<p style="padding-left: 30px;"></p>
</div>
</div>
</div>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Wed, 18 Dec 2019 08:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[December 2019 Newsletter: Phenotropic Profiling Actin-focused Cancer Therapeutics]]></title>
      <link>https://www.cytoskeleton.com/blog/december-2019-newsletter-phenotropic-profiling-actin-focused-cancer-therapeutics/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://cytoskeleton.com/phenotropic-profiling-actin-focused-cancer-therapeutics" title="November Newsletter" target="_blank"><img alt="December Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/finalthumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="December Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://cytoskeleton.com/phenotropic-profiling-actin-focused-cancer-therapeutics" title="December Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="Standard">As an integral component of the mammalian cell cytoskeleton, actin is involved in multiple physiological functions, including cell growth, motility, trafficking, and division. These basic functions require remodeling of the actin cytoskeleton, as well as extension and withdrawal of actin-based cellular neurites (e.g., lamellipodia, filopodia), all of which rely upon rapid dynamic cycling between filamentous actin (F-actin) and monomer actin (G-actin)<sup>1</sup>. Correspondingly, dysfunctional actin cytoskeletal dynamics are a pathophysiological feature of many human diseases, with perhaps cancer being the prototypical example. For these reasons, actin is a theoretically attractive anti-cancer therapeutic target. However, in practice, actin has proven to be a poor target because of toxic side effects due in large part to the inability of therapeutics to distinguish between actin isoforms<sup>.2,3,</sup>. Thus, the actin in cancerous and healthy cells are affected by cancer therapies acting directly upon actin, leading to toxic side effects in different organ systems (e.g., heart and diaphragm)<sup>2,3</sup>. Recently, drug discovery has shifted from actin to actin-associated structural proteins such as the Arp2/3 complex and tropomyosins (Tpms) as these proteins offer multiple isoforms for selective targeting and the opportunity to avoid toxic side effects<sup>2-4</sup>&nbsp;(Fig. A).</p>
<p class="Standard"></p>
<p style="text-align: justify;"><a href="https://cytoskeleton.com/phenotropic-profiling-actin-focused-cancer-therapeutics" title="December Newsletter" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 03 Dec 2019 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight:Transient Calcium Waves, Actin Dynamics, and Wound Healing]]></title>
      <link>https://www.cytoskeleton.com/blog/transient-calcium-waves-actin-dynamics-and-wound-healing/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/live-cell-reagents/spirochrome/sir-actin" title="CY-SC001" target="_blank"><img alt="HeLa cells expressing H2B-mCherry (Blue) stained with SiR-actin (red). Image taken by confocal microscopy. Courtesy of Daniel Gerlich and Claudia Blaukopf, Institute of Molecular Biotechnology, Vienna." src="https://www.cytoskeleton.com/media/wysiwyg/HeLa_actin_2.jpg" style="float: right;" title="HeLa cells expressing H2B-mCherry (Blue) stained with SiR-actin (red). Image taken by confocal microscopy. Courtesy of Daniel Gerlich and Claudia Blaukopf, Institute of Molecular Biotechnology, Vienna." width="275" /></a></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p>HeLa cells expressing H2B-mCherry (Blue) stained with SiR-actin (red). Image taken by confocal microscopy. Courtesy of Daniel Gerlich and Claudia Blaukopf, Institute of Molecular Biotechnology, Vienna.</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Recently, Lee et al. used a variety of <em>in vitro</em> and <em>ex vivo</em> experimental techniques, as well as custom MATLAB analyses, to investigate transient calcium waves as a means of cell-to-cell communication to coordinate the collective migration of human corneal limbal epithelial (HCLE) cells in wound healing<span>. Following injury, cells release the nucleotide ATP which binds P2X7 and P2Y2 purinergic receptors, triggering release of calcium and activation of associated mechanotransduction signaling pathways. The authors report that the injury-induced, sustained calcium mobilizations are mediated by pannexin channels, allowing epithelial cells to communicate and coordinate changes in the cells&rsquo; actin-based morphology to enable migration to the injury site. Calcium mobilizations are correlated with these morphological changes and subsequent increased motility, both of which require dynamic re-organization of the actin cytoskeleton. </span>Cytoskeleton&rsquo;s SiR-actin live cell imaging probe <a href="https://www.cytoskeleton.com/live-cell-reagents/spirochrome/sir-actin" title="CY-SC001" target="_blank">(Cat.# CY-SC001)</a> was essential in this study as it provided a sensitive and specific method to perform short and long-term live cell confocal imaging of morphological changes in the actin cytoskeleton of HCLE cells during pharmacological manipulation of the pannexin-supported calcium mobilizations to study how different populations of HCLE cells respond to injury and participate in wound healing.&nbsp;&nbsp;</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;">
<p class="Standard"><a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0213422" title="CY-SC001" target="_blank">Lee Y. et al. 2019. Sustained Ca2+ mobilizations: A quantitative approach to predict their importance in cell-cell communication and wound healing. PLoS ONE. 14, e0213422.</a></p>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p></p>
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/live-cell-reagents/spirochrome/sir-actin" title="CY-SC001" target="_blank">SiR-Actin Kit -&nbsp;<span>50 nmol SiR-Actin and 1 umol verapamil - (Cat. # CY-SC001)</span></a></p>
</div>
<div class="product-essential" style="padding-left: 30px;"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9saXZlLWNlbGwtcmVhZ2VudHMvc3Bpcm9jaHJvbWUvc2lyLWFjdGlu/product/632/form_key/rmRJEvHjGEod3coX/" enctype="multipart/form-data" id="product_addtocart_form" method="post" style="padding-left: 30px;"><span></span>
<div class="product-shop" style="padding-left: 30px;">
<div class="product-options" id="product-options-wrapper" style="padding-left: 30px;"></div>
</div>
</form></div>
<div class="product-name-view"></div>
<p style="padding-left: 30px;"></p>
</div>
</div>
</div>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Sun, 01 Dec 2019 08:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[November 2019 Newsletter: Tubulin Hyperglutamylation, Mitochondria, and Neurodegeneration]]></title>
      <link>https://www.cytoskeleton.com/blog/november-2019-newsletter-tubulin-hyperglutamylation-mitochondria-and-neurodegeneration/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://cytoskeleton.com/november-2019-newsletter-tubulin-hyperglutamylation-mitochondria-and-neurodegeneration" title="November Newsletter" target="_blank"><img alt="November Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/novnewsthumb_Page_1.jpg" style="margin-left: 30px; margin-right: 30px;" title="November Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://cytoskeleton.com/november-2019-newsletter-tubulin-hyperglutamylation-mitochondria-and-neurodegeneration" title="November Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Microtubules (MTs) are composed of &alpha;/&beta;-tubulin heterodimers and are one of three essential proteins that comprise the cytoskeleton of mammalian cells and have essential roles in cell development, growth, motility, mechanotransduction, and intracellular trafficking. Functional regulation of MTs is achieved through at least seven different post-translational modifications (PTMs) that usually occur post-polymerization and preferentially on the &alpha;/&beta;-tubulin heterodimers of stable (vs dynamic) MTs. PTMs are highly dynamic and often reversible processes that regulate a protein&rsquo;s functions, binding partners, and/or subcellular localization by addition of a chemical group or a peptide to amino acid residue(s) within the target protein<sup>1-4</sup>.</p>
<p class="Textbody">The polyglutamylation PTM, addition of variable length glutamate side-chains to primary sequence glutamate residues, was first described in the early 1990s. Glutamate residues in the C-terminal tails (CTTs) of &alpha;- and &beta;-tubulins are the most common substrates<sup>1-6</sup>&nbsp;(Fig. 1). Glutamylation enzymes are members of the tubulin tyrosine ligase-like (TTLL) family of proteins<sup>1-4,7,8</sup>. Cytosolic carboxypeptidases (CCP; a.k.a. Nna) function as deglutamylases with CCP1, 4, 5, and 6 removing glutamate side-chain residues in mammalian cells. Three enzymes (CCP1, CCP4, and CCP6) catalyze the shortening of polyglutamate chains, while CCP5 specifically removes the branching point glutamate residue<sup>1-4,9-11</sup>&nbsp;(Fig. 1). Physiological polyglutamylation modifies MTs within neuronal cell bodies and processes (i.e., dendrites and axons) to regulate a variety of MT-based neuronal functions<sup>1-4</sup>.</p>
<p></p>
<p style="text-align: justify;"><a href="https://cytoskeleton.com/november-2019-newsletter-tubulin-hyperglutamylation-mitochondria-and-neurodegeneration" title="November Newsletter" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Mon, 14 Oct 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Polyglutamylation Regulates Motility of Neuron-specific KIF1A Kinesin]]></title>
      <link>https://www.cytoskeleton.com/blog/Polyglutamylation-Regulates-Motility-of-Neuron-specific-KIF1A-Kinesin/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/tl590m" title="TL590M" target="_blank"><img alt="KIF1A kinesin motor proteins transport cargo anterogradely along microtubules in the axons of neurons." src="https://www.cytoskeleton.com/media/wysiwyg/Novemeber_Figure_1Artboard_4_copy_2-100_1.jpg" style="float: right;" title="KIF1A kinesin motor proteins transport cargo anterogradely along microtubules in the axons of neurons." width="275" /></a></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p>KIF1A kinesin motor proteins transport cargo anterogradely along microtubules in the axons of neurons.</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Recently, Lessard et al. investigated how polyglutamylation of tubulin&rsquo;s C-terminal tails (CTTs) regulates processivity of the neuron-specific kinesin motor KIF1A. KIF1A transports neuronal cargo anterogradely along axonal microtubules (MTs)<span> over long distances (~3 microns). Prior studies implicated interactions between the K-loop of KIF1A and polyglutamylated CTTs in the regulation of KIF1A motility. The K-loop is a lysine-rich surface loop that attaches the motor to MTs via interactions with glutamate-enriched tubulin CTTs. Single-molecule total internal reflection fluorescence microscopy was utilized to better understand how polyglutamylation regulates KIF1A motility. Dimeric KIF1A exhibited novel, stochastic pausing behavior during motility on paclitaxel-stabilized MTs.&nbsp; Such pauses enabled KIF1A to combine multiple sequential runs into a super-processive run length. Furthermore, the K-loop/CTT interaction positively regulated KIF1A&rsquo;s landing rates onto MTs and pause frequency and duration. Moreover, CTT polyglutamylation regulated this interaction and KIF1A&rsquo;s subsequent motile behavior. </span>Cytoskeleton&rsquo;s 99% pure rhodamine-labeled porcine brain tubulin (Cat.# TL590M) was essential as the motor substrate for TIRF microscopic analyses of how K-loop/CTT interactions regulate KIF1A&rsquo;s processivity. These results provide novel mechanistic insights into KIF1A-mediated axonal transport and the regulatory role of tubulin CTT polyglutamylation, which may further clarify how dysfunctional MT-based, kinesin-mediated axonal transport contributes to neurodegeneration.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;">
<p class="Standard"><a href="http://www.jbc.org/content/294/16/6353" title="Citation" target="_blank">Lessard D.V. et al. 2019. <span>Polyglutamylation of tubulin&rsquo;s C-terminal tail controls pausing and motility of kinesin-3 family member KIF1A</span>. <em>J. Biol. Chem</em>. 294, 6353-6363.</a></p>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p></p>
<div class="product-name-view">
<div class="product-name-view">
<div class="product-name-view">
<p style="padding-left: 30px;"></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/tl590m" title="TL590M" target="_blank">Tubulin protein (rhodamine): porcine brain (Cat. # TL590M)</a></p>
</div>
<p style="padding-left: 30px;"></p>
</div>
</div>
</div>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Wed, 02 Oct 2019 07:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[October 2019 Newsletter: RhoB GTPase Tumor Supporter or Suppressor?]]></title>
      <link>https://www.cytoskeleton.com/blog/october-2019-rhob-gtpase/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://cytoskeleton.com/october-2019-rhob-gtpase-tumor-promoter-or-suppressor" title="October Newsletter" target="_blank"><img alt="October Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/thumb.png" style="margin-left: 30px; margin-right: 30px;" title="October Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://cytoskeleton.com/october-2019-rhob-gtpase-tumor-promoter-or-suppressor" title="October Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p>RhoB is a Rho-family GTPase that regulates essential physiological processes such as cell division, morphology, motility, adhesion, and intracellular transport, primarily through dynamic remodeling of the actin cytoskeleton, and whose expression and/or activity is pathologically dysfunctional in human diseases such as cancer and neurodegenerative diseases<sup>1-3</sup>. Due to its unique C-terminal region and distinct post-translational modifications there, RhoB is localized not only to the plasma membrane (like other Rho GTPases), but also to endosomes, multivesicular bodies, and even the nucleus<sup>1,3</sup>&nbsp;(Fig. 1). Like other Rho-family GTPases, RhoB functions as a binary switch in signaling cascades, cycling between a GDP-bound, inactive state and a GTP-bound, active state. The GTP/GDP cycling is controlled by guanine nucleotide exchange factors (GEFs; activation by exchanging GDP for GTP) and GTPase-activating proteins (GAPs; inactivation by GTP hydrolysis)<sup>1-3</sup>.</p>
<p>RhoB expression and/or activity is regulated by a variety of physiological stimuli. Normally expressed at low levels under steady state conditions, RhoB expression and/or activity is rapidly up-regulated by hypoxia, growth factors, inflammatory cytokines, and stress stimuli including UV radiation<sup>1,3-8</sup>&nbsp;(Fig. 1). Upon activation, RhoB regulates cellular responses to UV-induced DNA damage, apoptosis, cell cycle progression, and cell migration (and invasion in the case of cancer cells)<sup>1,3</sup>. RhoB&rsquo;s distinctive subcellular localization to membrane vesicles enables RhoB-mediated regulation of intracellular transport. Endosome-localized RhoB regulates the trafficking (and thereby function) of receptor tyrosine kinase and cytokine receptor-mediated signaling cascades (e.g., EGFR, CXCR2, TNFR) and the activities of kinases such as Src and Akt<sup>9-13</sup>&nbsp;(Fig. 1). As a result, RhoB is able to regulate a wide range of essential signaling cascades involved in cellular development, proliferation, survival, and apoptosis &ndash; all pathways important in human physiology and disease<sup>1,3</sup>.</p>
<p></p>
<p style="text-align: justify;"><a href="https://cytoskeleton.com/october-2019-rhob-gtpase-tumor-promoter-or-suppressor" title="October Newsletter" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Mon, 30 Sep 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Wnt5a regulation of RhoA-mediated remodeling of actin cytoskeleton to control ESCC cell motility]]></title>
      <link>https://www.cytoskeleton.com/blog/Wnt5a-regulation-of-RhoA-mediated-remodeling-of-actin-cytoskeleton-to-control-ESCC-cell-motility/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="RhoA-mediated actin cytoskeleton remodeling is regulated by a Wnt5a signaling cascade." src="https://www.cytoskeleton.com/media/wysiwyg/Artboard_1-100.jpg" style="float: right;" title="RhoA-mediated actin cytoskeleton remodeling is regulated by a Wnt5a signaling cascade." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p>RhoA-mediated actin cytoskeleton remodeling is regulated by a Wnt5a signaling cascade.</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Recently, Wu et al. investigated if Wnt5a signaling affects migration of esophageal squamous cell carcinoma (ESCC) cells and the molecular pathways underlying any Wnt5a-mediated effects<span>. Wnt5a regulates the motility and invasive behavior of breast cancer and glioblastoma cells. A potential role for Wnt5a in ESCC cell migration remained to be demonstrated. Using a variety of pharmacological, molecular, cellular, and biochemical techniques, the authors establish that Wnt5a positively regulates the in vitro invasive behavior of multiple ESCC cell lines. Specifically, Wnt5a expression is up-regulated in invasive tumor tissues (versus non-invasive tumor tissues), resulting in activation of the Wnt5a receptors, ROR1/2 (receptor tyrosine kinase-like orphan receptor 1/2). These changes are the first steps in the sequential activation of a signaling cascade consisting of DAAM1 (disheveled 2/disheveled-associated activator of morphogenesis 1), the GTPase RhoA (but not Rac1, Rac2, or Cdc42), and finally RhoA-mediated re-organization of the actin cytoskeleton. Importantly, ESCC cell invasion requires the participation of each protein component in the above signaling cascade. </span>Cytoskeleton&rsquo;s RhoA, Rac1,2,3, and Cdc42 G-LISA activation assay kits (Cat. # BK121, BK125, and BK127, respectively) were essential reagents in this study which identified ROR1/2 as novel targets for therapeutic intervention in multiple cancers.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p class="Standard"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31114334" title="sept citation" target="_blank">Wu X. et al. 2019. <span>Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells</span>. <em>Cancer Manag. Res</em>. 11, 2803-2815.</a></p>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"></p>
<div class="product-name-view">
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk121/" title="bk121" target="_blank">RhoA G-LISA Activation Assay (Luminescence format) 96 assays (Cat. # BK121)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk125/" title="bk125" target="_blank">Rac1,2,3 G-LISA Activation Assay (Colorimetric format) 96 assays (Cat. # BK125)</a></p>
</div>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk127/" title="bk127" target="_blank">Cdc42 G-LISA Activation Assay (Colorimetric format)&nbsp; 96 assays (Cat. # BK127)</a></p>
</div>
<div class="product-essential"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9iazEyNw,,/product/479/form_key/hCYuLO1pVJmurd1z/" enctype="multipart/form-data" id="product_addtocart_form" method="post"><span></span>
<div class="product-shop">
<div class="product-options" id="product-options-wrapper"></div>
</div>
</form></div>
<div class="product-essential"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9iazE2NQ,,/product/694/form_key/qZBZDsOrS9LzxCVH/" enctype="multipart/form-data" id="product_addtocart_form" method="post"><span></span>
<div class="product-shop">
<div class="product-options" id="product-options-wrapper"></div>
</div>
</form></div>
</div>
</div>
<p style="padding-left: 30px;"></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 23 Sep 2019 07:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[September 2019 Newsletter: Membrane Tension and Actin Cytoskeleton Interact to Regulate Cell Motility]]></title>
      <link>https://www.cytoskeleton.com/blog/september-2019-membrane-tension/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/membrane-tension-actin-cytoskeleton" title="September Newsletter" target="_blank"><img alt="September Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/September-Newsletter-Thumb_Page_1.jpg" style="margin-left: 30px; margin-right: 30px;" title="September Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/membrane-tension-actin-cytoskeleton" title="September Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="Standard"><span>Plasma membrane tension regulates many cellular functions, including exocytosis, endocytosis, division, and motility<sup>1-6</sup>, all of which require a re-shaping of cellular morphology, which in turn relies upon an interplay between plasma membrane deformation and remodeling of the actin cytoskeleton<sup>1,3,5-9</sup>. This newsletter discusses coordinated interactions between the actin cytoskeleton and membrane tension during motility-associated morphogenesis.</span></p>
<p class="Standard"><strong><span>&nbsp;</span></strong></p>
<p class="Standard"><span>Directed cell motility requires dynamic re-organization of the actin cytoskeleton at the front and rear of the cell (leading edge and trailing edge, respectively) with actin-based lamellipodial protrusions extending and pulling the cell forward in parallel with retraction at the trailing edge via changes in adhesion sites and RhoA-mediated actomyosin contractility<sup>8,10,11</sup>. As actin-based protrusions push the leading edge of motile cells forward and there is contraction at the trailing edge, the plasma membrane is deformed, changing membrane tension. Directed motility relies upon a balance between actin cytoskeleton remodeling and changes in membrane tension due to deformation<sup>8</sup> (Fig. 1).</span></p>
<p></p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/membrane-tension-actin-cytoskeleton" title="September Newsletter" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Wed, 21 Aug 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner]]></title>
      <link>https://www.cytoskeleton.com/blog/Stability-of-HTLV-2-antisense-protein-is-controlled-by-PML-nuclear-bodies-in-a-SUMO-dependent-manner/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Schematic representation of SUMOylated APH-2 in a developed PML nuclear body." src="https://www.cytoskeleton.com/media/wysiwyg/September-Citation-Figure-third-Draft.gif" style="float: right;" title="Schematic representation of SUMOylated APH-2 in a developed PML nuclear body." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p>Schematic representation of SUMOylated APH-2 in a developed PML nuclear body.</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Dubuisson et al. recently identified a molecular, regulatory mechanism responsible for the instability of the antisense protein of HTLV-2 (APH-2). While human T lymphotropic virus type 1 (HTLV-1) has been linked to several diseases, the HTLV-2 virus is asymptomatic; thus, comparative studies have aimed to identify critical, functional differences. Both viruses have anti-sense proteins but dissimilarities exist between the two; for example, the HTLV-1 antisense protein, HBZ, plays a significant role in virus induced disease progression while the APH-2 protein is highly unstable and has a half-life of 20-30 minutes.&nbsp; Dubisson et al. sought to decipher the molecular mechanism responsible for this instability, and discovered that a post-translational modification, SUMOylation, regulates its stability.&nbsp; A critical first step in this break-through was the discovery that APH-2 is endogenously modified by SUMO 2/3 and localized to PML nuclear bodies. Additional molecular studies were performed to determine that SUMO 2/3 and PML are essential regulators of APH-2 stability, but had little effect on HBZ expression. &nbsp;Cytoskeleton&rsquo;s SUMO 2/3 Detection Kit (Cat. # BK162) was an essential reagent that was utilized to investigate the endogenous SUMO 2/3 state of APH-2, which provided a key finding for understanding APH-2 stability. &nbsp;This study adds to the growing body of knowledge whereby viruses utilize cellular SUMOylation machinery to their benefit, and is complementary to data showing therapeutic viral treatments, such as interferon activate SUMO mechanisms as part of its mechanism of action to combat viruses.&nbsp;&nbsp;</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p class="EndNoteBibliography"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29507418" title="Dubuisson Citation" target="_blank">Dubuisson L, et al. Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner. <em>Oncogene</em>. <strong>2018</strong>;37(21):2806-16, 10.1038/s41388-018-0163-x.</a></p>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"></p>
<div class="product-name-view">
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk162" title="bk162" target="_blank">Signal-Seeker&trade; SUMOylation 2/3 Detection Kit (30 assay)</a></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk165" title="bk165" target="_blank">Signal-Seeker&trade; SUMOylation 1 Detection Kit (30 assay)</a></p>
</div>
<div class="product-essential"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9iazE2NQ,,/product/694/form_key/qZBZDsOrS9LzxCVH/" enctype="multipart/form-data" id="product_addtocart_form" method="post"><span></span>
<div class="product-shop">
<div class="product-options" id="product-options-wrapper"></div>
</div>
</form></div>
</div>
</div>
<p style="padding-left: 30px;"></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Wed, 07 Aug 2019 07:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[August 2019 Newsletter Rac1B, Cancer, and Rac1]]></title>
      <link>https://www.cytoskeleton.com/blog/Rac1b-cancer-and-rac1/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://cytoskeleton.com/august-rac1b-cancer-and-rac1" title="July newsletter" target="_blank"><img alt="August Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Rac1B_Cancer_and_Rac1_Final_use_me.png" style="margin-left: 30px; margin-right: 30px;" title="August Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/august-rac1b-cancer-and-rac1" title="August Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="Standard">The Rac1B GTPase is an alternative splice variant of Rac1, and both GTPases are members of the Rho sub-family of the Ras super-family of GTPases. Insertion of 19 additional amino acids (a.k.a. exon 3b) in Rac1B confers faster GEF-independent GDP/GTP nucleotide exchange due to reduced affinity for GDP and reduced intrinsic GTP hydrolysis compared to Rac1<sup>1-3</sup>(Fig. 1). Biochemically, Rac1B behaves similarly to a constitutively-active Rac1 GTPase, but through a mechanism distinct from oncogenic Rho sub-family GTPase mutants<sup>4</sup>. Rac1B participates in many phases of oncogenesis, including regulation of cell cycle progression and increased resistance to apoptosis. Additionally, the GTPase has multiple roles in tumor progression, including malignant transformation, epithelial-mesenchymal transition (EMT), metastasis, and invasion<sup>3</sup>. This newsletter briefly discusses some of the more recent findings regarding the role of Rac1B in tumorigenesis and its relationship with Rac1.<a href="https://www.cytoskeleton.com/august-rac1b-cancer-and-rac1" title="August Newsletter" target="_self"></a></p>
<p>Rac1B is widely regarded as a pro-tumorigenic GTPase as studies find that Rac1B promotes cellular transformation in NIH3T3 mouse fibroblasts and may enhance tumor progression in cancers that over-express Rac1B (e.g., colorectal cancer, human lung adenocarcinomas, thyroid carcinomas)<sup>3,5</sup>. Rac1B&rsquo;s role in tumorigenesis involves activation of pathways that result in chronic inflammation, transcription of pro-proliferative genes, inhibition of signaling pathways which inhibit growth and stimulate cell cycle arrest, and modulation of signaling pathways that reduce cell adhesion and promote cell migration<sup>3</sup>(Fig 2). Rac1B is also an important player in matrix metalloproteinase-3 (MMP3)-induced EMT in breast, lung, and pancreas carcinomas<sup>3,6-8</sup>. Conversely, Rac1B can also exert anti-tumor effects in certain cancers (e.g., pancreatic ductal adenocarcinomas [PDAC]). In PDAC-derived cells, Rac1B inhibited EMT induced by TGF-&beta;1, as determined by measuring changes in cell morphology, gene expression of EMT markers, signaling cascades downstream of TGF-&beta;1 activation, cell migration, and growth inhibition following RNAi-induced exon 3b-targeted knockdown of Rac1B<sup>3,9,10</sup>. In addition, Rac1B offers potential as a therapeutic as different GTPase inhibitor compounds are selective for it over Rac1<sup>11</sup>. In addition, Rac1B may serve as a prognostic marker for some cancers (e.g., breast, colorectal, hepatocellular carcinoma, non-small cell lung cancer, pancreatic cancer, chronic pancreatitis, and thyroid cancer)<sup>12-14</sup>.</p>
<p></p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/august-rac1b-cancer-and-rac1" title="August Newsletter" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Mon, 05 Aug 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[July Newsletter: Rho-family GTPases, Neuronal Plasticity, and Depression]]></title>
      <link>https://www.cytoskeleton.com/blog/Rho-family-GTPases-neuronal-plasticity-and-depression/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/july-2019-rho-family-gtpases-neuronal-plasticity-and-depression" title="July newsletter" target="_blank"><img alt="July Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/JulyThumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="July Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/july-2019-rho-family-gtpases-neuronal-plasticity-and-depression" title="July newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p>Depression constitutes a spectra of symptoms that adversely affect an individual&rsquo;s cognitive, emotional, motivational, and physiological well-being; this collection of heterogenous symptoms and pathologies is termed major depressive disorder (MDD), and for as many as 40% of individuals suffering from MDD, medications are not able to provide sufficient and/or long-lasting therapeutic relief<sup>1,2</sup>. Functional imaging studies and neuropathological studies with post-mortem human brains implicate dysfunction in the nucleus accumbens (NAc) and ventral tegmental area (VTA), critical nuclei in the brain&rsquo;s dopaminergic (DAergic) reward pathways<sup>2-6</sup>. The VTA consists of a major population of DA neurons which primarily innervates the NAc<sup>2,5</sup>. Dysfunctional neurophysiology and plasticity in these nuclei likely contribute to some of the symptoms of MDD, specifically loss of pleasure and motivation (anhedonia)<sup>2-6</sup>. Anhedonia is studied using chronic social defeat stress (CSDS) which elicits depression-associated behaviors (e.g., reduced social interactions, increased anhedonia, negative body weight changes) in 70% of mice (i.e., termed stress-susceptible) while the remaining 30% do not undergo these adverse behavioral changes (i.e., termed stress-resilient)<sup>2,7</sup>.</p>
<p>The structure and function of DAergic neurons in VTA and the DA receptor 1 (D1R)- and D2R-expressing NAc neurons are remodeled during CSDS<sup>2,8-16</sup>. Stress-induced anhedonia to model depression-like behavior results in reduced spontaneous excitatory inputs to D1R-expressing MSNs, whereas D2R-expressing MSNs undergo the opposite change<sup>17,18</sup>. D1R-expressing (but not D2R) accumbal neurons also display reduced dendritic arborization (morphological plasticity), an important parameter in excitatory neurotransmission for the MSNs as dendritic spines are the primary site of excitatory synapses<sup>8,10-12,19,20</sup>.</p>
<p></p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/july-2019-rho-family-gtpases-neuronal-plasticity-and-depression" title="June PDF" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Wed, 17 Jul 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: RhoA-mediated morphological and functional plasticity in nucleus accumbens neurons]]></title>
      <link>https://www.cytoskeleton.com/blog/RhoA-mediated-morphological-and-functional-plasticity-in-nucleus-accumbens-neurons/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Circuitry of the basal ganglia nuclei associated with the limbic system. NAc, nucleus accumbens; VTA, ventral tegmental area; DA, dopamine; D2R, dopamine 2 receptor; D1R, dopamine 1 receptor; VP, ventral pallidum, SNr, substantia nigra pars reticulata; GPi, internal segment of the globus pallidus." src="https://www.cytoskeleton.com/media/wysiwyg/August_Citation_Figure_First_Draft-100.jpg" style="float: right;" title="Circuitry of the basal ganglia nuclei associated with the limbic system. NAc, nucleus accumbens; VTA, ventral tegmental area; DA, dopamine; D2R, dopamine 2 receptor; D1R, dopamine 1 receptor; VP, ventral pallidum, SNr, substantia nigra pars reticulata; GPi, internal segment of the globus pallidus." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p>Circuitry of the basal ganglia nuclei associated with the limbic system. NAc, nucleus accumbens; VTA, ventral tegmental area; DA, dopamine; D2R, dopamine 2 receptor; D1R, dopamine 1 receptor; VP, ventral pallidum, SNr, substantia nigra pars reticulata; GPi, internal segment of the globus pallidus.</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Francis et al. evaluated the ability of the small-molecule, selective RhoA inhibitor rhosin to regulate morphological and functional plasticity in dopamine 1 receptor (D1R)-expressing (D1R+) medium spiny neurons (MSNs) in the nucleus accumbens (NAc). NAc efferent neurons experience altered synaptic activity and dendritic morphology that correlate with depression-like behavior in animal models of depression and mood disorders. One such model is chronic social defeat stress which causes depression-like behavior accompanied by increased RhoA activation and a reduction in dendritic arborization of D1R+ MSNs of the NAc. Here, the authors found that the changes in dendritic morphology and RhoA activity coincided with hyperexcitability in D1R+ NAc neurons which also had reduced excitatory stimulation. Rhosin reversed stress-induced behavioral and synaptic activity deficits and enhanced the density of dendritic spines (sites of excitatory neurotransmission), thereby conferring resistance to stress-induced deficiencies in neuronal function. Cytoskeleton&rsquo;s RhoA G-LISA activation assay kit (<a href="https://www.cytoskeleton.com/bk124" title="bk124" target="_blank">Cat. # BK124</a>) was essential in these experiments as the kit was used to measure RhoA activation in NAc neurons of control and rhosin-treated mice. These novel data provide support for the treatment of stress-induced depression and mood disorders through modulation of Rho GTPase-mediated signaling cascades.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p class="Standard"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30955841" title="Francis Study" target="_blank">Francis T.C. et al. 2019. The selective RhoA inhibitor rhosin promotes stress resiliency through enhancing D1-medium spiny neuron plasticity and reducing hyperexcitability. <em>Biol. Psychiatry</em>. 85, 1001-1010.</a></p>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"></p>
<div class="product-name-view">
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk124" title="bk124">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays</a></p>
</div>
<p style="padding-left: 30px;"></p>
<div class="product-essential"><form action="https://www.cytoskeleton.com/checkout/cart/add/uenc/aHR0cHM6Ly93d3cuY3l0b3NrZWxldG9uLmNvbS9iazEyNA,,/product/476/form_key/V1f7zsrrqMmwag8l/" enctype="multipart/form-data" id="product_addtocart_form" method="post"><span></span>
<div class="product-shop">
<div class="product-options" id="product-options-wrapper"></div>
</div>
</form></div>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/t238p" title="t238-p" target="_blank">&nbsp;</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 01 Jul 2019 07:23:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Novel Colchicine-binding Site Tubulin Inhibitor and Multi-drug Resistance]]></title>
      <link>https://www.cytoskeleton.com/blog/Novel-Colchicine-binding-Site-Tubulin-Inhibitor-and-Multi-drug-Resistance/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Tubulin-RB3_SLD-TTL in complex with compound DJ95. TLL, tubulin tyrosine ligase. PDB ID: 6NNG." src="https://www.cytoskeleton.com/media/wysiwyg/t238-P.jpg" style="float: right;" title="Tubulin-RB3_SLD-TTL in complex with compound DJ95. TLL, tubulin tyrosine ligase. PDB ID: 6NNG." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<p>Tubulin-RB3_SLD-TTL in complex with compound DJ95. TLL, tubulin tyrosine ligase. PDB ID: 6NNG.</p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p class="Standard">Recently, Arnst et al. characterized the novel tubulin polymerization inhibitor DJ95<span> as a small-molecule chemotherapeutic agent against multi-drug resistant (MDR) cancers. Anti-cancer therapeutics either stabilize or destabilize microtubules (MTs), leading to apoptosis and cell death in either scenario. A growing therapeutic problem is MDR with over-expression of ATP-binding cassette (ABC) transporters being a primary mechanism.&nbsp; Efficacy of DJ95 was evaluated in multiple separate cancer, MDR, and ABC transporter-overexpressing cell lines, as well as the National Cancer Institute 60 cell line panel. DJ95 inhibited cancer cell migration, disrupted the MT cytoskeleton, and significantly impaired mitotic spindle formation in cells undergoing mitosis. Additionally, the high-resolution crystal structure of DJ95 in complex with tubulin was determined, confirming its direct binding to the colchicine site. Surface plasmon resonance (SPR) experiments calculated DJ95&rsquo;s binding affinity for tubulin. In an in vivo mouse xenograft model, DJ95 inhibited tumor growth and disrupted tumor vasculature. </span>Cytoskeleton&rsquo;s 99% pure porcine brain tubulin (<a href="https://www.cytoskeleton.com/t238p" title="T238-P" target="_blank">Cat. # T238P</a>) was the substrate in the in vitro X-ray crystallography and SPR binding affinity studies. Collectively, the data will guide further development of this novel, potent anti-cancer compound (and related indolylimidazopyridines) and continued evaluation of its suitability for treating MDR cancers.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p class="Standard"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31043459" title="Arnst Study" target="_blank">Arnst K.E. et al. 2019. <span>Colchicine binding site agent DJ95 overcomes drug resistance and exhibits antitumor efficacy</span>. <em>Mol. Pharmacol</em>. 96, 73-89.</a></p>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/t238p" title="t238-p" target="_blank">Tubulin protein (&gt;99% pure): porcine brain ( Cat # T238-P )</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 01 Jul 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[June Newsletter: Actin Methionine Oxidation: The Next Level of Dynamic Regulation]]></title>
      <link>https://www.cytoskeleton.com/blog/Actin-Methionine-Oxidation-The-Next-Level-of-Dynamic-Regulation/</link>
      <description><![CDATA[<table align="right" border="0" style="width: 268px; height: 311px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/actin-methionine-oxidation-the-next-level-of-dynamic-regulation/?___store=us" title="Link to newsletter" target="_self"><img alt="June Newsletter Thumb" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/JuneMOXactin_v3_Thumb.png" style="margin-left: 30px; margin-right: 30px;" title="June Newsletter Thumb" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/actin-methionine-oxidation-the-next-level-of-dynamic-regulation/?___store=us" title="June Newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p>Actin PTM Background</p>
<p>Actin is a well-characterized, abundant, and essential cytoskeletal protein. Its dynamic properties allow it to shift between monomeric (G-actin) and polymeric (F-actin) states, which is vital for many cellular processes.&nbsp; Actin&rsquo;s dynamicity and function is regulated by many internal and external cues that are facilitated by actin binding proteins (ABPs), signal transducers, and others.&nbsp; Additionally, several studies now indicate that actin itself is highly modified by post-translational modifications (PTMs); furthermore, intensive studies of specific actin PTMs have detailed their effect on actin dynamics, ABP interactions, and actin-dependent physiology<sup>1,2</sup>. For example, actin N-terminal acetylation, lysine acetylation, arginylation, SUMOylation, and ubiquitination have been studied.&nbsp; Here, current studies on physiologic oxidation of actin at methionine (Met)44 and Met47 are summarized.</p>
<p>Actin Oxidation: Focus on Methionine Sulfoxide (MetO)</p>
<p>The oxidation field in general has focused on pathological oxidation (oxidative stress) induced by naturally formed oxidants like H<sub>2</sub>O<sub>2</sub>, and while it was initially hypothesized that oxidation was &ldquo;toxic&rdquo;, it is now known that oxidation is a signaling mechanism for both pathological and physiological events<sup>3</sup>.&nbsp; Most of this work related to reactive oxygen species (ROS) focused on thiol-based cysteine (Cys) modifications. This is also true in the case of actin, whereby, most of the early work on actin oxidation utilized H<sub>2</sub>O<sub>2</sub> treatment and resulted in altered F-actin content and polymerization activity as defined by enhanced lag time, slower polymerization rate, and lower polymerization extent<sup>4-6</sup>. Further investigation showed that H<sub>2</sub>O<sub>2</sub>-induced oxidation of actin initially targeted Cys374, but also targeted several Mets, including, Met44, Met47, Met176, Met190, Met269, and Met355<em> in vitro</em><sup>7</sup>. MetO oxidation happens <em>in vivo</em> under normal or stress conditions; however, Manta and Gladsyshev suggested that ROS-induced MetO formation<em> in vivo</em> occurs very inefficiently relative to the kinetics of reducing enzymes like MsrA<sup>8</sup>. Thus, the question of whether actin&rsquo;s methionines can become oxidized enzymatically <em>in vivo</em> still remained unanswered. A seminal study by the Terman group identified a role for the enzyme, MICAL (molecule interacting with CasL), in mediating oxidation of Met44 and Met47 of actin <em>in vitro</em><sup>9</sup>. These <em>in vitro</em> studies showed that MetO at Met44 was sufficient to promote both severing of filaments and decreased polymerization. Additionally, mis-regulation of actin MetO produced profound morphological consequences as overexpression of MICAL in Drosophila resulted in deformed bristle formation but was rescued with M44L actin mutants; thereby, defining its role <em>in vivo</em><sup>9,10</sup><em>.</em> A recent study identified a physiologic role for MICAL-1 oxidation of F-actin by determining that this mechanism is critical for depolymerizing actin during the terminal steps of cytokinesis<sup>11</sup>. These studies shed light on the physiologic importance that actin MetO has on actin&rsquo;s molecular, cellular, and morphologic functions.&nbsp;</p>
<p></p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/actin-methionine-oxidation-the-next-level-of-dynamic-regulation/?___store=us" title="June PDF" target="_blank"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Mon, 17 Jun 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[May Newsletter: Microglia and Neurodegenerative Diseases]]></title>
      <link>https://www.cytoskeleton.com/blog/microglia-and-neurodegenerative-diseases/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/may-newsletter-microglia-and-neurodegenerative-diseases/?___store=us" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/May_2019_Magento_Thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://cytoskeleton.com/pdf-storage/news/Cytoskeleton%20Newsletter%20May%202019%20Microglia%20Neurodegeneration%20v6.pdf" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="Standard"><span>Microglia are the primary immune cells, the so-called professional phagocytes, of the mammalian brain. Microglia continually scan the entire brain in their resting state and when neurotoxic pathogens and damaged cellular machinery are detected, they are activated to eliminate them<sup>1-2</sup> (Fig. 1). In healthy neurons, microglia also contribute to essential cellular functions such as neurogenesis, neurodevelopment, and neural plasticity<sup>3-4</sup>. Of similar importance are the roles microglia have in neurodegenerative diseases characterized by aggregates of pathogenic, misfolded proteins such as Parkinson&rsquo;s disease (PD; Lewy bodies) and Alzheimer&rsquo;s disease (AD; A&beta; plaques). Microglia-mediated neuroinflammation is a common pathophysiology in PD and AD human brains, as well as in in vivo animal model brains <sup>1-2,4-9</sup>. Moreover, recent genetic and transcriptomic studies revealed microglia-associated signaling cascades as critical players in AD pathogenesis<sup>1-7</sup>. This newsletter discusses microglia activation and neuroinflammation in PD and AD.</span></p>
<p style="text-align: justify;">PD is characterized by a loss of dopamine (DA) neurons in the substantia nigra pars compacta, a corresponding loss of dopaminergic (DAergic) terminals throughout the basal ganglia, and Lewy bodies which are composed primarily of intracellular &alpha;-synuclein aggregates. Lewy bodies are a pathophysiological hallmark of PD and trigger microglia-mediated neuroinflammation, which itself is another neuropathological correlate of PD<sup>1,2,8,10</sup> (Fig. 1). In the brains of PD patients, Lewy body neurites are associated with activated microglia and &alpha;-synuclein deposits are correlated with inflammatory markers. In vitro cell culture and in vivo animal models also demonstrate a relationship between &alpha;-synuclein aggregates and microglial activation<sup>2,8,10</sup>.&nbsp;</p>
<p></p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/may-newsletter-microglia-and-neurodegenerative-diseases/?___store=us" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Thu, 23 May 2019 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventing LRP-1 Downregulation]]></title>
      <link>https://www.cytoskeleton.com/blog/myeloid-specific-deletion-of-epsins-1-and-2-reduces-atherosclerosis-by-preventing-lrp-1-downregulation/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Domain structures of wild-type and mutant amyloid precursor proteins." src="https://www.cytoskeleton.com/media/wysiwyg/march-citation-diagram.jpg" style="float: right;" title="Domain structures of wild-type and mutant amyloid precursor proteins." width="200" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<p><span style="font-size: xx-small;">Schematic of Atherogensis regulation through epsin&rsquo;s ubiquitin-dependent interaction with LRP-1 receptors</span></p>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>In a recent study, Dr. Chen and colleagues identified a critical role of myeloid epsins to promote atherogenesis through ubiquitin-dependent regulation of the LRP-1 receptor.&nbsp; They utilized elegant, myeloid-specific epsin double-knockout mouse models to define its role in atherogenesis progression and showed that epsin loss decreased atherosclerotic lesions.&nbsp; They investigated this pathological phenomenon at the cellular level and identified critical changes in macrophages, defined by suppression of a pro-inflammatory phenotype and enhancement of an anti-inflammatory phenotype.&nbsp; Further examination led to the molecular discovery that levels of LRP-1, a surface receptor that promotes an anti-inflammatory phenotype, were enhanced in the absence of myeloid epsins.&nbsp; Importantly, they discovered that LRP-1 and epsins interact through epsin&rsquo;s ubiquitin-interacting motif.&nbsp; In response to oxidizied-LDL, a pro-inflammatory stimulant, LRP-1&rsquo;s ubiquitination increased, which enhanced its interaction with epsins.&nbsp; Cytoskeleton&rsquo;s ubiquitin antibody (<a href="https://www.cytoskeleton.com/ubiquitin-antibody-aub01" title="Ubiquitin Antibody Mouse Monoclonal (Cat. # AUB01)" target="_blank">Cat. # AUB01</a>) was a critical reagent that was utilized to investigate the ubiquitination state of LRP-1, which provided a key finding in unraveling the mechanistic interaction and regulation of these proteins in atherogenesis.&nbsp;&nbsp; This study provides the foundation to target myeloid-specific epsins as a potential therapeutic to treat atherogenesis, and it will be interesting to see if they can regulate epsin through targeting its ubiquitin-interacting motif.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/30595089" title="Brophy ML et. al., Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventing LRP-1 Downregulation. 2019 Feb 15;124(4):e6-e19. doi: 10.1161/CIRCRESAHA.118.313028" target="_blank">Brophy ML et. al.,<em> </em>Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventing LRP-1 Downregulation. 2019 Feb 15;124(4):e6-e19. doi: 10.1161/CIRCRESAHA.118.313028</a></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/ubiquitin-antibody-aub01" title="Ubiquitin Antibody Mouse Monoclonal (Cat. # AUB01)" target="_blank">Ubiquitin Antibody Mouse Monoclonal (Cat. # AUB01)</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 18 Feb 2019 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[New 2019 Cytoskeleton Minicatalog]]></title>
      <link>https://www.cytoskeleton.com/blog/introducing-the-2019-cytoskeleton-minicatalog/</link>
      <description><![CDATA[<table align="center" border="0" style="width: 100%;">
<tbody>
<tr>
<td>
<table align="right" border="0" style="width: 200px;">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/pdf-storage/Cytoskeleton%20Mini-Catalog%202016%20web.pdf" title="Click here to download" target="_blank"><img alt="2018 Cytoskeleton Minicatalog Cover" src="https://www.cytoskeleton.com/media/wysiwyg/MCat-2019-Cover-THumb.jpg" title="2018 Cytoskeleton Minicatalog Cover" width="200" /></a></td>
</tr>
<tr>
<td style="text-align: center;"><a href="http://www.cytoskeleton.com/pdf-storage/Cytoskeleton%20Mini-Catalog%202016%20web.pdf" title="Click to Download" target="_blank"><span style="font-size: medium;">Click Here to View</span></a></td>
</tr>
</tbody>
</table>
<h1 style="text-align: center;"><a href="https://www.cytoskeleton.com/pdf-storage/Cytoskeleton%20Mini-Catalog%20web%20version.pdf" title="Introducing the New 2019 Cytoskeleton Minicatalog!" target="_blank"><span style="color: #000000; font-size: large;">Introducing the New 2019 Cytoskeleton Minicatalog!<br /></span></a></h1>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a href="https://www.cytoskeleton.com/signal-seeker" title="New Comprehensive Kits!" target="_blank"><span style="font-size: large;">GEF and K-Ras4B Mutated Proteins</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">New products = new discoveries!</span></p>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a href="https://www.cytoskeleton.com/signal-seeker" title="New Comprehensive Kits!" target="_blank"><span style="font-size: large;">Signal-Seeker&trade; Kits</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">New comprehensive kits!<br /></span></p>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a href="https://www.cytoskeleton.com/signal-seeker/signal-seeker-ptmtrue-antibodies" title="Acetyl-Lysine, Ubiquitin, and SUMO2/3 antibodies." target="_blank"><span style="font-size: large;">Signal-Seeker&trade; Antibodies</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">Acetyl-Lysine, Ubiquitin, and SUMO2/3!<br /></span></p>
</td>
</tr>
</tbody>
</table>
<p><img alt="Wind Turbine" src="https://www.cytoskeleton.com/media/wysiwyg/wind-turbine.jpg" style="display: block; margin-left: auto; margin-right: auto;" title="Wind Turbine" width="75" /></p>
<h1 align="justify" style="text-align: center;"><span style="font-size: large;"><strong>Renewable Energy and Recycling at Cytoskeleton, Inc.</strong></span></h1>
<p align="justify">In 2019, Cytoskeleton made the move to power its sole facility at Denver, Colorado, USA with 100% renewable energy (wind and solar). The local electric company (Xcel energy) has enabled this by its Colorado State mandate to produce 30% of its electricity from wind and solar by 2020 (and 100% by 2040). We are proud to support the 2016 Paris Agreement on Climate Change with this change.</p>
<p align="justify">In addition, late in 2018 a recycling program was started at Cytoskeleton. To date we achieve 75% recycled waste, while looking for more ways to recycle the remainder. More changes will take place to utilize post-consumer materials wherever possible.</p>
<p align="justify">We look forward to a peaceful, efficient and productive scientific culture in 2019 and beyond.</p>
<p align="justify">The Team at Cytoskeleton, Inc.</p>]]></description>
      <pubDate>Mon, 11 Feb 2019 10:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[February Newsletter: Live Cell Imaging and CNS Diseases and Disorders]]></title>
      <link>https://www.cytoskeleton.com/blog/live-cell-imaging-and-cns-diseases-and-disorders/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/live-cell-imaging-and-cns-diseases-and-disorders" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/01-2019-Thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="http://www.cytoskeleton.com/live-cell-imaging-and-cns-diseases-and-disorders" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Studying the causes of human central nervous system (CNS) diseases and disorders and developing impactful therapies requires in vitro and in vivo disease models that faithfully recapitulate the respective neuropathophysiology while also supporting the neurons with the necessary cellular machinery to respond to therapies in a manner that offers translational results. Moreover, it is imperative to study the earliest neuropathophysiological changes as these provide the best opportunity for early diagnosis and intervention. Changes in the structure and/or function of neuronal synapses are often the earliest pathological changes in many neurodegenerative diseases and CNS disorders. To detect early synaptic dysfunction, scientists utilize live cell imaging which provides single cell resolution with real-time analysis of changing experimental conditions. This newsletter discusses the use of live cell imaging in in vitro and in vivo studies of CNS diseases and disorders.</p>
<p></p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/live-cell-imaging-and-cns-diseases-and-disorders" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Live Cell Imaging Products, G-LISA Activation Assays, Actin and Tubulin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Wed, 23 Jan 2019 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: RhoA Mediates Inhibition of Neurite Outgrowth by Amyloid Precursor Protein Homodimers]]></title>
      <link>https://www.cytoskeleton.com/blog/rhoa-mediates-inhibition-of-neurite-outgrowth-by-amyloid-precursor-protein-homodimers/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Domain structures of wild-type and mutant amyloid precursor proteins." src="https://www.cytoskeleton.com/media/wysiwyg/fig1_2.jpg" style="float: right;" title="Domain structures of wild-type and mutant amyloid precursor proteins." width="200" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<p><span style="font-size: xx-small;">Domain structures of wild-type and mutant amyloid precursor proteins.</span></p>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Luu et al. recently studied the regulation of neurite (i.e., neuronal axons and dendrites) outgrowth by amyloid precursor protein (APP) homodimers in SH-SY5Y human neuroblastoma cells over-expressing either wild-type (WT) or mutant L17C APP. APP is a transmembrane glycoprotein highly expressed in the brain and spinal cord, and its metabolites are involved in various physiological and pathological functions. For the present study, the authors utilized mutant L17C APP which correlates with a 30% increase in APP homodimerization. In differentiated SH-SY5Y cells displaying a neuronal phenotype, over-expression of the mutant, but not WT, APP reduced neurite outgrowth. The mutant APP-mediated inhibition correlated with increased RhoA activity, a known negative regulator of neurite outgrowth. The mutant APP/RhoA-mediated decrease was rescued with application of either the Rho inhibitor Y27632 or conditioned media from cells over-expressing WT APP. In addition, over-expression of the microRNA miR-34a rescued the mutant phenotype concomitant with a decrease in RhoA activity. Cytoskeleton&rsquo;s RhoA G-LISA activation assay Kit (<a href="https://www.cytoskeleton.com/bk124" title="RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat.# BK124)" target="_blank">Cat. # BK124</a>) was an essential reagent in this study, providing an economical, sensitive, and reliable means to study the mechanistic role of RhoA in APP-mediated regulation of neuronal differentiation and morphogenesis, processes integral in neurodevelopment.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29675574" title="Luu L. et al. 2018. Amyloid precursor protein dimerization reduces neurite outgrowth. Mol. Neurobiol. doi: 10.1007/s12035-018-1070-4.">Luu L. et al. 2018. Amyloid precursor protein dimerization reduces neurite outgrowth. <em>Mol. Neurobiol</em>. doi: 10.1007/s12035-018-1070-4.</a></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk124" title="RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat.# BK124)" target="_blank">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat.# BK124)</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Wed, 16 Jan 2019 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: RCC2 Mediates Apoptosis Through Inhibition of GEF-Mediated Rac1 Activation]]></title>
      <link>https://www.cytoskeleton.com/blog/rcc2-mediates-apoptosis-through-inhibition-of-gef-mediated-rac1-activation/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Crystal structure of human RCC2 as determined by X-ray diffraction. RCC2 and sulfate ion complex. PDB ID: 5GWN." src="https://www.cytoskeleton.com/media/wysiwyg/RCC2_4_1.png" style="float: right;" title="Crystal structure of human RCC2 as determined by X-ray diffraction. RCC2 and sulfate ion complex. PDB ID: 5GWN." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<p><span style="font-size: xx-small;">Crystal structure of human RCC2 as determined by X-ray diffraction. RCC2 and sulfate ion complex. PDB ID: 5GWN.</span></p>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Wu et al. recently studied how over-expression or knockdown of regulator of chromosome condensation 2 (RCC2; also known as TD-60) protein affects the ability of nine chemotherapeutic drugs to induce apoptosis in three different in vitro cancer cell culture models of lung and ovarian tumors. RCC2 over-expression antagonized spontaneous and staurosporine (STS)-induced apoptosis, whereas RCC2 knockdown had the opposite effect. Besides apoptosis, cell proliferation and signaling of Rho-family GTPases (RhoA, Rac1, and Cdc42) were also evaluated since RCC2 inhibits GEF-mediated activation of Rac1. The authors found that the decrease in apoptosis in cells over-expressing RCC2 coincides with decreased Rac1 activation. Further experiments demonstrated that inhibition of Rac1 activation by over-expressed RCC2 is necessary for the development of a cell&rsquo;s resistance to chemotherapeutic-induced apoptosis. Neither RhoA nor Cdc42 activation changed. Cytoskeleton&rsquo;s RhoA, Rac1, and Cdc42 Activation Assay Combo Biochem Kit (<a href="RhoA%20/%20Rac1%20/%20Cdc42%20Activation%20Assay%20Combo%20Biochem%20Kit%20(bead%20pull-down%20format)%20-%203%20x%2010%20assays" title="https://www.cytoskeleton.com/bk030" target="_blank">Cat. # BK030</a>) was an essential reagent in this study, providing an economical, sensitive, and reliable means to study the mechanistic role of three Rho-family GTPases in anti-cancer therapeutics. Moreover, this study may offer a screening tool for evaluating a tumor&rsquo;s likely response to different chemotherapies since cells over-expressing RCC2 resisted many of the chemotherapies tested in this study.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29321004" title="Wu N. et al. 2018. RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation. BMC Cancer. 18, 67. " target="_blank">Wu N. et al. 2018. RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation. <em>BMC Cancer</em>. 18, 67.</a></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><a href="RhoA%20/%20Rac1%20/%20Cdc42%20Activation%20Assay%20Combo%20Biochem%20Kit%20(bead%20pull-down%20format)%20-%203%20x%2010%20assays" title="https://www.cytoskeleton.com/bk030" target="_blank">RhoA / Rac1 / Cdc42 Activation Assay Combo Biochem Kit (bead pull-down format) (Cat. # BK030)</a></span></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 17 Dec 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[December Newsletter: Actin Cytoskeleton and Mechanotransduction]]></title>
      <link>https://www.cytoskeleton.com/blog/actin-cytoskeleton-and-mechanotransduction/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/actin-cytoskeleton-and-mechanotransduction" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/December-2018-Newsletter-Thumb-200.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/actin-cytoskeleton-and-mechanotransduction" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Mechanotransduction is a multi-step biological process by which cells sense, interpret, and respond to mechanical (i.e., physical) force through conversion to biochemical signals that elicit specific cellular responses. The responses are often mechanical in nature as they involve force generation to produce cellular protrusions and retractions which require remodeling of the actin cytoskeleton, consisting of monomeric (globular; G-) and helical polymeric (filamentous; F-) actin and actin binding proteins (ABPs). ABPs dynamically organize F-actin into many different structural forms such as lamellipodia, stress fibers, filopodia, podosomes, actin asters, vortices, and stars. These different architectures serve specialized roles in the cell&rsquo;s multiplex response to mechanical stimulation. A primary means by which F-actin transduces these signals is through its connections to focal adhesions and adherens junctions, which coordinate contact between the cell&rsquo;s actin cytoskeleton and either the extracellular matrix or another cell, respectively(Fig. 1). Understanding the actin cytoskeleton&rsquo;s role in mechanotransduction goes beyond the basic biology underlying force-induced changes in actin-based cellular structures and functions. Diseases resulting from expression of mutant ABPs render cells unable to respond to mechanical forces physiologically. In this newsletter, the role of the actin cytoskeleton in mechanotransduction is discussed.</p>
<p></p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/actin-cytoskeleton-and-mechanotransduction" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Actin Proteins, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Wed, 28 Nov 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Tctex-1, Novel Binding Partner of KIM-1, and Phagocytosis of Apoptotic Cells]]></title>
      <link>https://www.cytoskeleton.com/blog/tctex-1-novel-binding-partner-of-kim-1-and-phagocytosis-of-apoptotic-cells/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Schematic of phagocytic cell engulfing an apoptotic cell as mediated by recognition of phosphatidylserine (PS) signals." src="https://www.cytoskeleton.com/media/wysiwyg/november-citation-diagram.jpg" style="float: right;" title="Schematic of phagocytic cell engulfing an apoptotic cell as mediated by recognition of phosphatidylserine (PS) signals." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<p><span style="font-size: x-small;">Schematic of phagocytic cell engulfing an apoptotic cell as mediated by recognition of phosphatidylserine (PS) signals.</span></p>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Ismail et al. characterized Tctex-1, a novel binding partner of kidney injury molecule-1 (KIM-1), and described the role both proteins have in efferocytosis, the phagocytosis of apoptotic cells. Efferocytosis is an important function in tissue repair, reducing inflammation and abnormal autoimmune responses. KIM-1 is a phosphatidylserine (PS) receptor and PS is a well-known identifier of apoptotic cells. The physical and functional interactions between Tctex-1 and KIM-1 were examined in proximal tubular epithelial cells (PTECs) which can act as amateur phagocytes. A previously unknown role for Tctex-1 in KIM-1-mediated efferocytosis in PTECs was described. Efferocytosis requires re-organization of the actin and microtubule networks, prompting the authors to examine actin cytoskeletal dynamics and the potential role of RhoA and Rac1 in efferocytosis mediated by Tctex-1/KIM-1. Notably, neither RhoA nor Rac1 activities were regulated by Tctex-1 during KIM-1-dependent efferocytosis in PTECs. These data suggested the unexpected hypothesis that non-canonical pathways not involving RhoA and Rac1 are utilized by Tctex-1. Cytoskeleton&rsquo;s rhodamine-phalloidin, RhoA and Rac1 G-LISA activation assay kits, and Total RhoA ELISA (Cat. # <a href="https://www.cytoskeleton.com/phdr1" title="Rhodamine Phalloidin (Cat. # PHDR1)" target="_blank">PHDR1</a>, <a href="https://www.cytoskeleton.com/bk124" title="RhoA G-LISA Activation Assay Kit (Colorimetric format)">BK124</a>, <a href="https://www.cytoskeleton.com/bk128" title="https://www.cytoskeleton.com/bk128" target="_blank">BK128</a>, <a href="https://www.cytoskeleton.com/bk150" title="Total RhoA ELISA" target="_blank">BK150</a>, respectively) were essential reagents in this study, the first to describe the physical and functional roles of Tctex-1 in KIM-1-dependent efferocytosis in kidney cells.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p><span style="color: black;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29693725" style="color: blue !important; text-decoration: underline !important;" target="_blank">Ismail O.Z. et al. 2018. Tctex-1, a novel interaction partner of Kidney Injury Molecule-1, is required for efferocytosis. J. Cell. Physiol. 233, 6877-6895.</a></span></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation:</strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/phdr1" style="color: blue !important; text-decoration: underline !important;" target="_blank">Rhodamine Phalloidin (Cat. # PHDR1)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk124" style="color: blue !important; text-decoration: underline !important;" target="_blank">RhoA G-LISA Activation Assay Kit (Colorimetric format) (Cat. # BK124)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk128" style="color: blue !important; text-decoration: underline !important;" target="_blank">Rac1 G-LISA Activation Assay Kit (Colorimetric Based) (Cat. # BK128)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk150" style="color: blue !important; text-decoration: underline !important;" target="_blank">Total RhoA ELISA (Cat. # BK150)</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 12 Nov 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[November Newsletter: Axon Regeneration and the Cytoskeleton ]]></title>
      <link>https://www.cytoskeleton.com/blog/axon-regeneration-and-the-cytoskeleton/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/axon-regeneration-and-the-cytoskeleton" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/November--2018-Newsletter-Thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/axon-regeneration-and-the-cytoskeleton" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The cytoskeleton of adult neurons in the central nervous system (CNS) is composed of different structural proteins, including microtubules (MTs) and F-actin. Normal cellular functions (e.g., morphology, motility, development, transport) rely upon the dynamicity of MTs and F-actin. Additionally, cytoskeletal dysfunction underlies many CNS diseases and injuries. For instance, the cytoskeletal dynamics in the adult CNS following axonal injury are not conducive to growth cone formation, axon regeneration, and recovery of function. To understand the role of the MT and F-actin cytoskeleton in adult CNS injury recovery, and how to modulate them for axon regeneration demands an understanding of cytoskeletal dynamics following axonal injury<sup>1,2</sup>. This newsletter discusses the roles of the MT and F-actin cytoskeleton in axon regeneration in the adult CNS.</p>
<p style="text-align: justify;">The dogma is that axon regeneration does not occur in adult CNS neurons under physiological conditions. In contrast, damaged axons in the peripheral nervous system (PNS) are regenerated following injury.&nbsp; The focus on understanding this difference centers on two prominent regeneration-associated signaling cascades in the adult CNS: 1. activation of intrinsic regeneration-associated genes [RAGs]), and 2. external cues that inhibit axon re-growth<sup>1,2</sup>.</p>
<p></p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/axon-regeneration-and-the-cytoskeleton" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Tubulin and Actin Live Cell Reagents, G-LISA Activation Assay Kits, Tubulin Kits, Actin Biochem Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Thu, 01 Nov 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: RhoA Activation and F-actin Stress Fiber Formation Underlies FAM13A-Mediated Changes in Cystic Fibrosis Lung Phenotype]]></title>
      <link>https://www.cytoskeleton.com/blog/rhoa-activation-and-f-actin-stress-fiber-formation-underlies-fam13a-mediated-changes-in-cystic-fibrosis-lung-phenotype/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Rho activation in Swiss 3T3 cells. F-actin is visualized with fluorescent green phalloidin staining (Cat.# PHDG1) and nuclear blue DNA staining with Dapi. Cells were activated with Cat.# CN03." src="https://www.cytoskeleton.com/media/wysiwyg/G-Switch_Rho_Stress_Fibers_3T3_with_CN03.jpg" style="float: right;" title="Rho activation in Swiss 3T3 cells. F-actin is visualized with fluorescent green phalloidin staining (Cat.# PHDG1) and nuclear blue DNA staining with Dapi. Cells were activated with Cat.# CN03." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<p><span style="font-size: xx-small;">Rho activation in Swiss 3T3 cells. F-actin is visualized with fluorescent green phalloidin staining (<a href="https://www.cytoskeleton.com/phdg1" title="Acti-stain 488 phalloidin (Cat. # PHDG1-A)" target="_blank">Cat.# PHDG1</a>) and nuclear blue DNA staining with Dapi. Cells were activated with <a href="https://www.cytoskeleton.com/cn03" title="Rho Activator II (Cat. # CN03)" target="_blank">Cat.# CN03</a>.</span></p>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Corvol et al. investigated the gene Family with sequence similarity 13 member A (<em>FAM13A</em>) and its contribution to the pathophysiology of cystic fibrosis (CF), a monogenic lung disease characterized by an excessive inflammatory response. Disease severity varies and is influenced by genetic modifiers. Here, the authors confirm that FAM13A is a genetic modifier of the CF lung phenotype and can impact the severity of lung disease in CF patients. To mimic inflammation that accompanies CF, lung epithelial cells and primary human bronchial epithelial cells from CF patients were treated with IL-1&beta; and TGF-&beta;, pro-inflammatory cytokines. Each cytokine decreased expression of FAM13A. FAM13A has a Rho GTPase activating protein (GAP) domain, prompting the authors to measure RhoA activity and associated F-actin stress fiber formation following siRNA-mediated reduction in FAM13A expression. An increase in both occurred, whereas E-cadherin expression decreased. Additionally, TGF-&beta; stimulation of siRNA-treated cells displayed a further reduction of E-cadherin concomitant with increased expression of &alpha;-smooth muscle actin and vimentin. These changes are characteristic of an epithelial to mesenchymal transition. Cytoskeleton&rsquo;s RhoA pull-down activation assay kit (<a href="RhoA%20Pull-down%20Activation%20Assay%20Biochem%20Kit%20(bead%20pull-down%20format)" title="https://www.cytoskeleton.com/bk036" target="_blank">Cat. # BK036</a>) was essential in identifying a molecular pathway underlying FAM13A-mediated alterations in CF lung phenotypes.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29239766" title="Corvol H. et al. 2018. FAM13A is a modifier gene of cystic fibrosis lung phenotype regulating rhoa activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition. J. Cyst. Fibros. 17, 190-203." target="_blank">Corvol H. et al. 2018. <em>FAM13A</em> is a modifier gene of cystic fibrosis lung phenotype regulating rhoa activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition. <em>J. Cyst. Fibros</em>. 17, 190-203.</a></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="RhoA%20Pull-down%20Activation%20Assay%20Biochem%20Kit%20(bead%20pull-down%20format)" title="https://www.cytoskeleton.com/bk036" target="_blank">RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) (Cat. # BK036)</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Tue, 09 Oct 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[October Newsletter: Microtubules and Polarity in Neurons]]></title>
      <link>https://www.cytoskeleton.com/blog/microtubules-and-polarity-in-neurons/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/microtubules-and-polarity-in-neurons" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/October-2018-Newsletter-SmThumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/rab-gtpases-and-neurodegeneration" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Neuronal polarity describes the spatial, morphological, structural, and functional differentiations that occur in neurons during early development that results in the formation of a single axon and multiple dendrites. Axons and dendrites are responsible for directional signaling in neurons - receiving, processing, and transmitting information from the postsynaptic dendrites to the axon of the postsynaptic neuron. The majority of excitatory inputs at the dendrites occur at dendritic spines. Polarization of the neuron begins with the loss of the symmetric shape of a round newborn neuron via formation of minor neurites<sup>1-4</sup>. Neuronal polarization depends upon: 1. the polarity of microtubules (MTs), one of the primary cytoskeletal polymers in cells, and 2. polarized cargo transport by kinesins and dynein along the MTs in axons and dendrites<sup>4,5</sup>. <br /><br />MTs are intrinsically polar filaments composed of alpha/beta-tubulin heterodimers with an exposed beta-tubulin at the plus end and an exposed alpha-tubulin at the minus end<sup>5-7</sup>. MT polarity directs: 1. location of MT assembly/disassembly; 2. where MT-associated proteins (MAPs; e.g., +TIPs, motors) bind MTs in the cell; and 3. motor-driven traffic along MTs. Importantly, MTs are integral for nearly all normal neuronal functions and MT disruption underlies several neural pathologies<sup>7-10</sup>...</p>
<p></p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/microtubules-and-polarity-in-neurons" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal-Seeker&trade; PTM Kits and Antibodies, Tubulin Kits and Reagents, Kinesin Reagents, ATPase/GTPase Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 02 Oct 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Tubulysins: Novel Payload Class for Antibody-Drug Conjugates]]></title>
      <link>https://www.cytoskeleton.com/blog/antibody-tubulysin-conjugates-linked-by-glucuronide-are-anti-mitotic-in-multiple-cancer-cell-lines-and-tumor-xenografts/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Figure 1. Tubulin polymerization using the fluorescence based tubulin polymerization assay (BK011P). Tubulin was incubated alone (Control), with Paclitaxel or Vinblastine. Each condition was tested in duplicate. Polymerization was measured by excitation at 360 nm and emission at 420 nm.  The three Phases of tubulin polymerization are marked for the control polymerization curve; I: nucleation, II: growth, III: steady state equillibrium." src="https://www.cytoskeleton.com/media/wysiwyg/bk011fig1.jpg" style="float: right;" title="Figure 1. Tubulin polymerization using the fluorescence based tubulin polymerization assay (BK011P). Tubulin was incubated alone (Control), with Paclitaxel or Vinblastine. Each condition was tested in duplicate. Polymerization was measured by excitation at 360 nm and emission at 420 nm.  The three Phases of tubulin polymerization are marked for the control polymerization curve; I: nucleation, II: growth, III: steady state equillibrium." width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<p><span style="font-size: xx-small;">Tubulin polymerization using the fluorescence based tubulin polymerization assay (<a href="https://www.cytoskeleton.com/bk011p" title="Tubulin polymerization assay using &gt;99% pure tubulin, fluorescence based  (Cat. # BK011P)" target="_blank">Cat. # BK011P</a>). Tubulin was incubated alone (Control), with Paclitaxel or Vinblastine. Each condition was tested in duplicate. Polymerization was measured by excitation at 360 nm and emission at 420 nm.&nbsp; The three Phases of tubulin polymerization are marked for the control polymerization curve; I: nucleation, II: growth, III: steady state equillibrium.</span></p>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Burke et al. investigated the potential of tubulysin M, a potent tubulin binder and anti-mitotic tetrapeptide, as the cytotoxic component of antibody-drug conjugates (ADCs). Structurally, the C11 acetoxy moiety within the tubuvaline residue of tubulysins is important for their high potency. However, tubulysin activity is compromised when this moiety undergoes deacetylation. Replacement of this moiety with an ether or ester group created stabilized tubulysin M analogues. Wild-type tubulysin M and two stabilized analogues, both in free drug and conjugate form, were evaluated pre-clinically as anti-cancer therapeutics in <em>in vitro</em> and <em>in vivo</em> model systems. First, <em>in vitro</em> cell and biochemical potencies of the free forms of these tubulysins was determined. The free and conjugated forms were further evaluated using assorted cancer cell lines and <em>in vivo</em> tumor xenograft models, including those with multi-drug resistant phenotypes. Cytoskeleton Inc. produced sheep brain tubulin (<a href="https://www.cytoskeleton.com/custom-services/protein-purification" title="Tubulin protein plus glycerol, Sheep Brain (&gt;99% pure) (Cat. # CS-T234S)" target="_blank">Cat.# CS-T234S</a>) in a specialized buffer for use in competitive fluorescence polarization tubulin binding assays to measure the biochemical potencies of tubulysin M and analogues in free drug form. These biochemical data complemented cell potency results and buttressed the rationale for further development and testing of stabilized tubulysins as a novel payload class for ADCs in targeted anti-cancer therapies.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;"><a href="http://mct.aacrjournals.org/content/17/8/1752" title="Burke P.J. et al. 2018. Glucuronide-linked antibody-tubulysin conjugates display activity in MDR+ and heterogeneous tumor models. Mol. Cancer Ther. 17, 1752-1760." target="_blank">Burke P.J. et al. 2018. Glucuronide-linked antibody-tubulysin conjugates display activity in MDR+ and heterogeneous tumor models. Mol. Cancer Ther. 17, 1752-1760.</a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/custom-services/protein-purification" title="Tubulin protein plus glycerol, Sheep Brain (&gt;99% pure) (Cat. # CS-T234S)" target="_blank">Tubulin protein plus glycerol, Sheep Brain (&gt;99% pure) (Cat. # CS-T234S)</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 17 Sep 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Misshapen Kinase Alters Actin Dynamics in the Regulation of Ring Canal Size and Stability]]></title>
      <link>https://www.cytoskeleton.com/blog/misshapen-kinase-alters-actin-dynamics-in-the-regulation-of-ring-canal-size-and-stability/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Immunofluorescence using Phosphotyrosine Antibody" src="https://www.cytoskeleton.com/media/wysiwyg/fig3.jpg" style="float: right;" title="Immunofluorescence using Phosphotyrosine Antibody" width="275" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<div><span style="font-size: xx-small; font-family: arial, helvetica, sans-serif; color: black;">Immunofluorescence using Phosphotyrosine Antibody:&nbsp;</span><span style="font-size: xx-small;">Human epidermoid carcinoma A431 cells, untreated (3A) or treated (3B) with EGF (100 ng/ml for 3 minutes), and NIH3T3, untreated (3C) or treated (3D) with H<sub>2</sub>O<sub>2</sub>-activated sodium orthovanadate (100 &micro;M for 10 minutes), were stained as described in the method. Phosphotyrosine and nuclei were visualized in green fluorescence and blue DAPI staining, respectively.</span> <!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="371">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
 </w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
</style>
<![endif]--></div>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Kline et al. recently studied regulation of intercellular bridges in Drosophila egg chambers. Known as ring canals, the bridges transfer cytoplasmic materials between neighboring cells; in this case, from nurse cells to the oocyte over the course of oogenesis. Ring canals are essential for maintaining an organism&rsquo;s fertility. Ring canal size and stability rely upon dynamic re-organization of F-actin. Here, the Ste20 family kinase misshapen (msn) has a novel role in regulating ring canal size and stability with changes in msn expression levels or localization altering the F-actin cytoskeleton. Phosphotyrosine (pTyr) signal in ring canals strongly overlaps with actin in control egg chambers. pTyr signal was used as a read-out to measure msn localization and activity in control vs msn-RNAi-treated egg chambers. In the latter, pTyr localized to nurse cell membranes and most ring canals. However, pTyr fluorescence in ring canals was variable, even within the same egg chamber, and did not overlap with actin signal. Hence, msn is not necessary for recruiting actin to the ring canal, but is essential for maintaining a ring canal&rsquo;s actin-based structure. Cytoskeleton&rsquo;s anti-phosphotyrosine antibody (<a href="https://www.cytoskeleton.com/phosphotyrosine-antibody" title="Phosphotyrosine Antibody Mouse Monoclonal 27B10" target="_blank">Cat.# APY03</a>; clone 11G2) was essential in the subcellular localization of pTyr signal in control and msn-depleted ring canals.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29753016" title="Kline A. et al. 2018. The misshapen kinase regulates the size and stability of the germline ring canals in the Drosophila egg chamber. Dev. Biol. 440, 99-112." target="_blank">Kline A. et al. 2018. The misshapen kinase regulates the size and stability of the germline ring canals in the Drosophila egg chamber. <em>Dev. Biol</em>. 440, 99-112.</a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/phosphotyrosine-antibody" title="Phosphotyrosine Antibody Mouse Monoclonal 27B10 (Cat. # APY03)" target="_blank">Phosphotyrosine Antibody Mouse Monoclonal 27B10 (Cat. # APY03)</a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Wed, 15 Aug 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[August Newsletter: Rab GTPases and Neurodegeneration]]></title>
      <link>https://www.cytoskeleton.com/blog/rab-gtpases-and-neurodegeneration/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/rab-gtpases-and-neurodegeneration" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Rabs-and-Neurodegeneration-August-2018-Newsletter-V2-Sm-Thumb.png" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/rab-gtpases-and-neurodegeneration" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p class="BasicParagraph" style="text-align: justify;">Rab GTPases, members of the Ras super-family of GTPases, express at least 60 isoforms in humans<sup>1</sup> with 24 enriched in, or specific for, the central nervous system (CNS)<sup>2</sup>. Rab GTPases are&nbsp; integral regulators of intracellular membrane trafficking, regulating the formation, maturation, transport, tethering, and fusion of vesicles in the endomembrane system<sup>3</sup>. In neurons, Rab-mediated membrane/vesicle trafficking is involved in virtually every aspect of neuron physiology, and dysfunction has been implicated in several neurodegenerative diseases<sup>2,4-7</sup> (Fig. 1). Indeed, dysfunctional membrane trafficking is an early marker of neurodegeneration<sup>5</sup>. Here, Rab-mediated trafficking defects in Parkinson&rsquo;s disease (PD) and Alzheimer&rsquo;s disease (AD) are reviewed.</p>
<p class="BasicParagraph" style="text-align: justify;">The cause of PD is primarily idiopathic &ndash; only a small fraction of PD cases are familial and attributable to mutations in proteins that also are involved in Rab activity and membrane trafficking. Mutant proteins include Rab39b, &alpha;-synuclein, PTEN-induced putative kinase (PINK1), and leucine-rich repeat kinase 2 (LRRK2)<sup>4,6,7</sup>. Rab39b is particularly interesting because loss-of-function mutations in this gene are directly linked to inherited early-onset PD with Lewy body pathology and also...</p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/rab-gtpases-and-neurodegeneration" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal-Seeker&trade; PTM Kits and Antibodies</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Mon, 06 Aug 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: RhoA Activation and Vascular Inflammation]]></title>
      <link>https://www.cytoskeleton.com/blog/rhoa-activity-underlies-tnf-stimulated-changes-in-neutrophil-morphology-motility-and-adhesion/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="         Actin cytoskeleton morphological changes induced by Rho/Rac/Cdc42 Activator I (Cat. # CN04) treatment of Swiss 3T3 cells.  Cells were fixed, stained with Acti-stain&trade; 488 phalloidin (Cat. # PHDG1), and visualized by fluorescence microscopy." src="https://www.cytoskeleton.com/media/wysiwyg/neutrophil.jpg" style="float: right;" title="         Actin cytoskeleton morphological changes induced by Rho/Rac/Cdc42 Activator I (Cat. # CN04) treatment of Swiss 3T3 cells.  Cells were fixed, stained with Acti-stain&trade; 488 phalloidin (Cat. # PHDG1), and visualized by fluorescence microscopy." width="215" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<div><span style="font-size: xx-small; font-family: arial, helvetica, sans-serif; color: black;"> Neutrophil, a class of leukocytes, with segmented nucleus and intracellular granules; 2D rendering.</span> <!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="371">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
 </w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
</style>
<![endif]--></div>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Activation of cytokine tumor necrosis factor (TNF)-mediated molecular pathways induces changes in the morphology, motility, and adhesion of neutrophils, a class of leukocytes, early in vascular inflammation and in related diseases, including atherosclerosis, sickle cell anemia, stroke, and sepsis. Neutrophils migrate to sites of inflammation where they adhere to the vascular endothelium. Alterations in a cell&rsquo;s shape, motile behavior, and/or adhesiveness, require dynamic re-organization of the actin cytoskeleton. Here, Silveira et al. report that actin polymerization was necessary for TNF&rsquo;s effects, which in turn, focused attention on GTPases such as RhoA, a well-known regulator of actin cytoskeletal dynamics and F-actin re-modeling. As might be expected, TNF increased RhoA activity in neutrophils, but through RhoA-mediated pathways independent of the downstream effector protein Rho kinase. Instead, mDia, a regulator of actin nucleation and member of the formin family of Rho effector proteins, was implicated. SMIFH2, a formin inhibitor, eliminated TNF-mediated increases in neutrophil morphological changes and adhesion. Cytoskeleton&rsquo;s RhoA G-LISA activation assay kit (<a href="https://www.cytoskeleton.com/bk124" title="RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)" target="_blank">Cat. # BK124</a>) was essential in quantifying RhoA activity in a sensitive and reliable manner. Deciphering the molecular pathways responsible for TNF-stimulated changes in neutrophil morphology, motility, and adhesion offers a therapeutic target for reducing leukocyte-regulated inflammatory responses.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814188/" title="Kim M.S. et al. 2018. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. 9, 5979-5992." target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"></span></a><a href="https://www.ncbi.nlm.nih.gov/pubmed/28798145" title="Silveira A.A.A. et al. 2018. TNF induces neutrophil adhesion via formin-dependent cytoskeletal reorganization and activation of beta-integrin function. J. Leukoc. Biol. 103, 87-98." target="_blank">Silveira A.A.A. et al. 2018. TNF induces neutrophil adhesion via formin-dependent cytoskeletal reorganization and activation of beta-integrin function. J. Leukoc. Biol. 103, 87-98.</a><a href="https://www.cytoskeleton.com/bk003" title="Actin Polymerization Biochem Kit (fluorescence format): rabbit skeletal muscle actin (Cat. # BK003)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"></span></a><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814188/" title="Kim M.S. et al. 2018. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. 9, 5979-5992." target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"></span></a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk124" title="RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)</span></a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 23 Jul 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[July Newsletter: SUMO Wrestling: All About Balance]]></title>
      <link>https://www.cytoskeleton.com/blog/sumo-wrestling-all-about-balance/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/sumo-wrestling-all-about-balance" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/July18LgThumb.png" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/sumo-wrestling-all-about-balance" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">In mammalian cells, the small ubiquitin-like modifier (SUMO) family contains four isoforms (SUMO1, SUMO2, SUMO3, and SUMO4). SUMO2 and SUMO3 are almost identical, with only a difference in three amino acid residues. SUMO1 shares 48% identity with SUMO2/3<sup>1</sup>. SUMO4 is about 85% identical to SUMO2/3, but it is unclear whether SUMO4 can be conjugated to substrates<sup>2</sup>. Similar to ubiquitination, SUMOylation requires a three enzymes system (E1, E2, and E3) to conjugate SUMO covalently to target substrates. Briefly, SUMO is first activated by the SUMO E1 activating heterodimeric enzyme SAE1/SAE2 by adenylation in an ATP-dependent reaction. The activated SUMO is then transferred to the SUMO E2 conjugating enzyme UBC9 and finally conjugated to a target protein by a SUMO E3 ligase (e.g., PIAS family members, Ran binding protein 2). The covalently linked SUMO can be removed by sentrin-specific proteases (SENPs), a process known as deSUMOylation<sup>3</sup> (Fig. 1). SUMOylation is an essential post-translational modification (PTM) that regulates the activity, subcellular localization, stability, and functions of target proteins and thereby modulates almost all major cellular pathways<sup>4</sup>. Therefore, it is not surprising that many diseases are associated with dysregulation of SUMOylation. In this newsletter, the roles of SUMOylation/deSUMOylation in cancer are discussed.</p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/sumo-wrestling-all-about-balance" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal-Seeker&trade; PTM Kits and Antibodies</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 10 Jul 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Identifying Potential PTM Crosstalk of Acetylated Mitochondrial Proteins]]></title>
      <link>https://www.cytoskeleton.com/blog/identifying-potential-ptm-crosstalk-of-acetylated-mitochondrial-proteins/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="margin-left: 15px; width: 231px; height: 0px;">
<tbody>
<tr>
<td style="text-align: justify;"><a href="https://www.cytoskeleton.com/paclitaxel-induces-post-translational-modifications-of-rhogdi-alpha-a-potential-mechanism" title="Click to View Poster"><img alt="Visualization of acetylated mitochondrial proteins in Swiss 3T3 cells. Acetylated mitochondrial-localized proteins were labeled with acetyl-lysine antibody (Cat. # AAC02) and alexa-488 secondary (green), or a fluorescent mitochondrial marker (mitotracker orange) shown in red." src="https://www.cytoskeleton.com/media/wysiwyg/Ac_and_mito_and_Dapi.jpg" title="Visualization of acetylated mitochondrial proteins in Swiss 3T3 cells. Acetylated mitochondrial-localized proteins were labeled with acetyl-lysine antibody (Cat. # AAC02) and alexa-488 secondary (green), or a fluorescent mitochondrial marker (mitotracker orange) shown in red." width="300" /></a></td>
</tr>
<tr>
<td style="text-align: justify;">
<p><span style="font-size: xx-small;">Visualization of acetylated mitochondrial proteins in Swiss 3T3 cells. Acetylated mitochondrial-localized proteins were labeled with acetyl-lysine antibody (Cat. # AAC02) and alexa-488 secondary (green), or a fluorescent mitochondrial marker (mitotracker orange) shown in red.</span></p>
</td>
</tr>
</tbody>
</table>
<p>Post-translational modification (PTM) crosstalk is recognized as a major cell-regulatory mechanism; a theory validated by in-depth, functional analysis of several well-investigated proteins. Recently, Horita et al. examined the PTM crosstalk that occurs in acetylated mitochondrial proteins in response to a mitochondrial stress-inducing agent, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). Visual changes in the acetylated state of mitochondrial proteins were investigated by immunofluorescence and showed dynamic changes in response to H<sub>2</sub>O<sub>2</sub>. These investigators validated the acetylation state of 10 mitochondrial targets and also measured endogenous changes to the acetylation state of these proteins using Signal-Seeker acetyl-lysine detection tools. The endogenous acetylation (Ac), ubiquitination (Ub), SUMOylation 2/3 (SUMO 2/3), and tyrosine phosphorylation (pY) state of four target mitochondrial proteins were investigated with these toolkits to examine if PTM crosstalk commonly occurs on mitochondrial proteins. Each of the four proteins had unique PTM profiles, but diverging acetylation and ubiquitin or SUMO 2/3 signals appeared to be a common theme. Cytoskeleton&rsquo;s pY, Ub, SUMO 2/3, and Ac Signal-Seeker PTM detection kits (Cat. # <a href="https://www.cytoskeleton.com/bk160" title="Signal-Seeker&trade; Phosphotyrosine Detection Kit (Cat. # BK160)" target="_blank">BK160</a>, <a href="https://www.cytoskeleton.com/bk161" title="Signal-Seeker&trade; Ubiquitination Detection Kit (Cat. # BK161)" target="_blank">BK161</a>, <a href="https://www.cytoskeleton.com/bk162" title="Signal-Seeker&trade; SUMOylation 2/3 Detection Kit (Cat. # BK162)" target="_blank">BK162</a>, and <a href="https://www.cytoskeleton.com/bk163" title="Signal-Seeker&trade; Acetyl-Lysine Detection Kit (Cat. # BK163)" target="_blank">BK163 </a>respectively) were essential tools used in this study to examine endogenous and dynamic PTM crosstalk.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/29786648" title="Horita H. et al. 2018. Utilizing Optimized Tools to Investigate PTM Crosstalk: Identifying Potential PTM Crosstalk of Acetylated Mitochondrial Proteins. Proteomes. Doi: 10.3390/proteomes6020024." target="_blank">Horita H. et al. 2018. Utilizing Optimized Tools to Investigate PTM Crosstalk: Identifying Potential PTM Crosstalk of Acetylated Mitochondrial Proteins. Proteomes. Doi: 10.3390/proteomes6020024.</a></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk160" title="Signal-Seeker&trade; Phosphotyrosine Detection Kit (30 assay) (Cat. # BK160)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Phosphotyrosine Detection Kit&nbsp;(Cat. # BK160)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk161" title="Signal-Seeker&trade; Ubiquitination Detection Kit (30 assay) (Cat. # BK161)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Ubiquitination Detection Kit&nbsp;<span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">(Cat. # </span>BK161)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk162" title="Signal-Seeker&trade; SUMOylation 2/3 Detection Kit (Cat. # BK162)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; SUMOylation 2/3 Detection Kit&nbsp;<span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">(Cat. # </span>BK162)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk163" title="Signal-Seeker&trade; Acetyl-Lysine Detection Kit (Cat. # BK163)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Acetyl-Lysine Detection Kit <span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">(Cat. # </span>BK163)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/BLR01" title="BlastR Rapid Lysate Prep Kit (Cat. # BLR01)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">BlastR Rapid Lysate Prep Kit (Cat. # </span>BLR01)</span></a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Mon, 18 Jun 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[June Newsletter: Why Does K-Ras Display Oncogenic Specificity?]]></title>
      <link>https://www.cytoskeleton.com/blog/why-does-k-ras-display-oncogenic-specificity/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/why-does-k-ras-display-oncogenic-specificity" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Oncogenic-specificity-of-K-Ras-June-2018-Newsletter-Thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/why-does-k-ras-display-oncogenic-specificity" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Ras GTPases regulate cell proliferation pathways, making them important molecules in oncogenesis and cancer cell migration and invasion. The four isoforms of Ras, H-Ras, N-Ras, K-Ras4A, and K-Ras4B (due to alternative splicing), were identified over 30 years ago for their oncogenic activation in human tumors. Activating Ras mutations are single amino acid substitutions (e.g., G12C, G12V, G12D) and have been identified in approximately 30% of all human cancers.</p>
<p style="text-align: justify;"><br />The same signaling pathways activate all Ras isoforms via guanine exchange factor (GEF)-mediated exchange of GDP for GTP, followed by binding to the same effector proteins. However, Ras oncogenic isoforms are differentially expressed aacross different cancers with oncogenic specificity significantly favoring K-Ras,. Indeed, K-Ras is the most common mutated Ras isoform (86% of all Ras mutations) and is correlated with over 21% of human cancers. In particular, K-Ras is the predominant or exclusive Ras gene mutated in three of the top four cancers with the highest mortality rates in the US: lung, colon, and pancreatic cancers. In most instances, the K-Ras4B is the primary isoform mutated in K-Ras-associated cancers. This newsletter discusses potential explanations for the biological basis of K-Ras&rsquo;s oncogenic specificity.</p>
<p></p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/why-does-k-ras-display-oncogenic-specificity" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Ras and GEF Proteins, Kits, and more</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 05 Jun 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Regulating RhoA Activity by Modulating RhoGDI Alpha Post-Translational Modifications]]></title>
      <link>https://www.cytoskeleton.com/blog/regulating-rhoa-activity-by-modulating-rhogdialpha-post-translational-modifications/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="margin-left: 15px; width: 231px; height: 0px;">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/paclitaxel-induces-post-translational-modifications-of-rhogdi-alpha-a-potential-mechanism" title="Click to View Poster"><img alt="Schematic of paclitaxel induced post-translational modifications of RhoGDI" src="https://www.cytoskeleton.com/media/wysiwyg/rhogdi-postersmall.jpg" style="float: right;" title="Schematic of paclitaxel induced post-translational modifications of RhoGDI" width="300" /></a></td>
</tr>
<tr>
<td style="text-align: center;"><a href="https://www.cytoskeleton.com/paclitaxel-induces-post-translational-modifications-of-rhogdi-alpha-a-potential-mechanism" title="Paclitaxel induces post-translational modifications of RhoGDI alpha: a potential mechanism to regulate RhoA activity" target="_blank">Click to View Poster</a></td>
</tr>
</tbody>
</table>
<p>Scientists at Cytoskeleton Inc. recently investigated post-translational modifications (PTMs) that regulate the Rho GTPase family of proteins. Here, the authors characterized the functional regulation of RhoGDI&alpha; by SUMOylation 2/3 (SUMO 2/3) and acetyl-lysine PTMs. These studies led to the identification of endogenous SUMO 2/3 and acetylation (Ac) modifications of RhoGDI&alpha;. Interestingly, the microtubule stabilizer paclitaxel induced both Ac and SUMO 2/3 of RhoGDIa in a time-dependent fashion.&nbsp; These changes in the PTM state of RhoGDI&alpha; altered the protein&rsquo;s ability to inhibit RhoA activity. Experiments performed with the HDAC inhibitor, TSA, provided evidence of crosstalk between RhoGDIa SUMO 2/3 and Ac in a cell-type dependent fashion and further support the hypothesis that these PTMs may alter RhoGDIa&rsquo;s function. Cytoskeleton's SUMO 2/3, and Ac Signal-Seeker&trade; PTM detection kits (Cat. # <a href="http://r20.rs6.net/tn.jsp?t=wmpufb8ab.0.0.lz7cl9dab.0&amp;id=preview&amp;r=3&amp;p=http%3A%2F%2Fwww.cytoskeleton.com%2Fbk162" target="_blank">BK162</a>, and <a href="http://r20.rs6.net/tn.jsp?t=wmpufb8ab.0.0.lz7cl9dab.0&amp;id=preview&amp;r=3&amp;p=http%3A%2F%2Fwww.cytoskeleton.com%2Fbk163" target="_blank">BK163</a>, respectively) were essential reagents in this study, providing a novel toolset for simple and effective investigation of established and novel PTMs for any target protein.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="padding-left: 30px;">
<p class="Pa1"><a href="https://www.cytoskeleton.com/paclitaxel-induces-post-translational-modifications-of-rhogdi-alpha-a-potential-mechanism" title="Horita H et al. Paclitaxel induces post-translational modifications of RhoGDI alpha: a potential mechanism to regulate RhoA activity. Mol. Biol. Cell. ASCB Annual Meeting 2017, Poster B624." target="_blank">Horita H et al. Paclitaxel induces post-translational modifications of RhoGDI alpha: a potential mechanism to regulate RhoA activity. Mol. Biol. Cell. ASCB Annual Meeting 2017, Poster B624.</a></p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk160" title="Signal-Seeker&trade; Phosphotyrosine Detection Kit (30 assay) (Cat. # BK160)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Phosphotyrosine Detection Kit&nbsp;(Cat. # BK160)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk161" title="Signal-Seeker&trade; Ubiquitination Detection Kit (30 assay) (Cat. # BK161)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Ubiquitination Detection Kit&nbsp;<span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">(Cat. # </span>BK161)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk162" title="Signal-Seeker&trade; SUMOylation 2/3 Detection Kit (Cat. # BK162)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; SUMOylation 2/3 Detection Kit&nbsp;<span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">(Cat. # </span>BK162)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk163" title="Signal-Seeker&trade; Acetyl-Lysine Detection Kit (Cat. # BK163)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Acetyl-Lysine Detection Kit <span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">(Cat. # </span>BK163)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/BLR01" title="BlastR Rapid Lysate Prep Kit (Cat. # BLR01)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">BlastR Rapid Lysate Prep Kit (Cat. # </span>BLR01)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/txd01" title="Paclitaxel (Taxol) (Cat. # TXD01)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Paclitaxel (Taxol) (Cat. # </span>TXD01)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/phdg1" title="Acti-stain&trade; 488 phalloidin (Cat. # PHDG1)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Acti-stain<sup>&trade;</sup> 488 phalloidin (Cat. # </span>PHDG1)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk124" title="RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)</span></a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]-->]]></description>
      <pubDate>Tue, 15 May 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[May Newsletter: Ubiquitin-Proteasome System as a Therapeutic Target: Does Tubulin Care?]]></title>
      <link>https://www.cytoskeleton.com/blog/ubiquitin-proteasome-system-as-a-therapeutic-target-does-tubulin-care/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/ubiquitin-proteasome-system-as-a-therapeutic-target-does-tubulin-care" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/UPS-and-Tubulin-May-2018-Newsletter-V2.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/ubiquitin-proteasome-system-as-a-therapeutic-target-does-tubulin-care" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The ubiquitin-proteasome system (UPS) is a well-characterized protein degradation system in cells whose dysfunction is implicated in many diseases, including neurodegeneration and cancer. Major UPS components are ubiquitin (Ub), Ub ligases, Ub hydrolases (deubiquitinases [DUBs]), and the proteasome. Activation of the UPS begins with attachment of an 8 kDa ubiquitin protein to a target protein by a three step cascade carried out by Ub ligases. Ub itself can be ubiquitinated, leading to poly-ubiquitination, a marker for proteasomal recognition and ultimately degradation (Fig. 1). This is an oversimplification as there are several unique Ub specific chains, as well as mono-ubiquitination, that can regulate multiple facets of a protein&rsquo;s function. Due to the prevalence of UPS dysfunction in disease and an increased molecular understanding of how ubiquitination degrades protein, interest in targeting the UPS for therapeutic intervention has grown substantially.</p>
<p style="text-align: justify;">Given the proteasome&rsquo;s role in regulated degradation of poly-ubiquitinated proteins and its dysfunction in cancer, researchers posited that inhibition of the proteasome may be effective for treating cancer cachexia (wasting syndrome). This hypothesis spurred the development of early proteasome inhibitors like MG-132. MG-132&rsquo;s pharmacological properties precluded its use clinically; however, it launched the...</p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/ubiquitin-proteasome-system-as-a-therapeutic-target-does-tubulin-care" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal Seeker<sup>&trade;</sup> Kits, Beads, and Antibodies, Spirochrome<sup>&trade;</sup> Live Cell Imaging Probes, Tubulin Kits and more</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Mon, 30 Apr 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Anti-Psychotic Drug Aripiprazole Inhibits Cancer Cells via Src Inhibition]]></title>
      <link>https://www.cytoskeleton.com/blog/anti-psychotic-drug-aripiprazole-inhibits-cancer-cells-via-src-inhibition/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="         Actin cytoskeleton morphological changes induced by Rho/Rac/Cdc42 Activator I (Cat. # CN04) treatment of Swiss 3T3 cells.  Cells were fixed, stained with Acti-stain&trade; 488 phalloidin (Cat. # PHDG1), and visualized by fluorescence microscopy." src="https://www.cytoskeleton.com/media/wysiwyg/G-Switch_Rho_Stress_Fibers_3T3_with_CN03.jpg" style="float: right;" title="         Actin cytoskeleton morphological changes induced by Rho/Rac/Cdc42 Activator I (Cat. # CN04) treatment of Swiss 3T3 cells.  Cells were fixed, stained with Acti-stain&trade; 488 phalloidin (Cat. # PHDG1), and visualized by fluorescence microscopy." width="215" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<div><span style="font-size: x-small;">Actin cytoskeleton morphological changes induced by Rho/Rac/Cdc42 Activator I (<a href="http://www.cytoskeleton.com/cn04" title="Cat. # CN04" target="_blank">Cat. # CN04</a>) treatment of Swiss 3T3 cells.&nbsp; Cells were fixed, stained with Acti-stain&trade; 488 phalloidin (<a href="http://www.cytoskeleton.com/cn04" title="Cat. # CN04" target="_blank">Cat. # PHDG1</a>), and visualized by fluorescence microscopy.</span></div>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Kim et al. recently evaluated the potential anti-tumor effects of aripiprazole (ARP), an atypical anti-psychotic used to treat neuropsychiatric disorders. In the search for novel anti-cancer therapeutics, the authors examined if ARP affects the viability and migration of various cancer cell lines (e.g., U251 glioma cells, MDA-MB-231, HEK293) by a variety of in vitro and in vivo experiments. ARP inhibited cancer cell growth, survival, and motility by inducing apoptosis. Next, possible molecular targets of ARP were explored. Many anti-cancer compounds target the oncogenic tyrosine kinase Src as it is important for cancer cell survival, proliferation, migration, and invasion. ARP inhibited phosphorylation of Src, its auto-phosphorylation activity, and Src&rsquo;s kinase activity. To decipher how ARP affects Src, ARP&rsquo;s effects on actin polymerization were examined as re-arrangement of the actin cytoskeleton activates Src. In conjunction with phalloidin staining images, the polymerization data demonstrated that the actin cytoskeletal dynamics were not molecular targets of ARP-mediated cancer cell apoptosis. Cytoskeleton&rsquo;s actin polymerization assay kit (Cat.# <a href="http://www.cytoskeleton.com/bk003" title="Cat. # BK003" target="_blank">BK003</a>) was essential in demonstrating that ARP does not carry out its Src-mediated anti-tumor effects through an interaction with actin and regulation of actin dynamics, thus eliminating one molecular substrate in the search for ARP&rsquo;s mechanism of anti-cancer actions.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814188/" title="Kim M.S. et al. 2018. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. 9, 5979-5992." target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"></span></a><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814188/" title="Kim M.S. et al. 2018. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. 9, 5979-5992." target="_blank">Kim M.S. et al. 2018. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. 9, 5979-5992.</a><a href="https://www.cytoskeleton.com/bk003" title="Actin Polymerization Biochem Kit (fluorescence format): rabbit skeletal muscle actin (Cat. # BK003)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"></span></a><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814188/" title="Kim M.S. et al. 2018. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. 9, 5979-5992." target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"></span></a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk003" title="Actin Polymerization Biochem Kit (fluorescence format): rabbit skeletal muscle actin (Cat. # BK003)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Actin Polymerization Biochem Kit (fluorescence format): rabbit skeletal muscle actin (Cat. # BK003)</span></a></p>
<!--[if gte mso 9]><xml>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="371">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
 </w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:10.0pt;
	mso-para-margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->]]></description>
      <pubDate>Tue, 10 Apr 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[April Newsletter: Rho Family GEFs and Dendritic Spine Structural Plasticity]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-family-gefs-and-dendritic-spine-structural-plasticity/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/april-newsletter-rho-family-gefs-and-dendritic-spine-structural-plasticity" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Rho-GEFs-and-spine-plasticity-April-2018-Newsletter-200px.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/april-newsletter-rho-family-gefs-and-dendritic-spine-structural-plasticity" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Dendritic spines are the post-synaptic component of most excitatory glutamatergic synapses and primary site of synaptic structural plasticity for modulating synaptic function. Activity-dependent structural plasticity in spines (i.e., spine morphogenesis) depends upon dynamic re-organization of F-actin, the primary structural component of spines. Spine morphogenesis is important for normal learning and memory and the development of neurodegenerative diseases and neurological disorders.</p>
<p style="text-align: justify;">The RhoA, Rac1, and Cdc42 GTPases regulate spine morphogenesis; RhoA inhibits spine growth and stability, whereas Rac1 and Cdc42 exert the opposite effect. In reality, Rho family regulation of spine structural plasticity is much more complex. Precise spatiotemporal regulation of Rho GTPases is with guanine exchange factors (GEFs) triggering&nbsp; GTP/GDP exchange and GTPase activating proteins (GAPs) stimulating intrinsic GTPase activity. At least eight Rho family GEFs regulate spine morphogenesis and these GEFs are activated through a variety of receptor signaling pathways, including glutamatergic NMDA receptors (NMDARs) and receptor tyrosine kinases (RTKs). NMDARs mediate calcium influx and subsequent activation of calcium/calmodulin-dependent kinases (CaMKs), which phosphorylate Rho family GEFs, essential for GEF activity. In this newsletter, the regulation of spine structural plasticity by the Rho family GEFs Kalirin7 (Kal7; the most abundant isoform in adult brain), Trio-9 (the most abundant isoform in hippocampus), Tiam1, RasGRF2, DOCK10, DOCK180, ephrexin1, and ephrexin5 is discussed.</p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/april-newsletter-rho-family-gefs-and-dendritic-spine-structural-plasticity" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>GEF Proteins, Exhange Assays, Spirochrome Live Cell Imaging Probes, and more</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 03 Apr 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[March Newsletter: Post-translational Modifications of β-catenin and TCF/LEF-1 Regulate Canonical Wnt Signaling]]></title>
      <link>https://www.cytoskeleton.com/blog/post-translational-modifications-of-beta-catenin-and-tcflef-1-regulate-canonical-wnt-signaling/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/post-translational-modifications-of-beta-catenin-and-tfc-lef-1-regulate-canonical-wnt-signaling" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Beta-catenin-and-PTMs-March-2018-Newsletter-V2-thumb_1.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/post-translational-modifications-of-beta-catenin-and-tfc-lef-1-regulate-canonical-wnt-signaling" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Protein post-translational modifications (PTMs) such as phosphorylation, acetylation, ubiquitination, and SUMOylation, to name but a few, have evolved to diversify the functions of a single protein and account for the vast increase in proteome complexity and functional diversity. A prime example of the complex and dynamic regulatory power PTMs confer is the Wnt/&beta;-catenin signaling pathway. This pathway regulates cellular proliferation, differentiation, and migration during embryonic development and adult cell homeostasis. In addition, dysregulation of Wnt/&beta;-catenin signaling is implicated in multiple pathological conditions, including carcinogenesis and degenerative diseases. In canonical Wnt-mediated signaling, &beta;-catenin is a key effector and interacts, as a co-transcription factor, with the DNA binding proteins TCF (T cell factor) and LEF-1 (lymphoid enhancer factor 1) to activate the transcription of Wnt/&beta;-catenin target genes including cyclin D1, c-jun, and c-myc. In this newsletter, the functional regulation of &beta;-catenin and TCF/LEF-1 by PTMs is discussed.</p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/post-translational-modifications-of-beta-catenin-and-tfc-lef-1-regulate-canonical-wnt-signaling" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal-Seeker&trade; Kits, Antibodies, Beads, and more</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 13 Mar 2018 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Actin Bundling Protein EFhd2 Mediates LPS-Induced Macrophage Migration]]></title>
      <link>https://www.cytoskeleton.com/blog/actin-bundling-protein-efhd2-mediates-lps-induced-macrophage-migration/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Protocol video highlighting key steps and tools used in this comprehensive enrichment system." src="https://www.cytoskeleton.com/media/wysiwyg/actin/F-actin-complexs-v1.gif" style="float: right;" title="Protocol video highlighting key steps and tools used in this comprehensive enrichment system." width="215" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div align="justify" style="text-align: justify;">
<div>
<div>
<div><span style="font-size: xx-small;">Nucleation of actin filaments (F-actin) mediated by a complex consisting of the actin nucleation factors Arp2, Arp3, and WASP (VCA domain).</span></div>
</div>
</div>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Tu et al. recently characterized the functional relationship between the novel actin bundling protein EFhd2 and actin during lipopolysaccharide (LPS)-induced macrophage migration, an important component of innate immune responses. The authors found that LPS-mediated macrophage migration depends upon EFhd2 and its regulation of actin polymerization and subsequent re-organization of the actin cytoskeleton. EFhd2 and F-actin co-localization in macrophages is essential for LPS&rsquo;s actions and coincides with a LPS-induced increase in the ratio of F-actin to G-actin in these cells, an effect prevented by knock-out of EFhd2. Under cell-free conditions, EFhd2 increases actin polymerization in a concentration-dependent manner and to a magnitude similar to that induced by the nucleation factors Arp2/3 + VCA domain of the Wiskott-Aldrich syndrome protein (WASP). This suggests that EFhd2&rsquo;s effects are through a direct regulation of the actin cytoskeleton. Cytoskeleton&rsquo;s actin polymerization assay kit, G-actin/F-actin in vivo assay kit, Acti-stain 555 phalloidin, Arp2/3 protein complex, and VCA domain of WASP (Cat. # <a href="http://www.cytoskeleton.com/bk003" title="Cat. # BK003" target="_blank">BK003</a>, <a href="http://www.cytoskeleton.com/bk037" title="Cat. # BK037" target="_blank">BK037</a>, <a href="http://www.cytoskeleton.com/phdh1" title="Cat. # PHDH1" target="_blank">PHDH1</a>, <a href="http://www.cytoskeleton.com/rp01p" title="Cat. # RP01P">RP01P</a>, and <a href="http://www.cytoskeleton.com/vcg03" title="Cat. # VCG03" target="_blank">VCG03</a>, respectively) were essential reagents in this characterization study. These kits and reagents provided the tools necessary to examine how EFhd2 and its regulation of actin polymerization and cytoskeletal dynamics participate in LPS-induced macrophage motility.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial,Helvetica,sans-serif; padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29288926" title="Tu Y. et al. 2018. EFhd2/swiprosin-1 regulates LPS-induced macrophage recruitment via enhancing actin polymerization and cell migration. Int. Immunopharmacol. 55, 263-271." target="_blank">Tu Y. et al. 2018. EFhd2/swiprosin-1 regulates LPS-induced macrophage recruitment via enhancing actin polymerization and cell migration. Int. Immunopharmacol. 55, 263-271.</a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk003" title="Actin Polymerization Biochem Kit (fluorescence format): rabbit skeletal muscle actin (Cat. # BK003)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Actin Polymerization Biochem Kit (fluorescence format): rabbit skeletal muscle actin (Cat. # BK003)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk037" title="G-Actin/F-actin In Vivo Assay Biochem Kit (Cat. # BK037)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">G-Actin/F-actin In Vivo Assay Biochem Kit (Cat. # </span>BK037)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/phdh1" title="Acti-stain 555 phalloidin (Cat. # PHDH1)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Acti-stain 555 phalloidin (Cat. # </span>PHDH1)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/rp01p" title="Arp2/3 protein complex: porcine brain (Cat. # RP01P)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Arp2/3 protein complex: porcine brain (Cat. # </span>RP01P)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/vcg03" title="WASP protein VCA domain: GST tagged: human (Cat. # VCG03)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">WASP protein VCA domain: GST tagged: human (Cat. # </span>VCG03)</span></a></p>]]></description>
      <pubDate>Tue, 06 Mar 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[February Newsletter: Post-translational Modifications Modulate p53 Tumor Suppressor Functions]]></title>
      <link>https://www.cytoskeleton.com/blog/post-translational-modifications-modulate-p53-tumor-suppressor-functions/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/post-translational-modifications-modulate-p53-tumor-suppressor-functions" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/newsletter-thumblg.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/post-translational-modifications-modulate-p53-tumor-suppressor-functions" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The multi-domain, tetrameric p53 protein was discovered in 1979<sup>1-3</sup>, first mistakenly described as an oncogene, before its true function as a powerful tumor suppressor was realized<sup>4,5</sup>. p53 consists of two N-terminal transactivation domains (TAD1 and TAD2), a proline-rich domain (P-rich), a sequence-specific DNA binding domain (DBD), a linker domain, tetramerization domain (TD), and a lysine-rich, basic C-terminal regulatory (REG) domain<sup>5</sup> (Fig. 1). As a transcription factor, p53 can regulate the expression of up to 3000 genes&nbsp; involved in apoptosis, senescence, cell cycle arrest, DNA repair, apoptosis, tumor microenvironment, autophagy, and invasion/metastasis<sup>6-8</sup>. p53 functionality is spatiotemporally regulated by up to fifty post-translational modifications (PTMs)that occur within multiple domains<sup>9-12</sup> (Fig. 1). Here, regulation of p53 by ubiquitination, phosphorylation, and acetylation is discussed.</p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/post-translational-modifications-modulate-p53-tumor-suppressor-functions" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal-Seeker&trade; Kits, Antibodies, Beads, and more</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 20 Feb 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Tools and Protocols for Successful PTM Investigation for Target Proteins]]></title>
      <link>https://www.cytoskeleton.com/blog/tools-and-protocols-for-successful-ptm-investigation-for-target-proteins/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><a href="https://www.jove.com/video/56912/utilizing-comprehensive-immunoprecipitation-enrichment-system-to" title="Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins" target="_blank"><img alt="Protocol video highlighting key steps and tools used in this comprehensive enrichment system." src="https://www.cytoskeleton.com/media/wysiwyg/Image_for_JoVE_Citation_Highlight.png" style="float: right;" title="Protocol video highlighting key steps and tools used in this comprehensive enrichment system." width="215" /></a></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<p><a href="https://www.jove.com/video/56912/utilizing-comprehensive-immunoprecipitation-enrichment-system-to" title="Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins" target="_blank">Protocol video highlighting key steps and tools used in this comprehensive enrichment system.</a></p>
</div>
</td>
</tr>
</tbody>
</table>
<p>The use of peer-reviewed, video articles to report technical methodology are an expanding resource that has great benefits compared to text formats, such as providing intricate details that are not effectively captured in written manuscripts. Recently, Horita et al. employed this format to describe a methodology for investigating post-translational modification (PTM) crosstalk.</p>
<ul>
<li>Step-by-step instructions to detect acetylation, ubiquitination, SUMOylation 2/3, and tyrosine phosphorylation in a single lysate.</li>
<li>Highlights critical components/steps such as a lysate filter system that effectively removes, rather than shears, contaminating genomic DNA.&nbsp;</li>
<li>Developed for use with the Signal-Seeker&trade; PTM detection kits that are effective tools for examining dynamic and endogenous levels of several different PTMs.&nbsp;</li>
</ul>
<p>As investigators move forward with PTM research and investigate a specific PTM&rsquo;s physiologic role, it will be paramount to have effective tools and methodology, like those described in this study, to measure endogenous levels of a PTM for a target protein.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial,Helvetica,sans-serif; padding-left: 30px;"><a href="https://www.jove.com/video/56912/utilizing-comprehensive-immunoprecipitation-enrichment-system-to" title="Horita, H., Law, A., Middleton, K. Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins. J. Vis. Exp. (131), e56912, doi:10.3791/56912 (2018)." target="_blank">Horita, H., Law, A., Middleton, K. Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins. J. Vis. Exp. (131), e56912, doi:10.3791/56912 (2018). </a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><a href="https://www.cytoskeleton.com/bk160" title="Signal-Seeker&trade; Phosphotyrosine Detection Kit (30 assay) (Cat. # BK160)" target="_blank">Signal-Seeker&trade; Phosphotyrosine Detection Kit (30 assay) (Cat. # BK160)</a><br /></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk161" title="Signal-Seeker&trade; Ubiquitination Detection Kit (30 assay) (Cat. # BK161)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Ubiquitination Detection Kit (30 assay) (Cat. # </span>BK161)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk162" title="Signal-Seeker&trade; SUMOylation 2/3 Detection Kit (30 assay) (Cat. # BK162)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; SUMOylation 2/3 Detection Kit (30 assay) (Cat. # </span>BK162)</span></a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk163" title="Signal-Seeker&trade; Acetyl-Lysine Detection Kit (30 assay) (Cat. # BK163)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">Signal-Seeker&trade; Acetyl-Lysine Detection Kit (30 assay) (Cat. # </span>BK163)</span></a></p>
<p style="padding-left: 30px;"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><a href="https://www.cytoskeleton.com/signal-seeker/blastr-filtration-system/blr01" title="BlastR Rapid Lysate Prep Kit (Cat. # BLR01)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">BlastR Rapid Lysate Prep Kit (Cat. #</span> BLR01)</a><br /></span></p>
<p style="padding-left: 30px;"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><a href="https://www.cytoskeleton.com/signal-seeker/blastr-filtration-system/blr02" title="BlastR Rapid Filtration Kit (Cat. # BLR02)" target="_blank"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays">BlastR Rapid Filtration Kit (Cat. #</span> BLR02)</a><br /></span></p>
<p></p>]]></description>
      <pubDate>Wed, 07 Feb 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[New 2018 Cytoskeleton Minicatalog]]></title>
      <link>https://www.cytoskeleton.com/blog/introducing-the-2018-cytoskeleton-minicatalog/</link>
      <description><![CDATA[<table align="center" border="0" style="width: 100%;">
<tbody>
<tr>
<td>
<table align="right" border="0" style="width: 200px;">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/pdf-storage/Cytoskeleton%20Mini-Catalog%202016%20web.pdf" title="Click here to download" target="_blank"><img alt="2018 Cytoskeleton Minicatalog Cover" src="https://www.cytoskeleton.com/media/wysiwyg/CoverJPG.jpg" title="2018 Cytoskeleton Minicatalog Cover" width="200" /></a></td>
</tr>
<tr>
<td style="text-align: center;"><a href="http://www.cytoskeleton.com/pdf-storage/Cytoskeleton%20Mini-Catalog%202016%20web.pdf" title="Click to Download" target="_blank"><span style="font-size: medium;">Click Here to View</span></a></td>
</tr>
</tbody>
</table>
<h1 style="text-align: center;"><span style="color: #000000; font-size: large;">New Products, New Discoveries!</span></h1>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a href="https://www.cytoskeleton.com/signal-seeker" title="New Comprehensive Kits!" target="_blank"><span style="font-size: large;">Signal-Seeker&trade; Kits</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">New comprehensive kits!<br /></span></p>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a href="https://www.cytoskeleton.com/signal-seeker/signal-seeker-ptmtrue-antibodies" title="Acetyl-Lysine, Ubiquitin, and SUMO2/3 antibodies." target="_blank"><span style="font-size: large;">Signal-Seeker&trade; Antibodies</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">Acetyl-Lysine, Ubiquitin, and SUMO2/3!<br /></span></p>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a href="https://www.cytoskeleton.com/custom-services/protein-purification" title="New GEF Proteins" target="_blank"><span style="font-size: large;">GEF and K-Ras Proteins</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">Reliable, pure, active GEF proteins!<br /></span></p>
</td>
</tr>
</tbody>
</table>]]></description>
      <pubDate>Wed, 31 Jan 2018 10:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[January Newsletter: The GEF Trio and Its Role in Autism Spectrum Disorders]]></title>
      <link>https://www.cytoskeleton.com/blog/the-gef-trio-and-its-role-in-autism-spectrum-disorders/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="https://www.cytoskeleton.com/the-gef-trio-and-its-role-in-autism-spectrum-disorders" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Jan-2018-Newsletter-p1-thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="https://www.cytoskeleton.com/the-gef-trio-and-its-role-in-autism-spectrum-disorders" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Intellectual disabilities (e.g., neurodevelopmental disorders, autism spectrum disorders [ASDs]) are associated with abnormal development of dendrites and dendritic spines. ASDs are a complex set of behaviorally defined disorders, characterized by impairments in social interaction, communication, and restricted or stereotyped behaviors. Recent studies estimate that 1% of the world-wide population has an ASD<sup>1</sup>. Dendritic spines are comprised of F-actin and the structural and functional plasticity of spines depend upon the dynamic regulation of actin by Rho-family GTPases. Indeed, Rac and PAK effector proteins are essential regulators of normal brain development and function, including dendritic spine initiation, elongation, and branching<sup>2-4</sup>. Recent genetic studies revealed that individuals with intellectual disabilities express mutated versions of genes involved in Rho-family GTPase signaling such as a Rho-family GTPase activating protein (GAP), the serine/threonine kinase PAK3, and the Rac/Cdc42 guanine exchange factor (GEF) aPIX5. In addition, the PAK inhibitor FRAX486 is an effective treatment for fragile X syndrome (FXS), the most common inherited form of autism and cognitive disability. FRAX486 reversed dendritic spine and behavioral abnormalities in an in vivo model of FXS<sup>6</sup>. Moreover, Rac1 activation or inhibition of cofilin, an actin depolymerizing protein, rescues ASD-like phenotypes in Shank3 knock-out mice, an in vivo model of ASDs<sup>7-12</sup>.</p>
<p style="text-align: justify;"><a href="https://www.cytoskeleton.com/the-gef-trio-and-its-role-in-autism-spectrum-disorders" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>GTPase Assay Kits, Spirochrome&trade; Live Cell Imaging Probes, GEF Proteins, and more</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 16 Jan 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Acetylated Microtubule Bundling, MAP Binding, and Functional Regulation of Kinesin-1]]></title>
      <link>https://www.cytoskeleton.com/blog/acetylated-microtubule-bundling-map-binding-and-functional-regulation-of-kinesin-1/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="Figure 1: Schematic representation of the entry points into the MT lumen. Showing, from left to right, a frayed/growing MT plus end capturing TAT and tau molecules, treadmilling, 2 nm2 pores, a 200 nm2 open MT plus end, and a breathing MT lattice." src="https://www.cytoskeleton.com/media/wysiwyg/Figure_1_v3.png" style="float: right;" title="Figure 1: Schematic representation of the entry points into the MT lumen. Showing, from left to right, a frayed/growing MT plus end capturing TAT and tau molecules, treadmilling, 2 nm2 pores, a 200 nm2 open MT plus end, and a breathing MT lattice." width="215" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">Figure 1: Schematic representation of the entry points into the MT lumen. Showing, from left to right, a frayed/growing MT plus end capturing TAT and tau molecules, treadmilling, 2 nm<sup>2</sup> pores, a 200 nm<sup>2</sup> open MT plus end, and a breathing MT lattice.</div>
</td>
</tr>
</tbody>
</table>
<p>Balabanian et al. recently investigated the functional regulation of kinesin-1 motility using intact microtubules (MTs) in the form of either a single filament or bundles that were isolated from living COS-7 cells. Post-translational modifications (PTMs), MT bundling, and binding of microtubule-associated proteins (MAPs) are influential modulators of MT stability and motor protein activity. Here, the authors investigated the effects of the acetylation PTM, MT bundling, and binding of the MAP tau on kinesin-1 motility. Cytoskeleton&rsquo;s SiR-tubulin live cell imaging probe and paclitaxel (Cat. # <a href="https://www.cytoskeleton.com/sir-tubulin" title="SiR-Tubulin Kit" target="_blank">CY-SC002</a> and <a href="https://www.cytoskeleton.com/txd01" title="Paclitaxel (Taxol)" target="_blank">TXD01</a>, respectively) were essential reagents in this kinesin-1 motility study, providing the tools necessary to examine the MT network in living cells and then confirm that it was maintained upon detergent extraction and isolation, followed by the necessary paclitaxel stabilization. The <em>in vitro</em> paclitaxel-stabilized, isolated MT single filaments and bundles faithfully recapitulated important structural attributes of an intact MT network in living cells. This <em>in vitro</em> model enabled the study of how kinesin-1 is functionally regulated by MT architecture, MAP binding, and PTMs such as acetylation. In sum, this model system provides a greater understanding of the physiological regulation of kinesin motors and kinesin-regulated transport of cargoes along MTs.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial,Helvetica,sans-serif; padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28978447" title="Balabanian L. et al. 2017. Acetylated microtubules are preferentially bundled leading to enhanced kinesin-1 motility. Biophys. J. 113, 1551-1560. " target="_blank">Balabanian L. et al. 2017. Acetylated microtubules are preferentially bundled leading to enhanced kinesin-1 motility. Biophys. J. 113, 1551-1560. </a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/sir-tubulin" title="Spirochrome SiR-Tubulin Kit (Cat. # CY-SC002)" target="_blank">Spirochrome SiR-Tubulin Kit (Cat. # CY-SC002)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/txd01" title="Paclitaxel (Taxol) (Cat. # TXD01)" target="_blank">Paclitaxel (Taxol) (Cat. # TXD01)</a></p>
<p></p>]]></description>
      <pubDate>Wed, 03 Jan 2018 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Anti-cancer Therapeutic Buparlisib: Mitosis or PI3K Inhibitor?]]></title>
      <link>https://www.cytoskeleton.com/blog/anti-cancer-therapeutic-buparlisib-mitosis-or-pi3k-inhibitor/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img alt="5M7E Tubulin-BKM120 complex" height="263" src="https://www.cytoskeleton.com/media/wysiwyg/5M7E_screenshotLABELED.png" style="float: right;" title="5M7E Tubulin-BKM120 complex" width="215" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;">
<div><span style="font-size: xx-small;">Alpha/beta tubulin heterodimer in complex with tubulin tyrosine ligase, stathmin-4, and the small molecule compound BKM120 (Buparlisib).</span></div>
</div>
</td>
</tr>
</tbody>
</table>
<p>Bohnacker et al. recently investigated the primary site of action of the anti-cancer therapeutic BKM120 (a.k.a., Buparlisib), a clinically-advanced phosphoinositide 3-kinase (PI3K) inhibitor. Although PI3K inhibition is considered the primary mechanism of action, some studies report that BKM120 exerts potent off-target effects on tubulin, which raises questions about its substrate. Here, the authors aimed to decipher BKM120&rsquo;s molecular interactions with tubulin and PI3K to identify its anti-tumorigenic site of action. The authors reported that BKM120&rsquo;s anti-cancer activity is through mitotic arrest via microtubule destabilization, rather than PI3K inhibition. Chemical derivatives of BK120 were synthesized and examined to separate targeting of PI3K versus tubulin in pursuit of a more potent and selective PI3K inhibitor. The BKM120-derived molecule, PQR309, strongly inhibited PI3K with no detectable effect on tubulin polymerization and/or microtubule stability. Cytoskeleton&rsquo;s 99% pure porcine brain tubulin, tubulin polymerization assay kit, biotinylated porcine brain tubulin, and TRITC rhodamine-labeled tubulin (Cat.# <a href="https://www.cytoskeleton.com/t240" title="Tubulin protein (&gt;99% pure): porcine brain Cat. # T240" target="_blank">T240</a>, <a href="https://www.cytoskeleton.com/bk006p" title="Tubulin polymerization assay using &gt;99% pure tubulin, OD based - Porcine BK006P" target="_blank">BK006P</a>, <a href="https://www.cytoskeleton.com/t333p" title="Tubulin protein (biotin): porcine brain T333P" target="_blank">T333P</a>, and <a href="https://www.cytoskeleton.com/tl590m" title="Tubulin protein (rhodamine): porcine brain Cat. # TL590M" target="_blank">TL590M</a>, respectively) were essential reagents in this study, providing the tools necessary to examine how BKM120 and BKM120-derived molecules affected tubulin polymerization and microtubule dynamics as assessed by in vitro assembly and microtubule plus-end tracking assays, with the goal of designing novel, specific, and potent PI3K inhibitors.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial,Helvetica,sans-serif; padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28276440" title="Bohnacker T. et al. 2017. Deconvolution of Buparlisib&rsquo;s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nat. Commun. 8, 14683. " target="_blank"><span style="font-size: 10pt;"></span>Bohnacker T. et al. 2017. Deconvolution of Buparlisib&rsquo;s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nat. Commun. 8, 14683. </a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/t240" title="Tubulin protein (&gt;99% pure): porcine brain Cat. # T240" target="_blank">Tubulin protein (&gt;99% pure): porcine brain (Cat. # T240)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk006p" title="Tubulin polymerization assay using &gt;99% pure tubulin, OD based - Porcine" target="_blank">Tubulin polymerization assay using &gt;99% pure tubulin, OD based - Porcine (Cat. # BK006P)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/t333p" title="Tubulin protein (biotin): porcine brain T333P" target="_blank">Tubulin protein (biotin): porcine brain (Cat. # T333P)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/tl590m" title="Tubulin protein (rhodamine): porcine brain" target="_blank">Tubulin protein (rhodamine): porcine brain (Cat. # TL590M)</a></p>
<p style="padding-left: 30px;"></p>]]></description>
      <pubDate>Mon, 18 Dec 2017 15:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[December Newsletter: Profilin: Multi-functional Roles of an Actin Binding Protein]]></title>
      <link>https://www.cytoskeleton.com/blog/profilin-multi-functional-roles-of-an-actin-binding-protein/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/profilin-multi-functional-roles-of-an-actin-binding-protein" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Dec-2017-Newsletter-Thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="http://www.cytoskeleton.com/profilin-multi-functional-roles-of-an-actin-binding-protein" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The profilin (Pfn) family of proteins were originally characterized and studied as regulators of actin polymerization. First identified in 1976, these small (14-17 kDa) proteins exist as four isoforms in humans (Pfn1-4). Pfn1 is expressed in most cell types, Pfn2 is primarily localized to the brain, and Pfn3 and Pfn4 are localized to the testes. Pfn expression is essential for the embryonic development of mice. However, forty years later, the role of Pfn proteins in regulating actin polymerization, activating intracellular signal transduction pathways via binding to polyphosphoinositides, regulating microtubule end turnover, binding ligands via poly-L-proline domains, and potentially suppressing tumorigenicity is still being investigated. This newsletter describes the different biological interactions that Pfns are involved in and how these interactions affect actin polymerization.</p>
<p style="text-align: justify;"><strong>Profilins and Actin Polymerization</strong></p>
<p style="text-align: justify;">Cellular processes such as trafficking, motility, division, and growth require remodeling of the actin cytoskeleton. Pfns regulate actin polymerization and can both inhibit and promote actin polymerization. Pfns bind to monomeric G-actin in a 1:1 ratio with a binding affinity of 0.1 &micro;M, effectively sequestering the G-actin from incorporation into growing filaments. Notably, the intracellular concentration of Pfns has been estimated to be 10-80 &micro;M, which is not sufficient to maintain the high concentrations of G-actin found in the cell.</p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/profilin-multi-functional-roles-of-an-actin-binding-protein" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Actin Proteins, Actin Biochem Kits, and more.</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 12 Dec 2017 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Vav2 GEF Binds Phosphorylated Cortactin for Activation of Rac3 in Invadopodia]]></title>
      <link>https://www.cytoskeleton.com/blog/vav2-gef-binds-phosphorylated-cortactin-for-activation-of-rac3-in-invadopodia/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img height="174" src="https://www.cytoskeleton.com/media/wysiwyg/vav2data.png" style="float: right;" width="215" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;"><span style="font-size: xx-small;">GTPase target characterization of Ras and Rho GEFs using a GEF-mediated exchange assay with BODIPY-FL-GDP to measure changes in fluorescence emission intensity as fluorescent GDP was competed off by unlabeled 500 &micro;M GTP. Rho GEFs Vav1, Vav2, Tiam1, and hDbs were tested against RhoA, Rac1, and Cdc42. GEFs were used at a concentration of 1 &micro;M and GTPases at a concentration of 2 &micro;M.</span><strong> </strong></div>
</td>
</tr>
</tbody>
</table>
<p>Rosenberg et al. recently investigated the molecular mechanism responsible for cortactin&rsquo;s regulation of actin polymerization underlying the maturation and function of invadopodia in breast cancer cells. Release of epidermal growth factor (EGF) stimulates formation of invadopodia, actin-enriched cell protrusions essential for extracellular matrix degradation and cancer cell invasion. The EGF receptor-Src-Arg kinase signaling cascade results in phosphorylation of cortactin. The authors found that two tyrosine-phosphorylated residues on cortactin (Y421 and Y466) bind the SH2 domain of Vav2, a guanine nucleotide exchange factor (GEF) for Rho-family GTPases such as Rac. Tyrosine-phosphorylated cortactin recruits Vav2 to invadopodia, which facilitates their maturation and subsequent invadopodia-mediated matrix degradation and cancer cell invasion. Invadopodial function depends upon re-arrangement of the actin cytoskeleton, all of which requires phospho-cortactin-mediated recruitment of Vav2 to the invadopodia. Furthermore, Vav2&rsquo;s regulation of actin cytoskeletal dynamics involves Rac3 activation, though the exact role of GTP-bound Rac3 remains unclear. Cytoskeleton&rsquo;s RhoGEF Exchange Assay Kit and biotinylated actin (Cat. # <a href="http://www.cytoskeleton.com/bk100" title="RhoGEF exchange assay (BK100)" target="_blank">BK100</a> and <a href="https://www.cytoskeleton.com/ab07" title="Actin protein (biotin): skeletal muscle" target="_blank">AB07</a>, respectively) were essential reagents in this study, providing the tools necessary to identify Vav2&rsquo;s substrate targets and effects on actin cytoskeletal dynamics to aid in the development of anti-cancer therapeutics that act by interfering with invadopodia function.</p>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial, Helvetica, sans-serif;"></div>
<div style="font-family: Arial,Helvetica,sans-serif; padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28356423" title="Rosenberg B.J. et al. 2017. Phosphorylated cortactin recruits Vav2 guanine nucleotide exchange factor to activate Rac3 and promote invadopodial function in invasive breast cancer cells. Mol. Biol. Cell. 28, 1347-1360. " target="_blank"><span style="font-size: 10pt;"></span>Rosenberg B.J. et al. 2017. Phosphorylated cortactin recruits Vav2 guanine nucleotide exchange factor to activate Rac3 and promote invadopodial function in invasive breast cancer cells. Mol. Biol. Cell. 28, 1347-1360. </a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/bk100" title="RhoGEF exchange assay (BK100)" target="_blank">RhoGEF Exchange Assay (Cat. # BK100)</a></p>
<p style="padding-left: 30px;"><a href="https://www.cytoskeleton.com/ab07" title="Actin protein (biotin): skeletal muscle" target="_blank">Actin Protein (Biotin): Skeletal Muscle (Cat. # AB07)</a></p>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong><span>Products in the GEF Protein Series</span>: <br /></strong></span></span></p>
<div style="font-size: 9pt; margin-left: 30px;"><a href="https://www.cytoskeleton.com/ge01" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">Dbs protein GEF domain: His tagged: human recombinant (Cat. # GE01)</a>&nbsp;</div>
<div style="font-size: 9pt; margin-left: 30px;"><a href="https://www.cytoskeleton.com/sos1-protein-human-cs-ge02" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">SOS1 exchange domain (aa 564-1049) protein (Cat. # CS-GE02)</a>&nbsp;</div>
<div style="font-size: 9pt; margin-left: 30px;"><a href="https://www.cytoskeleton.com/small-g-proteins/modulator-proteins/rasgrf1-gef-protein-cs-ge03" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">RasGRF1 GEF Protein (Cdc25 Exchange Domain, aa 1038-1270) (Cat. # CS-GE03)</a>&nbsp;</div>
<div style="font-size: 9pt; margin-left: 30px;"><a href="https://www.cytoskeleton.com/small-g-proteins/modulator-proteins/tiam1-gef-protein-cs-ge04-695" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">Tiam1 GEF Protein (DHPH Exchange Domain, aa 1040-1406) (Cat. # CS-GE04)</a>&nbsp;</div>
<div style="font-size: 9pt; margin-left: 30px;"><a href="https://www.cytoskeleton.com/small-g-proteins/modulator-proteins/vav1-gef-protein-cs-ge05" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">Vav1 GEF Protein (DHPHC1 Exchange Domain, Y174D mutant, aa 168-522) (Cat. # CS-GE05)</a>&nbsp;</div>
<div style="font-size: 9pt; margin-left: 30px;"><a href="https://www.cytoskeleton.com/small-g-proteins/modulator-proteins/vav2-gef-protein-cs-ge06" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">Vav2 GEF Protein (DH Exchange Domain, aa 189-374) (Cat. # CS-GE06)</a>&nbsp;</div>
<div style="font-size: 9pt; margin-left: 30px;"><a href="https://www.cytoskeleton.com/small-g-proteins/modulator-proteins/arno-gef-protein-cs-ge07" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">ARNO GEF domain wild type (Cat. # CS-GE07)</a></div>
<p></p>]]></description>
      <pubDate>Tue, 21 Nov 2017 09:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[November Newsletter: Mitochondrial Acetylation: Emerging Concepts and Therapeutic Potential]]></title>
      <link>https://www.cytoskeleton.com/blog/mitochondrial-acetylation-emerging-concepts-and-therapeutic-potential/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/mitochondrial-acetylation-emerging-concepts-and-therapeutic-potential" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Nov-2017-Newsletter-V5-img-thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="http://www.cytoskeleton.com/mitochondrial-acetylation-emerging-concepts-and-therapeutic-potential" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Acetylation of the epsilon amino group of lysine residues (N<sup>&epsilon;</sup>-acetylation) is an ancient, highly conserved post-translational modification (PTM) that links acetyl coenzyme A (acetyl-CoA) metabolism and cellular signaling. This occurs largely through the opposing activities of lysine acetyl transferases (KATs) and lysine deacetylases (KDACs). In humans, there are 3 major KAT families (GCN5, CBP/p300, and MYST) that all use acetyl-CoA as an essential cofactor to donate an acetyl group to target lysine residues. There are two KDAC families, the zinc-dependent histone deacetylases (HDAC1-11) and the NAD+-dependent sirtuins (SIRT1-7).</p>
<p style="text-align: justify;">It is well documented that acetylation of nuclear histones plays a major role in regulating chromatin compaction and transcriptional activity wherein acetylation favors a more open, transcriptionally active chromatin. Recent proteomic studies have identified over 4,500 non-histone proteins as targets of acetylation, thereby establishing lysine acetylation as a major global PTM. This PTM is present in many, if not all, cellular compartments, including the nucleus, cytoplasm, cell membrane, and mitochondria. Functionally, reversible lysine acetylation has been shown to regulate enzyme activity, protein-protein interactions, and protein localization and stability. In addition, it plays critical regulatory roles in many cellular processes, including gene expression, cellular metabolism, apoptosis, cytoskeleton regulation, and membrane trafficking.</p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/mitochondrial-acetylation-emerging-concepts-and-therapeutic-potential" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal Seeker Kits&trade; Kits, PTM Antibodies, Beads, and more.</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Tue, 31 Oct 2017 08:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: RhoA Activity Regulated by Src-Mediated Phosphorylation of ARHGAP42]]></title>
      <link>https://www.cytoskeleton.com/blog/rhoa-activity-regulated-by-src-mediated-phosphorylation-of-arhgap42/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<div>
<div>
<div style="text-align: justify;">
<table align="right" border="0" cellspacing="5" style="width: 214px; margin-left: 15px;">
<tbody>
<tr>
<td><img src="https://www.cytoskeleton.com/media/wysiwyg/G-Switch_Rho_Stress_Fibers_3T3_with_CN03.jpg" style="float: right;" width="214" /></td>
</tr>
<tr>
<td>
<div align="justify" style="text-align: justify;"><span style="font-size: xx-small;">Bottom: Rho activation in Swiss 3T3 cells. F-actin is visualized with fluorescent green phalloidin staining (Cat.# <a href="http://www.cytoskeleton.com/phdg1" target="_blank">PHDG1</a>) and nuclear blue DNA staining with Dapi. Cells were activated with Cat.# <a href="http://www.cytoskeleton.com/cn03" target="_blank">CN03</a>.</span></div>
</td>
</tr>
</tbody>
</table>
Luo et al. recently discovered the novel GTPase activating protein (GAP), ARHGAP42, through a phosphotyrosine proteomics study. ARHGAP42 de-activates multiple Rho family GTPases, including RhoA. Here, the authors characterized the functional regulation of ARHGAP42 by the non-receptor tyrosine kinase Src and the subsequent downstream effects on ARHGAP42-mediated de-activation of GTP-bound (active) RhoA through engagement of RhoA&rsquo;s GTPase function. The changes in ARHGAP42 and RhoA activities were correlated with changes in RhoA-regulated actin cytoskeletal dynamics and cell motility in mouse embryonic fibroblasts. ARHGAP42 associates with actin stress fibers and focal adhesions, is auto-inhibited by its N-terminal BAR (Bin/amphiphysin/Rvs) domain, and is activated by Src-mediated phosphorylation of tyrosine residue 376. Following this Src-mediated activation, ARHGAP42 de-activates RhoA through GAP-stimulated GTP hydrolysis which results in increased cell migration mediated by dynamic changes in focal adhesions and the actin cytoskeleton. Cytoskeleton&rsquo;s RhoA G-LISA activation assay kit and RhoGAP assay kit (Cat. # <a href="http://www.cytoskeleton.com/bk124" title="Cat. # BK124" target="_blank">BK124 </a>and <a href="http://www.cytoskeleton.com/bk105" title="Cat. # BK105" target="_blank">BK105</a>, respectively) were essential reagents in this study, providing the tools necessary to measure the activities of both ARHGAP42 and RhoA to describe the novel functional regulation of ARHGAP42 by the non-receptor tyrosine kinase Src.<span> <br /></span></div>
<br />
<div style="font-family: Arial, Helvetica, sans-serif;"><span></span><strong>Link to citation:</strong></div>
<div style="font-family: Arial,Helvetica,sans-serif; padding-left: 30px;"><span style="font-size: 10pt;"></span><a href="https://www.ncbi.nlm.nih.gov/pubmed/28584191" title="ARHGAP42 is activated by Src-mediated tyrosine phosphorylation to promote cell motility." target="_blank">Luo W. et al. 2017. ARHGAP42 is activated by Src-mediated tyrosine phosphorylation to promote cell motility. <em>J. Cell Sci.</em> doi:&nbsp;10.1242/jcs.197434.</a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<p style="padding-left: 30px;"><a href="http://www.cytoskeleton.com/bk124" title="RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)" target="_blank">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays (Cat. # BK124)</a></p>
<p style="padding-left: 30px;"><a href="http://www.cytoskeleton.com/bk105" title=" RhoGAP assay (BK105)" target="_blank">RhoGAP assay (Cat. # BK105)</a></p>]]></description>
      <pubDate>Thu, 21 Sep 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[September Newsletter: Microtubule Stabilization by the Post-translational Modification of Acetylation]]></title>
      <link>https://www.cytoskeleton.com/blog/microtubule-stabilization-by-the-post-translational-modification-of-acetylation/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/microtubule-stabilization-by-the-post-translational-modification-of-acetylation" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-July-2017-thumb.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="http://www.cytoskeleton.com/microtubule-stabilization-by-the-post-translational-modification-of-acetylation" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The acetylation post-translational modification (PTM) of tubulin occurs primarily on the lysine at position 40 (Lys40) on the alpha-tubulins of assembled microtubules (MTs). The predominant alpha-tubulin acetyltransferase is TAT1/MEC-17. Deacetylation of acetylated tubulin is mediated by histone deacetylase 6 (HDAC6) or SIRT2, the mammalian homolog of silent information regulator 2/sirtuin type 2. Lys40 has long been considered the sole site of acetylation and while other lysine residues on alpha-tubulin and beta-tubulin are targets for acetylation based on proteomic analyses, functional studies focus on the Lys40 residue within the MT lumen. This newsletter discusses tubulin acetylation, MT stability, and the functionality of acetylated MTs (Fig. 1).</p>
<p style="text-align: justify;">Acetylation is a marker for stabilized, long-lived MTs (defined as MTs resistant to nocodazole- and colchicine-induced depolymerization) with a half-life of hours. Notably, acetylation itself does not cause MT stabilization. However, a recent genetic ablation study strongly supports the conclusion that Lys40 acetylation is required for maintaining long-lived, stable MTs in mammalian cells. Loss of TAT1 resulted in a loss of stable, acetylated MTs that are normally present after nocodazole treatment eliminates dynamic MTs. Conversely, TAT1 overexpression significantly increased the amount of nocodazole-resistant (stable) MTs and fibroblasts lacking the tubulin deacetylase HDAC6 have more nocodazole-resistant MTs. The dogma that acetylation is restricted to stable MTs has been revised in recent years as tubulin acetylation is also found on subpopulations of dynamic MTs (half-life of minutes), such as those found in both young and mature neurons.</p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/microtubule-stabilization-by-the-post-translational-modification-of-acetylation" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Signal Seeker Kits&trade; Kits, PTM Antibodies, Beads, and more.</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Mon, 11 Sep 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[August Newsletter: Actin Ring-Based Periodic Membrane Skeleton in Neuronal Axons]]></title>
      <link>https://www.cytoskeleton.com/blog/actin-ring-based-periodic-membrane-skeleton-in-neuronal-axons/</link>
      <description><![CDATA[<table align="right" border="0">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/actin-ring-based-periodic-membrane-skeleton-in-neuronal-axons" title="Link to newsletter" target="_self"><img alt="Link to newsletter" height="259" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-Aug-2017.jpg" style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" width="200" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a href="http://www.cytoskeleton.com/actin-ring-based-periodic-membrane-skeleton-in-neuronal-axons" title="Click to view this newsletter" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Actin is an integral part of the neuronal cytoskeleton as it is involved in the regulation of neuronal polarization, cell morphology, the development of neuronal processes (i.e., growth cones with lamellipodial and filopodial extensions and dendritic spines), intracellular trafficking, and synaptic plasticity (dynamic changes in dendritic spine number and/or morphology)<sup>1-3</sup>. Actin&rsquo;s presence in growth cones and dendritic spines have garnered the attention of scientists for decades; however, actin is also found in neuronal axons, though its presence there has been described as the &ldquo;black sheep of the neuronal actin family&rdquo;<sup>4</sup>. This is because the exact details of actin&rsquo;s structure and role in the axon are unknown. Recently, significant advances have been made in unraveling the structure of axonal actin with the discovery of the periodic membrane skeleton (PMS) by nanoscopic microscopy5 (Fig. 1). This newsletter discusses the discovery, structure, and possible functions of the PMS in axons.</p>
<p style="text-align: justify;">Discovered in 2013, the PMS is a type of cortical actin and the primary component of the actin cortex, a mixture of F-actin and actin binding proteins which supports eukaryotic cells&rsquo; plasma membrane and membrane-associated processes such as endo- and exocytosis and cell motility<sup>4,5</sup>. In neuronal axons, including the initial segment6, the PMS consists of short actin filaments bundled into evenly spaced rings that wrap around the circumference of the axon with a periodicity of 180-190 nanometers<sup>5-9</sup> (Fig. 1). The short filaments are stabilized by an adducin cap which controls the diameter of actin rings and axons, as well as actin filament growth within the rings<sup>6,10</sup>. Adjacent actin rings are secured through cross-linkage by spectrin tetramers (bII in the axon proper and bIV in the axon initial segment)<sup>6,8,11</sup>.</p>
<p style="text-align: justify;"><a href="http://www.cytoskeleton.com/actin-ring-based-periodic-membrane-skeleton-in-neuronal-axons" title="Click to read more" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;<strong>Also included in this newsletter:</strong></p>
<ul>
<li>Spirochrome&trade; Live Cell Imaging Probes, Actin Proteins, Acti-stain Phalloidins, Actin Activation Assay Biochem Kits and more.</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol></ol>]]></description>
      <pubDate>Wed, 16 Aug 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Toolsets to Define PTMs for Any Target Protein]]></title>
      <link>https://www.cytoskeleton.com/blog/toolsets-to-define-ptms-for-any-target-proteins/</link>
      <description><![CDATA[<div style="font-family: Arial, Helvetica, sans-serif;">
<div style="font-size: 9pt;">
<div style="margin-top: 0px; margin-bottom: 0px; font-family: Arial, Helvetica, sans-serif; font-size: 10pt;">
<div style="margin-top: 0px; margin-bottom: 0px;">
<table style="text-align: center; width: 100%;" border="0" cellspacing="0" cellpadding="0" align="center">
<tbody>
<tr>
<td class=" imgCaptionImg" style="color: #323232; padding: 0px;" width="100%">
<div><span class="imgCaptionAnchor"><img style="vertical-align: middle;" src="https://mlsvc01-prod.s3.amazonaws.com/b2371b4f001/173c82aa-a82f-44ac-b612-ab72fe8a9663.jpg" alt="" width="100%" /></span></div>
</td>
</tr>
<tr>
<td class="imgCaptionText" style="text-align: center; font-style: normal; font-weight: 400; color: #323232; vertical-align: top; font-family: Arial,Helvetica,sans-serif; font-size: 8pt; width: 225.225px; height: 25px; padding-bottom: 0px; padding-right: 0px; padding-left: 0px;">Comparison of BlastR lysis buffer to non-denaturing lysis buffers  and detection of total SUMOylation 2/3, acetylation, ubiquitination, and  tyrosyl phosphorylation profiles were detected with their respective  antibodies.<br /></td>
</tr>
</tbody>
</table>
<div>
<div><span>
<div style="text-align: justify;"><br />Recently, Horita et al. examined the  post-translational modification (PTM) profile changes in the  EGFR&rarr;Ras&rarr;c-Fos signaling pathway in response to EGF stimulation. PTMs  are dynamic and often reversible modifications that alter protein  structure and function. While tyrosine phosphorylation (pY) is  well-characterized in the EGFR signaling pathway, other PTMs like  acetylation (Ac), SUMOylation (SUMO), and ubiquitination (Ub) have not  been thoroughly investigated. A novel toolset termed Signal-Seeker&trade; kits  were utilized to investigate the pY, Ac, SUMO, and Ub status of the  EGFR signaling axis. All 10 of the previously identified PTMs of the  EGFR&rarr;Ras&rarr;c-Fos signaling pathway were identified, and a novel  modification, c-Fos Ac, was also discovered. Importantly, utilizing the  toolset enabled investigation of the PTM status of proteins in various  cellular compartments that ranged from low to high abundance. The  dynamic and endogenous levels of these PTMs were investigated in a  single lysis system, providing insight into potential crosstalk between  these four PTMs. Cytoskeleton's pY, Ub, SUMO 2/3, and Ac Signal-Seeker&trade;  PTM detection kits (Cat. # <a title="Signal-Seeker&trade; Phosphotyrosine Detection Kit (30 assay)" href="http://www.cytoskeleton.com/bk160" target="_blank">BK160</a>, <a title="http://www.cytoskeleton.com/bk161" href="http://www.cytoskeleton.com/bk161" target="_blank">BK161</a>, <a title="Signal-Seeker&trade; SUMOylation 2/3 Detection Kit (30 assay)" href="http://www.cytoskeleton.com/bk162" target="_blank">BK162</a>, and <a title="Signal-Seeker&trade; Acetyl-Lysine Detection Kit (30 assay)" href="http://www.cytoskeleton.com/bk163" target="_blank">BK163</a>, respectively)  were essential reagents in this study, and provide a novel toolset for  simple and effective investigation of established and novel PTMs for any  target protein.</div>
</span></div>
<span>&nbsp;</span></div>
</div>
</div>
<div style="font-family: Arial, Helvetica, sans-serif;"><span>
<div style="color: black; text-align: left; font-style: normal; font-weight: normal; line-height: normal;"><span style="line-height: 115%; color: black;">
<div>
<div style="text-align: justify;"><span style="line-height: 115%; color: black;">
<div><span style="color: black;"> </span></div>
</span></div>
</div>
</span></div>
</span><strong>Link to citation:</strong><span style="font-size: 10pt;">&nbsp;</span></div>
</div>
</div>
<div style="margin-left: 30px; font-family: Arial, Helvetica, sans-serif; font-size: 9pt;">
<div style="font-family: Arial,Helvetica,sans-serif; color: black; text-align: left; font-style: normal; font-weight: normal; line-height: normal; font-size: 9pt;"><span style="color: black;">
<div><br /><a style="color: blue; text-decoration: underline;" href="http://www.bioscirep.org/content/ppbioscirep/37/4/BSR20170919.full.pdf" target="_blank">Horita  H. et. al. A simple toolset to identify endogenous post-translational  modifications for a target protein: a snapshot of the EGFR signaling  pathway. Biosci. Rep. DOI:&nbsp;10.1042/BSR20170919</a></div>
</span></div>
</div>
<p><span title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays"><strong>Products used in this citation: </strong></span></p>
<div style="margin-left: 30px;"><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk160" target="_blank">Signal-Seeker&trade; Phosphotyrosine Enrichment Kit (30 assay) (Cat. # BK160)</a><br />
<div><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk160-s" target="_blank">Signal-Seeker&trade; Phosphotyrosine Enrichment Kit (10 assay) (Cat. # BK160-S)</a>&nbsp;</div>
<div><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk161" target="_blank">Signal-Seeker&trade; Ubiquitination Enrichment Kit (30 assay) (Cat. # BK161)</a><br /><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk161-s" target="_blank">Signal-Seeker&trade; Ubiquitination Enrichment Kit (10 assay) (Cat. # BK161-S)</a></div>
<div><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk162" target="_blank">Signal-Seeker&trade; SUMOylation 2/3 Enrichment Kit (30 assay) (Cat. # BK162)</a><br /><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk162-s" target="_blank">Signal-Seeker&trade; SUMOylation 2/3 Enrichment Kit (30 assay) (Cat. # BK162-S)</a></div>
<div style="color: blue !important; text-decoration: underline !important;">
<div><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk163" target="_blank">Signal-Seeker&trade; Acetyl-Lysine Enrichment Kit (30 assay) (Cat. # BK163)</a><br /><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk163-s" target="_blank">Signal-Seeker&trade; Acetyl-Lysine Enrichment Kit (30 assay) (Cat. # BK163-S)</a></div>
</div>
</div>
<p><span style="font-size: 10pt;"> </span></p>]]></description>
      <pubDate>Tue, 08 Aug 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Nanometer Scale Temperature Measurements of Myosin ATPase Activity]]></title>
      <link>https://www.cytoskeleton.com/blog/nanometer-scale-temperature-measurements-of-myosin-atpase-activity/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img title="Actin and Myosin Interactions" src="https://www.cytoskeleton.com/media/wysiwyg/citation_diagram.jpg" alt="Actin and Myosin Interactions" width="400" /><br /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;">
<div style="text-align: justify;">
<div style="text-align: justify;">
<p style="text-align: center;"><span style="font-size: xx-small;">Actin and Myosin Interactions</span></p>
</div>
</div>
</div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Laha et al. recently developed a new thermometric approach for measuring temperature changes of individual proteins on a nanometer (nm) scale. Spatial and temporal resolution of 80 nm and 1 mK, respectively, was achieved by attaching 2 nm cadmium telluride quantum dots (CdTe QDs) directly to bovine cardiac and rabbit skeletal muscle myosins. The goal was to demonstrate that temperature changes of individual motors performing work (i.e., ATP hydrolysis) can be quantified by measuring the corresponding fluorescence intensity shifts of temperature-sensitive CdTe QDs. Heat released by myosin-mediated ATP hydrolysis was quantified as a means of calculating efficiency since heat loss is inversely related to work performed. Using this nanothermometry, rabbit skeletal myosin was more efficient than bovine cardiac myosin at ATP hydrolysis. Nanometer scale sensitivity significantly improved muscle efficiency measurements toward the goal of single cell thermometry to support efforts to provide early diagnosis and treatment of muscle and metabolic diseases on a nanoscale level. Cytoskeleton&rsquo;s CytoPhos Phosphate Assay, rabbit skeletal muscle myosin, and bovine cardiac muscle myosin (Cat. # <a title="CytoPhos Endpoint Phosphate Assay (BK054)" href="http://www.cytoskeleton.com/bk054" target="_blank">BK054</a>, <a title="Myosin II protein: rabbit skeletal muscle" href="http://www.cytoskeleton.com/my02" target="_blank">MY02</a>, and <a title="Myosin protein: bovine cardiac muscle" href="http://www.cytoskeleton.com/my03" target="_blank">MY03</a>, respectively) were essential reagents in this study, providing the tools necessary to measure muscle efficiency as a function of a motor&rsquo;s temperature change during work.</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a title="Laha S.S. et al. 2017. Nanothermometry measure of muscle efficiency. Nano Lett. 17, 1262-1268." href="https://www.ncbi.nlm.nih.gov/pubmed/28112520" target="_blank">Laha S.S. et al. 2017. Nanothermometry measure of muscle efficiency. Nano Lett. 17, 1262-1268.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="CytoPhos Endpoint Phosphate (Cat. # BK054)" href="http://www.cytoskeleton.com/bk054" target="_blank">CytoPhos Endpoint Phosphate (Cat. # BK054)</a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="Myosin II protein: rabbit skeletal muscle (Cat. # MY02)" href="http://www.cytoskeleton.com/my02" target="_blank">Myosin II protein: rabbit skeletal muscle (Cat. # MY02)</a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="Myosin protein: bovine cardiac muscle (Cat. # MY03)" href="http://www.cytoskeleton.com/my03" target="_blank">Myosin protein: bovine cardiac muscle (Cat. # MY03)</a></div>
<ol> </ol>]]></description>
      <pubDate>Tue, 25 Jul 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[July Newsletter: Post-translational Regulation of Mdm2, an E3 Ubiquitin Ligase for Tumor Suppressor p53]]></title>
      <link>https://www.cytoskeleton.com/blog/post-translational-regulation-of-mdm2-an-e3-ubiquitin-ligase-for-tumor-suppressor-p53/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/post-translational-regulation-of-mdm2-an-e3-ubiquitin-ligase-for-tumor-suppressor-p53" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-July-2017SMALL.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/post-translational-regulation-of-mdm2-an-e3-ubiquitin-ligase-for-tumor-suppressor-p53" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The ubiquitin E3 ligase Mdm2 (murine double minute 2; human homolog,  Hdm2) is well known for its oncogenic activities and as the master  regulator of the powerful tumor suppressor p53<sup>1,2</sup>. Moreover, Mdm2 may function as an oncogenic protein independent of p53<sup>3</sup>.  Mdm2 is able to inhibit p53-mediated gene expression through two  pathways: inhibition of transcriptional activity by direct binding and  ubiquitin-mediated degradation via its E3 ligase activity<sup>4</sup>; however, the effectiveness of p53 inhibition by direct Mdm2 binding has been questioned<sup>5</sup>.</p>
<p style="text-align: justify;">Under normal, non-stress conditions, Mdm2 maintains p53  expression and activity at a minimal level to tightly regulate its  apoptotic/cell death transcriptional activities. Under conditions of  cellular stress, Mdm2-mediated ubiquitination of p53 ceases, allowing  p53 to activate transcription of apoptotic genes and those involved in  inhibiting cell growth. Much research concludes this is due to Mdm2's  auto-inhibition by self-ubiquitination<sup>1-3</sup>. However, this story appears to be more complex than originally thought<sup>5</sup> and involves multiple post-translational modifications (PTMs). Here, we  discuss Mdm2's regulation by ubiquitination, SUMOylation,  phosphorylation, and acetylation<sup>6-8</sup> (Fig. 1).</p>
<p style="text-align: justify;"><a title="Click to read more" href="http://www.cytoskeleton.com/post-translational-regulation-of-mdm2-an-e3-ubiquitin-ligase-for-tumor-suppressor-p53" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Signal Seeker&trade; Kits, PTM Antibodies and Beads</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 18 Jul 2017 15:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: ARNO-Arf1 Pathway Regulates RhoA Activity to Control Podosome Formation]]></title>
      <link>https://www.cytoskeleton.com/blog/arno-arf1-pathway-regulates-rhoA-activity-to-control-podosome-formation/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img title=" FNR01 image overlay with phase contrast background. Fluorescent fibronectin (Cat. # FNR01) treated MCF10A cells (image kindly provided by A. Varadara and M. Karthykenyan, Univ. S.Carolina, Columbia, SC)." src="https://www.cytoskeleton.com/media/wysiwyg/Arf-cell-imgs-combined.jpg" alt=" FNR01 image overlay with phase contrast background. Fluorescent fibronectin (Cat. # FNR01) treated MCF10A cells (image kindly provided by A. Varadara and M. Karthykenyan, Univ. S.Carolina, Columbia, SC)." width="200" /><br /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;">
<div style="text-align: justify;">
<div style="text-align: justify;">
<p><span style="font-size: xx-small;">Arf activation by wild-type ARNO GEF in MDCK cells. &nbsp;ARNO proteins localized with a 9e10 anti-myc primary antibody and CY2-conjugated secondary antibody (green). &nbsp;F-actin labeled with rhodamine-phalloidin (red). &nbsp;Cells expressing wild-type ARNO protein have robust lamellipodia (arrows). &nbsp;Scale bar = 50 microns. Image provided by Dr. Lorraine Santy, Penn State University.</span></p>
</div>
</div>
</div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, Rafiq et al. examined Arf1 control of podosome assembly. Podosomes are actin-rich structures surrounded by adhesion and scaffolding proteins that are involved in cell motility and invasion. Podosomes mediate the adhesion of motile cells to the extracellular matrix and are important for the attachment to, and degradation of, the matrix by motile cells. To better understand podosome formation and maintenance, the contribution of Arf1 and its guanine exchange factors (GEFs), as well as the signaling pathways downstream of Arf1 activation, were evaluated in macrophage-like THP1 cells and fibroblasts. Inhibition of Arf1 or the Arf GEF ARNO with small interfering RNAs (Arf1 and ARNO), pharmacological inhibitors (Brefeldin A [BFA] and SecinH3 for Arf1), or expression of dominant-negative mutants (Arf1 and ARNO) significantly impaired podosome formation and maintenance. Conversely, induction of podosome formation increased levels of active Arf1. Arf1 activity was inversely related to RhoA activity as Arf1 inhibition resulted in increased activation of RhoA and myosin IIA filament assembly. Notably, levels of active Rac1 and Cdc42 were unchanged following manipulation of Arf1 activity. Cytoskeleton&rsquo;s Cdc42 and Arf1 G-LISA activation assay kits (<a title="Cdc42 G-LISA Activation Assay (Colorimetric format) - 96 assays (Cat. # BK127)" href="http://www.cytoskeleton.com/bk127" target="_blank">Cat. # BK127</a> and <a title="Arf1 G-LISA Activation Assay Kit (Colorimetric Based) - 96 assays (Cat. # BK132) " href="http://www.cytoskeleton.com/bk132" target="_blank">BK132</a>, respectively) and cell-permeable Rho inhibitor (<a title="Rho Inhibitor I (Cat. # CT04)" href="http://www.cytoskeleton.com/ct04" target="_blank">Cat. # CT04</a>) were essential reagents in this study, providing the tools necessary to measure the activity of multiple GTPases in a quantitative and sensitive manner.</p>
<p>&nbsp;</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><span style="color: black;"><a style="color: blue !important; text-decoration: underline !important;" href="https://www.ncbi.nlm.nih.gov/pubmed/28007915" target="_blank">Rafiq  N.B.M. et al. 2017. Podosome assembly is controlled by the GTPase ARF1  and its nucleotide exchange factor ARNO. J. Cell Biol. 216, 181-197.</a></span></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span style="font-size: 10pt;"><span style="font-size: 10pt;"><a style="color: blue !important; text-decoration: underline !important;" href="http://www.cytoskeleton.com/bk127" target="_blank">Cdc42 G-LISA  Activation Assay (Colorimetric format) - 96 assays (Cat. # BK127)</a><br /><a style="color: blue !important; text-decoration: underline !important;" href="http://www.cytoskeleton.com/bk132" target="_blank">Arf1 G-LISA Activation Assay Kit (Colorimetric Based) - 96 assays (Cat. # BK132)</a><br /><a style="color: blue !important; text-decoration: underline !important;" href="http://www.cytoskeleton.com/ct04" target="_blank">Rho Inhibitor I (Cat. # CT04)</a><span style="font-size: 10pt;"><strong>&nbsp;</strong></span></span></span></div>
<ol> </ol>]]></description>
      <pubDate>Thu, 22 Jun 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[June Newsletter: Posttranslational Regulation of Key Transcription Factors in Pluripotent Stem Cells]]></title>
      <link>https://www.cytoskeleton.com/blog/posttranslational-regulation-of-key-transcription-factors-in-pluripotent-stem-cells/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/posttranslational-regulation-of-key-transcription-factors-in-pluripotent-stem-cells" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-June-2017.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/posttranslational-regulation-of-key-transcription-factors-in-pluripotent-stem-cells" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Pluripotent stem cells (PSCs), characterized by their unlimited self-renewal and differentiation potential, have garnered special attention as therapeutics because of their capacity to differentiate into any cells of the respective adult organism<sup>1</sup>.&nbsp; There are two general types of PSCs: 1. embryonic stem cells (ESCs) and 2. induced pluripotent stem cells (iPSCs). By definition, PSCs exist in a pluripotent state until differentiation into specialized cells. To maintain stem cells as pluripotent, select transcription factors activate pluripotency-promoting genes and concomitantly suppress differentiation-promoting genes. In turn, the expression level and transactivation ability of these transcription factors are regulated by post-translational modifications (PTMs)<sup>2,3</sup>. Three key pluripotent transcription factors are Oct4, Sox2, and Nanog<sup>3</sup>. Their regulation of transcription is complex with each transcription factor able to function independently of the other while also capable of&nbsp; auto-inhibition (e.g., Oct4)<sup>4</sup> or forming a heterodimer whereby one factor is regulated by the complex (e.g., Nanog activity is strictly regulated by the Oct4/Sox2 heterodimer)<sup>5,6</sup>. Understanding the precise regulation of the stability (expression level) and transcriptional activity (DNA-binding affinity) of Oct4, Sox2, and Nanog by PTMs is essential in the study of stem cell homeostasis<sup>7</sup>. <br /><br /><br /><a title="Click to read more" href="http://www.cytoskeleton.com/posttranslational-regulation-of-key-transcription-factors-in-pluripotent-stem-cells" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Signal Seeker&trade; Kits, PTM Antibodies, Beads, Spirochrome&trade; Live Cell Imaging Probes</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 13 Jun 2017 15:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[May Newsletter: Arf6 GEFs and Cancer Cell Invasion and Metastasis]]></title>
      <link>https://www.cytoskeleton.com/blog/arf6-gefs-and-cancer-cell-invasion-and-metastasis/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/arf6-gefs-and-cancer-cell-invasion-and-metastasis1" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-May-2017-Thumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/arf6-gefs-and-cancer-cell-invasion-and-metastasis1" target="_blank"><strong>Click to view&nbsp;this newsletter. </strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The small GTPase ADP-ribosylation factor 6 (Arf6) belongs to the Arf subfamily of Ras superfamily GTPases. Of the three classes of Arf GTPases, Arf6 is the only member of class III and uniquely localizes to the plasma membrane and endosomes, positioning it to regulate cellular processes dependent upon dynamic changes in the actin cytoskeleton, including endocytosis, exocytosis, trafficking/recycling of membrane-localized proteins, and membrane protrusions (e.g., ruffles). These cellular functions underlie physiological and pathological cell motility and intracellular trafficking. Arf6 cycles between an inactive, GDP-bound state and an active, GTP-bound state to act as a molecular switch in the cellular processes listed above. Activation of Arf6 by exchange of GDP for GTP is mediated by guanine exchange factors (GEFs) while inactivation by GTP hydrolysis is mediated by GTPase activating proteins (GAPs)<sup>1-3</sup>. In this newsletter, we discuss the mechanistic roles Arf6 and its GEFs have in cancer cell invasion and metastasis. <br /><br /><a title="Click to read more" href="http://www.cytoskeleton.com/arf6-gefs-and-cancer-cell-invasion-and-metastasis1" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Arf Activation Assay Kits, F-actin Visualization Reagents, Other Live Cell Imaging Probes</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 16 May 2017 15:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Fibronectin Recycling and Fibrillogenesis Regulation by Transforming Growth Factor ß]]></title>
      <link>https://www.cytoskeleton.com/blog/fibronectin-recycling-and-fibrillogenesis-regulation-by-transforming-growth-factor-b/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img title="FNR01 image overlay with phase contrast background. Fluorescent fibronectin (Cat. # FNR01) treated MCF10A cells (image kindly provided by A. Varadaraj and M. Karthikenyan, Univ. S.Carolina, Columbia, SC)." src="https://www.cytoskeleton.com/media/wysiwyg/FNR01_overlay_with_DIC_v3b.jpg" alt="FNR01 image overlay with phase contrast background. Fluorescent fibronectin (Cat. # FNR01) treated MCF10A cells (image kindly provided by A. Varadaraj and M. Karthikenyan, Univ. S.Carolina, Columbia, SC)." width="200" /><br /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;">
<div style="text-align: justify;">
<div style="text-align: justify;">
<p><span style="font-size: xx-small;"><a href="http://r20.rs6.net/tn.jsp?f=001DQ5OSCRey1cWklujXS9QUkPk-tPLOepgHbB48BZlZ2-AA-42Re27IXZfHuGefCT4zrQ9QvDMaUlelpD1Jast88WJR16XBzn0kuKXr5IPP3AMSZ4QbrbHcldwhZypCpSU53YjJXRxLC1HP81Fkakd5IuLl_7rzUEQWnWDWsR-Crejlr11xgpeJdKKeS6LfzEzXi6_5-ye0A1EJLXLAD3amQFPR4ye0vAtq7jz_Dd_HlveOsvCGd3qcGxwfZpj78xgnpPeqFvqmiy4kQayZItTqwmoUQBFZ935WAO-aYEEt5pNIEHTR7T9U2OuIV0Mbl7QUmLfe_BKqzh-PiGo6hcgi4X19yCyYTo7&amp;c=ENTE__PL853KJmSKMbPEuPTf9X9MCrBUHIc8sKoh6ZVHt3wzfOOmHA==&amp;ch=GbMf_WC2NChYct4ZlLlWazikXIR5I8M2oBMJa9_Q8vdVuOJsVLEGgA==" target="_blank">FNR01</a> image overlay with phase contrast background. Fluorescent fibronectin (<a href="http://r20.rs6.net/tn.jsp?f=001DQ5OSCRey1cWklujXS9QUkPk-tPLOepgHbB48BZlZ2-AA-42Re27IXZfHuGefCT4zrQ9QvDMaUlelpD1Jast88WJR16XBzn0kuKXr5IPP3AMSZ4QbrbHcldwhZypCpSU53YjJXRxLC1HP81Fkakd5IuLl_7rzUEQWnWDWsR-Crejlr11xgpeJdKKeS6LfzEzXi6_5-ye0A1EJLXLAD3amQFPR4ye0vAtq7jz_Dd_HlveOsvCGd3qcGxwfZpj78xgnpPeqFvqmiy4kQayZItTqwmoUQBFZ935WAO-aYEEt5pNIEHTR7T9U2OuIV0Mbl7QUmLfe_BKqzh-PiGo6hcgi4X19yCyYTo7&amp;c=ENTE__PL853KJmSKMbPEuPTf9X9MCrBUHIc8sKoh6ZVHt3wzfOOmHA==&amp;ch=GbMf_WC2NChYct4ZlLlWazikXIR5I8M2oBMJa9_Q8vdVuOJsVLEGgA==" target="_blank">Cat. # FNR01</a>) treated MCF10A cells (image kindly provided by A. Varadaraj and M. Karthikenyan, Univ. S.Carolina, Columbia, SC).</span></p>
</div>
</div>
</div>
<address> </address></td>
</tr>
</tbody>
</table>
<p>Recently, Varadaraj et al. examined transforming growth factor &szlig; (TGF-&szlig;) regulation of the extracellular matrix (ECM) protein fibronectin (FN). Soluble FN dimers polymerize to form insoluble, matrix-associated FN polymers in a process known as fibrillogenesis. The resulting FN fibril network is a scaffold for cell migration, repair, and adhesion mediated by binding to a5&szlig;1 integrin receptors. TGF-&szlig; stimulates ECM remodeling and cell migration through the induction of FN fibrillogenesis, which is necessary for TGF-&szlig;&rsquo;s effects. Here, the authors found that FN&rsquo;s role in TGF-&szlig;-mediated ECM remodeling and cell migration can occur via increased FN trafficking, i.e., recycling between the plasma membrane and cytosol. In response to TGF-&beta;, cell surface FN is endocytosed and undergoes Rab11-mediated recycling and subsequent incorporation into fibrils, a process dependent on an interaction between the cytoplasmic domain of the type II TGF-&beta; receptor (T&beta;RII) and a5&szlig;1 integrin. Cytoskeleton&rsquo;s rhodamine-labeled and biotinylated fibronectin (Cat. # <a title="Rhodamine fibronectin Cat. # FNR01" href="http://www.cytoskeleton.com/fnr03" target="_blank">FNR01</a> and <a title="Fibronectin (Biotinylated) Cat. # FNR03" href="http://www.cytoskeleton.com/fnr03" target="_blank">FNR03</a>, respectively) were essential reagents in this interesting study, providing the tools necessary to discover that TGF-&szlig; induces FN trafficking/recycling, a novel process that offers a rapid pathway by which FN can regulate cell migration, wound repair, and fibrosis.</p>
<p>&nbsp;</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a href="http://r20.rs6.net/tn.jsp?f=001DQ5OSCRey1cWklujXS9QUkPk-tPLOepgHbB48BZlZ2-AA-42Re27IfdENrlXxd-itJg8h3je7xKhXKTDfyEb8jfPSF31eIRnBg69Mkm5TM2jBrxIRb9ccq83MJ30hHV_HLzgeLaQYdD5p7j79ig8VZn7NB7kxcpSf0A3y0YYWEJ7xQIktWbC8pemp1FJJX4DhXsU7MYZnA0i4Xqeu8seggNFHNSq_hT3XCSxGL4K4jfaND4myzrkSLvEpu77DUPUWSymYhI6gr7OwRzmNbDMdJprHjNMmwjOMrlMFM_OTmHKqk2dpv7JEcof-pCMjZ4MVdOXAaYyPADP9qwA_hNK9MU30TW-t0hCyafZiqe-KUQzaIyFxhuUsVQe5vHTZVPo&amp;c=ENTE__PL853KJmSKMbPEuPTf9X9MCrBUHIc8sKoh6ZVHt3wzfOOmHA==&amp;ch=GbMf_WC2NChYct4ZlLlWazikXIR5I8M2oBMJa9_Q8vdVuOJsVLEGgA==" target="_blank">Varadaraj A. et al. 2017. TGF-&szlig; triggers rapid fibrillogenesis via a novel T&szlig;RII dependent fibronectin trafficking mechanism. Mol. Biol. Cell. DOI: 10.1091/mbc.E16-08-0601.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span style="font-size: 10pt;"><span style="font-size: 10pt;"><span style="font-size: 10pt;">
<p><a href="http://r20.rs6.net/tn.jsp?f=001DQ5OSCRey1cWklujXS9QUkPk-tPLOepgHbB48BZlZ2-AA-42Re27IQujqBle5Cm2cjRqGeEKpYKYezLyHUENvpF4MaCRXTUrIdU2q0fN3tsIQ4bBYxkY1qvIsG6jMypHHOCd4PLr5r4ltabN9gHts96R5oY9HMS8Aw9rjPx38BtVv8OtjqUvJSjU8P0pYsf1WQzpj5p86A39KAnd5H_-j2ELi69XsyIM3UqLeKeGCaQFG8xNeMxtx5uLZhuj8_TYOx09ChdxtYjzHjl7vBCL5h5H-u83Ub1iI5N7_KgptuUkQcR5NqKfiwsZrhUJfkYYTdB0ElZvh7wuulzIFKzSrEfszFevlmaRVNQ-WlmkQ1z78f9GTdQkOA==&amp;c=ENTE__PL853KJmSKMbPEuPTf9X9MCrBUHIc8sKoh6ZVHt3wzfOOmHA==&amp;ch=GbMf_WC2NChYct4ZlLlWazikXIR5I8M2oBMJa9_Q8vdVuOJsVLEGgA==" target="_blank">Human SOS1 Protein (Exchange Domain 564-1049) (Cat. # CS-SOS1)</a> <br /> <a href="http://r20.rs6.net/tn.jsp?f=001DQ5OSCRey1cWklujXS9QUkPk-tPLOepgHbB48BZlZ2-AA-42Re27IXZfHuGefCT4zrQ9QvDMaUlelpD1Jast88WJR16XBzn0kuKXr5IPP3AMSZ4QbrbHcldwhZypCpSU53YjJXRxLC1HP81Fkakd5IuLl_7rzUEQWnWDWsR-Crejlr11xgpeJdKKeS6LfzEzXi6_5-ye0A1EJLXLAD3amQFPR4ye0vAtq7jz_Dd_HlveOsvCGd3qcGxwfZpj78xgnpPeqFvqmiy4kQayZItTqwmoUQBFZ935WAO-aYEEt5pNIEHTR7T9U2OuIV0Mbl7QUmLfe_BKqzh-PiGo6hcgi4X19yCyYTo7&amp;c=ENTE__PL853KJmSKMbPEuPTf9X9MCrBUHIc8sKoh6ZVHt3wzfOOmHA==&amp;ch=GbMf_WC2NChYct4ZlLlWazikXIR5I8M2oBMJa9_Q8vdVuOJsVLEGgA==" target="_blank">Rhodamine Fibronectin (Cat. # FNR01)</a><br /> <a href="http://r20.rs6.net/tn.jsp?f=001DQ5OSCRey1cWklujXS9QUkPk-tPLOepgHbB48BZlZ2-AA-42Re27IXZfHuGefCT4fElVRH7RvSjQSpRPCwjgrHib_KTxhcRlFmbSFzw7XBm9Z8eX3ZV7oVcu9ax8ZMGV2kbRpCxDzZQpAWdCY1YH-uNyQA3khyq5KxX0jCFfsBfS2Xh5oBh3vcjXXUO6m5_SYKBXximpbX5fHcw6Iir6gEwFyj4Mldyq3W-rWvUV_fiqzY_zDa6L-DBrPKvtDWorEC0uRRNWoIFsHXjEtfQT3_WrCalPhZbqUzfnMi4MT1u7ZOQSMI-QpB_sImMknO-hDBlkDnufdkH0c68YwlkceGRhoiOycX7-&amp;c=ENTE__PL853KJmSKMbPEuPTf9X9MCrBUHIc8sKoh6ZVHt3wzfOOmHA==&amp;ch=GbMf_WC2NChYct4ZlLlWazikXIR5I8M2oBMJa9_Q8vdVuOJsVLEGgA==" target="_blank">Biotinylated Fibronectin (Cat. # FNR03)</a>&nbsp;</p>
</span></span></span></div>
<ol> </ol>]]></description>
      <pubDate>Tue, 09 May 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[April Newsletter: Post-translational Regulation of Phosphatase and Tensin Homolog (PTEN)]]></title>
      <link>https://www.cytoskeleton.com/blog/post-translational-regulation-of-phosphatase-and-tensin-homolog-pten/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/april-newsletter-posttranslational-regulation-of-phosphatase-and-tensin-homolog-pten" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-April-2017-Thumb.gif" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter." href="http://www.cytoskeleton.com/april-newsletter-posttranslational-regulation-of-phosphatase-and-tensin-homolog-pten" target="_self"><strong>Click to view&nbsp;this newsletter.&nbsp;</strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The phosphatidylinositol (3,4,5)-trisphosphate phosphatase and tensin homolog (PTEN) is a tumor supressor protein discovered 20 years ago by two independent laboratories1. PTEN is also known to regulate diverse cellular functions such as adhesion, migration, proliferation, growth, and survival. PTEN is composed of five domains: an N-terminal phosphatidylinositol (4,5)-bisphosphate (PIP2)-binding domain, a catalytic tensin-type phosphatase domain, a C2 tensin-type domain that binds phospholipids, a C-terminal tail domain, and a PDZ-binding domain (Fig. 1). The role of PTEN as a tumor suppressor is attributed to its lipid phosphatase activity which inhibits the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway integral for cell survival and growth by converting phosphatidylinositol (3,4,5)- trisphosphate (PIP3) into PIP2. <br /><br /><br /><a title="Click to read more" href="http://www.cytoskeleton.com/april-newsletter-posttranslational-regulation-of-phosphatase-and-tensin-homolog-pten" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Signal Seeker&trade; Kits and Pathway Tools, PTM Antibodies, Beads, and more. </li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 17 Apr 2017 13:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: PD-L1: Regulation by the Post-Translational Modification of Monoubiquitination]]></title>
      <link>https://www.cytoskeleton.com/blog/pd-l1-regulation-by-the-post-translational-modification-of-monoubiquitination/</link>
      <description><![CDATA[<table style="width: 100%; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="center">
<tbody>
<tr>
<td><img style="display: block; margin-left: auto; margin-right: auto;" title="Model: Profile of PD-L1 post-translational modifications and their roles in regulating PD-L1 protein levels." src="https://www.cytoskeleton.com/media/wysiwyg/PDL1-Figure5_1.gif" alt="Model: Profile of PD-L1 post-translational modifications and their roles in regulating PD-L1 protein levels." width="600" height="414" /><br /></td>
</tr>
<tr>
<td>
<div style="text-align: justify;">
<div style="text-align: justify;">
<p style="text-align: center;"><span style="font-size: xx-small;">Model: Profile of PD-L1 post-translational modifications and their roles in regulating PD-L1 protein levels.</span></p>
</div>
</div>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span>Recently, Horita et al. profiled four post-translational  modifications  (PTMs) of the programmed cell death ligand 1 (PD-L1)  protein, an  important immune checkpoint inhibitor and key target in  anti-cancer  treatments. Using a set of high-affinity, high-specificity  endogenous  PTM detection reagents, the authors examined PD-L1's levels  of tyrosine  phosphorylation, ubiquitination, acetylation, and  SUMOylation in A431  cells treated with epidermal growth factor (EGF).  These studies led to  the novel identification of PD-L1 modified  tyrosine phosphorylation,  acetylation, and mono- and  multi-ubiquitination. Critical temporal  studies led to the observation  that mono- and multi-ubiquitination  preceded an EGF-stimulated increase  in total PD-L1 protein expression.  Pharmacological inhibition of the  EGF receptor (EGFR) activation further  demonstrated that mono- and  multi-ubiquitination of PD-L1 relies upon  EGFR activation.&nbsp;  Importantly, inhibition of ubiquitin E1 activating  enzyme blocked any  increase in total PD-L1 protein, revealing a  potential mechanistic role  for ubiquitinated PD-L1 in the regulation of  total PD-L1 protein  levels. Cytoskeleton's Signal Seeker kits (Cat.#  <a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk160" target="_blank">BK160</a>, <a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk161" target="_blank">BK161</a>, <a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk162" target="_blank">BK162</a>), EGF (<a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/cn02" target="_blank">Cat.# CN02</a>), anti-acetyl lysine antibody  (<a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/acetyl-lysine-antibody" target="_blank">Cat.# AAC01</a>), and anti-tubulin antibody (<a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/atn02" target="_blank">Cat.# ATN02</a>)  were essential  reagents in this study, providing the tools necessary  for an insightful,  novel characterization of PTMs that can regulate  PD-L1, an important  protein in immune homeostasis, and anti-cancer  therapies.</span></p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a title="Horita H. et al. 2017. Identifying regulatory posttranslational modifications of PD-L1: A focus on monoubiquitination. Neoplasia. 19, 346-353. " href="http://www.sciencedirect.com/science/article/pii/S1476558617300295" target="_blank">Horita H. et al. 2017. Identifying regulatory posttranslational modifications of PD-L1: A focus on monoubiquitination. <em>Neoplasia. </em>19, 346-353.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161" target="_blank"></a></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161" target="_blank">Signal-Seeker&trade; Phosphotyrosine Enrichment Kit (30 assay) (Cat. # BK160)</a></span><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161" target="_blank"></a></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161" target="_blank">Signal-Seeker&trade; Phosphotyrosine Enrichment Kit (10 assay) (Cat. # BK160-S)</a></span><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161" target="_blank"></a></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161" target="_blank">Signal-Seeker&trade; Ubiquitination Enrichment Kit (30 assay) (Cat. # BK161)</a></span><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161-s" target="_blank"></a></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk161-s" target="_blank">Signal-Seeker&trade; Ubiquitination Enrichment Kit (10 assay) (Cat. # BK161-S)</a></span><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk162" target="_blank"></a></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk162" target="_blank">Signal-Seeker&trade; SUMOylation 2/3 Enrichment Kit (30 assay) (Cat. # BK162)</a></span><span>&nbsp;</span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span><span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk162-s" target="_blank">Signal-Seeker&trade; SUMOylation 2/3 Enrichment Kit (30 assay) (Cat. # BK162-S)</a></span></span><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/acetyl-lysine-antibody" target="_blank"></a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/acetyl-lysine-antibody" target="_blank">Acetyl Lysine Antibody Mouse Monoclonal (Cat. # AAC01)</a><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/cn02" target="_blank"></a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/cn02" target="_blank">Rac/Cdc42 Activator II (Cat. # CN02)</a><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/atn02" target="_blank"></a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a style="color: blue ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/atn02" target="_blank">Anti-alpha/beta tubulin: sheep polyclonal (Cat. # ATN02)</a></div>
<ol> </ol>]]></description>
      <pubDate>Wed, 29 Mar 2017 14:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[March Newsletter: Tau Post-Translational Modifications: Therapeutic Targets for Alzheimer’s Disease]]></title>
      <link>https://www.cytoskeleton.com/blog/march-newsletter-tau-post-translational-modifications-therapeutic-targets-for-alzheimers-disease/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/march-newsletter-tau-post-translational-modifications-therapeutic-targets-for-alzheimers-disease" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Tau_post-translational_modifications_Therapeutic_targets_for_Alzheimer_s_disease_2_.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter." href="http://www.cytoskeleton.com/march-newsletter-tau-post-translational-modifications-therapeutic-targets-for-alzheimers-disease" target="_self"><strong>Click to view&nbsp;this newsletter.&nbsp;</strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Worldwide, more than 47 million people have been diagnosed with dementia, and the majority of these cases are caused by Alzheimer&rsquo;s disease (AD); aside from the social burden, this neurodegenerative disease has an associated cost of 1.09% of the global gross domestic product. Severe cognitive impairment that leads to deficits in skilled movements, language, and recognition are pathophysiological hallmarks of AD. On a molecular level, neuropathological hallmarks include formation of beta-amyloid plaques and neurofibrillary tangles (NFTs) comprised of paired helical filaments of hyper-phosphorylated Tau proteins. This newsletter focuses on the mechanistic control of Tau by post-translational modifications (PTMs) and the development of novel AD therapeutics based on regulating the PTM status of Tau. <br /><br /><a title="Click to read more" href="http://www.cytoskeleton.com/march-newsletter-tau-post-translational-modifications-therapeutic-targets-for-alzheimers-disease" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Signal Seeker&trade; Kits and Pathway Tools, PTM Antibodies, Beads, and more. </li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 21 Mar 2017 13:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Selective G12D K-Ras Inhibitors Discovered via Phage Display Technology]]></title>
      <link>https://www.cytoskeleton.com/blog/selective-g12d-k-ras-inhibitors-discovered-via-phage-display-technology/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img title="K-Ras bound to a small molecule to prevent activation by Cat. # SOS1" src="https://www.cytoskeleton.com/media/wysiwyg/K-Ras_bound_to_a_small_molecule_to_prevent_activation_by_SOS1.png" alt="K-Ras bound to a small molecule to prevent activation by Cat. # SOS1" width="200" /><br /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;">
<div style="text-align: justify;">
<p><span style="font-size: xx-small;">GDP-K-Ras complexed to a phenol moiety (small arrow head; PDB code 4EPT; 2-hydroxyphenyl)(pyrrolidin-1-yl)methanethione) as described in Sun Q. et al. 2012. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem. Int. Ed. Engl. 51, 6140&ndash;6143.</span></p>
</div>
</div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span>Recently, Sakamoto et al. discovered novel peptide inhibitors of  the G12D mutant K-Ras GTPase. Of the three Ras isoforms (H-, K-, and  N-), K-Ras is considered the most relevant anti-cancer drug target as  K-Ras mutations underlie 86% of Ras-linked cancers with 83% of K-Ras  mutations at the G12 residue. Development of K-Ras-targeting anti-cancer  drugs remains elusive due to the paucity of small, druggable pockets on  the GTPase&rsquo;s surface and picomolar binding affinity between K-Ras and  GDP/GTP nucleotides. Here, the authors screened random peptide libraries  displayed on T7 phage against recombinant G12D K-Ras in the presence of  GDP to identify selective G12D K-Ras inhibitors. Sequence optimization  produced a selective G12D K-Ras inhibitor (IC50, 1.6 nM) in a  SOS1-mediated GDP/GTP exchange assay. At 30 </span><span>m</span><span>M,  this inhibitor also reduced proliferation and downstream K-Ras  signaling in cancer cells. While less than optimal cell membrane  permeability and loss of activity under reducing conditions were  shortcomings with this peptide, the discovery of selective G12D K-Ras  inhibitors provides a blueprint for the design of future,  clinically-relevant K-Ras inhibitors. Cytoskeleton&rsquo;s SOS1 exchange  domain protein (564-1049 amino acids; Cat.# CS-SOS1) was used in the  GDP/GTP exchange assay to confirm inhibition of G12D K-Ras activation  using BODIPY-FL-GDP.</span></p>
<p>&nbsp;</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><span style="color: black;"><a style="color: blue; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/28153726" target="_blank">Sakamoto  K. et al. 2017. K-Ras(G12D)-selective inhibitory peptides generated by  random peptide T7 phage display technology. Biochem. Biophys. Res.  Commun. DOI: 10.1016/j.bbrc.2017.01.147. </a></span></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span style="font-size: 10pt;"><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/sos1-protein-human-cs-sos1" target="_blank">Human SOS1 Protein (Exchange Domain 564-1049) (Cat. # CS-SOS1)</a> <br /></span></div>
<ol> </ol>]]></description>
      <pubDate>Thu, 16 Mar 2017 07:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[February Newsletter: Actin-binding proteins and F-actin in dendrite cell migration ]]></title>
      <link>https://www.cytoskeleton.com/blog/feb-newsletter-actin-binding-proteins-and-f-actin-in-dendrite-cell-migration/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/feb-newsletter-actin-binding-proteins-and-f-actin-in-dendrite-cell-migration" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Feb17-Newsletter-Img-Thumb.gif" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter." href="http://www.cytoskeleton.com/feb-newsletter-actin-binding-proteins-and-f-actin-in-dendrite-cell-migration" target="_self"><strong>Click to view&nbsp;this newsletter.&nbsp;</strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Dendritic cells (DCs) are antigen-presenting cells of the mammalian immune system that exist in either an immature, unactivated state or a mature, activated state. Immature DCs (iDCs) patrol peripheral tissues for foreign and/or pathogenic antigens (i.e., antigen sampling), localizing to sites of inflammation. Once there, iDCs find and internalize antigens by phagocytosis, macropinocytosis, or cell surface receptor-mediated endocytosis. During these activities, iDCs fluctuate between fast and slow motility, respectively, presumably to provide an optimal speed for efficient antigen sampling and capture. Concomitant with antigen capture and processing, iDCs undergo maturation, including changes in F-actin and myosin II functional localization which underlies the shift to primarily fast motility. Degraded antigens are presented on the mature dendritic cell surface as major histocompatibility complex (MHC)-II-peptide complexes. Activated DCs migrate chemotactically via lymphatic vessels to na&iuml;ve T cells in lymphoid organs (e.g., lymph nodes) where the captured antigens are presented to T cells (i.e., immunological synapse), thereby activating them and the adaptive immune system response (Fig. 1).<br /><br /></p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/feb-newsletter-actin-binding-proteins-and-f-actin-in-dendrite-cell-migration" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Actin Live Cell Imaging, Acti-Stain&trade; Phalloidins, Actin Biochem Kits, Actin and Actin Binding Protein Antibodies</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Wed, 22 Feb 2017 17:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Characterization of Novel 3D In Vitro Model of Cancer Cell Invasion]]></title>
      <link>https://www.cytoskeleton.com/blog/characterization-of-novel-3d-in-vitro-model-of-cancer-cell-invasion/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title=" 	Swiss 3T3 cell stained with anti-vinculin (red), Dapi (blue nucleus) and F-actin is stained with Acti-stain&trade; 488 (green F-actin, Cat.# PHDG1)." src="https://www.cytoskeleton.com/media/wysiwyg/febcitationdiagram.jpg" alt=" 	Swiss 3T3 cell stained with anti-vinculin (red), Dapi (blue nucleus) and F-actin is stained with Acti-stain&trade; 488 (green F-actin, Cat.# PHDG1)." width="235" height="163" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;">
<div style="text-align: justify;">
<p><span style="font-size: xx-small;">Composition and architecture of extracellular matrix (ECM). Basement membrane is a type of ECM composed of laminin and collagen IV fibers embedded within a collagen I-enriched ECM.</span></p>
</div>
</div>
<address> </address></td>
</tr>
<tr>
<td><address><img style="display: block; margin-left: auto; margin-right: auto;" src="https://www.cytoskeleton.com/media/wysiwyg/FNR01_overlay_with_DIC_v3b.jpg" alt="" width="235" /></address></td>
</tr>
<tr>
<td style="text-align: justify;"><span style="font-size: xx-small;"><a title="Cat. # FNR01" href="http://www.cytoskeleton.com/fnr01" target="_blank">FNR01 </a>image overlay with phase contrast background. Fluorescent fibronectin (<a title="Cat. # FNR01" href="http://www.cytoskeleton.com/fnr01" target="_blank">Cat. # FNR01</a>) treated MCF10A cells (image kindly provided by A. Varadara and M. Karthykenyan, Univ. S.Carolina, Columbia, SC).</span></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, Guzman et al. characterized a novel 3D in vitro model of multicellular cancer cell invasion that offers adjustable physiological and biochemical parameters. Shortcomings of current models are poor microscopic imaging dynamics and inability to study transmigration of cancer cells across the basement membrane (BM) and then invasion of an extracellular matrix (ECM), as happens in vivo. The BM is a type of ECM that surrounds a tumor, formed in a multi-step process initiated by cancer cells binding laminin at the cell surface to form a scaffold upon which type IV collagen polymers form. This new model offers improved imaging dynamics while also recapitulating in vivo tumor cytoarchitecture with an intact, degradable, cell-assembled, sheet-like BM layer embedded in a collagen I-enriched ECM. Cytoskeleton&rsquo;s HiLyte488-conjugated laminin (<a title="Cat. # LMN02" href="cytoskeleton.com/lmn02" target="_blank">Cat. # LMN02</a>) was used to confirm that in vitro BM layer formation paralleled the in vivo process; that is, the laminin scaffold was dispersed across the surface of the multicellular tumor spheroids in a thin, patchy layer, serving as the foundation of the BM layer. This innovative 3D cancer cell invasion model offers researchers the ability to both tease apart molecular mechanisms underlying invasion and test new therapeutics in a physiologically- and biochemically-relevant setting.</p>
<p>&nbsp;</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a title="Guzman A. et al. 2016. A novel 3D in vitro metastasis model elucidates differential invasive strategies during and after breaching basement membrane. Biomaterials. 115, 19-29. " href="https://www.ncbi.nlm.nih.gov/pubmed/27880891" target="_blank">Guzman A. et al. 2016. A novel 3D in vitro metastasis model elucidates differential invasive strategies during and after breaching basement membrane. <em>Biomaterials. </em><strong>115, </strong>19-29.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="Laminin (Green fluorescent, HiLyte 488)" href="http://www.cytoskeleton.com/lmn02" target="_blank">Laminin (Green Fluorescent, HiLyte 488) (Cat. # LMN02)</a></div>
<ol> </ol>]]></description>
      <pubDate>Tue, 21 Feb 2017 15:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[New 2017 Cytoskeleton Minicatalog]]></title>
      <link>https://www.cytoskeleton.com/blog/introducing-the-2017-cytoskeleton-minicatalog/</link>
      <description><![CDATA[<table style="width: 100%;" border="0" align="center">
<tbody>
<tr>
<td>
<table style="width: 200px;" border="0" align="right">
<tbody>
<tr>
<td><a title="Click here to download" href="http://www.cytoskeleton.com/pdf-storage/Cytoskeleton%20Mini-Catalog%202016%20web.pdf" target="_blank"><img title="2017 Cytoskeleton Minicatalog Cover" src="https://www.cytoskeleton.com/media/wysiwyg/MCat17-Cover-Img-Thumb.gif" alt="2017 Cytoskeleton Minicatalog Cover" width="200" /></a></td>
</tr>
<tr>
<td style="text-align: center;"><a title="Click to Download" href="http://www.cytoskeleton.com/pdf-storage/Cytoskeleton%20Mini-Catalog%202016%20web.pdf" target="_blank"><span style="font-size: medium;">Click Here to Download</span></a></td>
</tr>
</tbody>
</table>
<h1 style="text-align: center;"><span style="color: #000000; font-size: large;">New Products, New Discoveries!</span></h1>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a title="New SUMO Kits and More!" href="http://www.cytoskeleton.com/signal-seeker" target="_blank"><span style="font-size: large;">Signal Seeker Kits</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">New SUMO Kits and More!</span></p>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a title="GOBlot Western Blot Processor" href="http://www.cytoskeleton.com/western-blot-processor-goblot" target="_blank"><span style="font-size: large;">GOBlot&trade; Western Blot Processor</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">New Colors Available!</span></p>
<h2 style="text-align: center;"><span style="color: #ff0000;"><a title="New Far-Red Probes!" href="http://www.cytoskeleton.com/far-red-spirochrome-bioreagents" target="_blank"><span style="font-size: large;">Spirochrome Live Cell Reagents</span></a></span></h2>
<p style="text-align: center;"><span style="font-size: large;">New Far-Red Probes!</span></p>
</td>
</tr>
</tbody>
</table>
<hr />
<p>&nbsp;</p>
<table style="width: 100%;" border="0" align="center">
<tbody>
<tr>
<td>
<table style="width: 250px; margin-left: 15px;" border="0" align="right">
<tbody>
<tr>
<td><a title="New Signal-Seeker Kits" href="http://www.cytoskeleton.com/signal-seeker" target="_blank"><img style="display: block; margin-left: auto; margin-right: auto;" title="Phosphorylated Rac1 Modified GTPase Cycle" src="https://www.cytoskeleton.com/media/wysiwyg/Phosphorylated_Rac1_Modified_GTPase_Cycle.jpg" alt="Phosphorylated Rac1 Modified GTPase Cycle" width="250" /></a></td>
</tr>
<tr>
<td style="text-align: center;"><span style="font-size: x-small;">Legend: Rac1 GTPase cycle<br /> regulation by phosphorylation</span></td>
</tr>
</tbody>
</table>
<h2><span style="font-size: large;">New SUMO Signal Seeker&trade; Kit and More!</span></h2>
<p style="text-align: justify;">The functional component of the SUMO 2/3 Enrichment Kit is an anti-SUMO-2/3 antibody (clone: 11G2) which is provided as a chemically crosslinked Protein G bead conjugate. The affinity bead reagent was optimized to give no detectable leaching of either heavy or light chains in an IP assay, making the resulting data extremely specific, sensitive and clean. The affinity beads immunoprecipitate a wide range of SUMO-2/3 targeted proteins in cell extracts). Both endogenous mono- and poly- SUMOylated proteins are easily detected with characteristic multiple bands in the Western Blot detection method.</p>
<p><span style="color: #000000;"><span style="color: #ff0000;"><strong>NEW </strong></span>Signal Seeker&trade; SUMO Enrichment Kit, <a title="Signal-Seeker&trade; SUMOylation Enrichment Kit (30 assays), Cat. # BK162" href="http://www.cytoskeleton.com/bk162" target="_blank">Cat. # BK162</a></span></p>
<p><span style="color: #000000;">Signal Seeker&trade; Phosphotyrosine Enrichment Kit, <a title="Signal-Seeker&trade; Phosphotyrosine Enrichment Kit (30 assays), Cat. # BK160" href="http://www.cytoskeleton.com/bk160" target="_blank">Cat. # BK160</a></span></p>
<p><span style="color: #000000;">Signal Seeker&trade; Ubiquitination Enrichment Kit, <a title="Signal-Seeker&trade; Ubiquitination Enrichment Kit (30 assays), Cat. # BK161" href="http://www.cytoskeleton.com/bk161" target="_blank">Cat. # BK161</a></span></p>
</td>
</tr>
</tbody>
</table>
<hr />
<p>&nbsp;</p>
<table style="width: 100%;" border="0" align="center">
<tbody>
<tr>
<td>
<h2><span style="font-size: large;">GOBlot&trade; Western Blot Processor: More New Colors!</span></h2>
<p><a title="GOBlot Western Blot Processor: More New Colors!" href="http://www.cytoskeleton.com/western-blot-processor-goblot" target="_blank"><img style="display: block; margin-left: auto; margin-right: auto;" title="New GOBlot Colors" src="https://www.cytoskeleton.com/media/wysiwyg/goblot-rainbow-updated.jpg" alt="New GOBlot Colors" width="100%" /></a></p>
<p style="text-align: justify;">The GOBlot&trade; Western Blot Processor (patents pending) was developed to be an affordable and helpful device for all scientists. With input from over 300 research scientists, the flexible routines and capabilities of the processor were defined. Western blot automation with the GOBlot saves the average researcher 3 hours a day while improving the reproduciblity of results. For more information click here.</p>
<p><span style="color: #000000;">GOBlot&trade; Western Blot Processor, <a title="GOBlot Western Blot Processor: More New Colors!" href="http://www.cytoskeleton.com/western-blot-processor-goblot">Cat. # WBM01</a></span></p>
</td>
</tr>
</tbody>
</table>
<hr />
<p>&nbsp;</p>
<table style="width: 100%;" border="0" align="center">
<tbody>
<tr>
<td>
<table style="width: 180px; margin-left: 15px;" border="0" align="right">
<tbody>
<tr>
<td><a title="Far-red Actin and Tubulin live cell imaging reagents" href="http://www.cytoskeleton.com/live-cell-reagents/spirochrome" target="_blank"><img title="Spirochrome Image Gallery" src="https://www.cytoskeleton.com/media/wysiwyg/gen-img-gal.jpg" alt="Spirochrome Image Gallery" width="180" /></a></td>
</tr>
</tbody>
</table>
<h2>New Far-Red and Lysosome Spirochrome Live Cell Probes!</h2>
<p style="text-align: justify;">We are excited to introduce Spirochrome's latest offering for live cell studies of the endosomal pathway. The new SiR-Lysosome and SiR700-Lysosome products can simply be added to tissue culture media or injected into tissue and the endosomes and lysosomes will be rapidly labeled with red or far-red fluorescence respectively. As for other Spirochrome probes, the new probes are compatible with dual fluorescence microscopy, cell-permeable, fluorogenic, non-cytotoxic, and compatible with super-resolution microscopy. Read more about their research applications and citations below.</p>
<p><span style="color: #000000;"><span style="color: #ff0000;"><strong>NEW</strong> </span>SiR700-Actin Kit, <a title="SiR700-Actin Kit" href="http://www.cytoskeleton.com/cy-sc013" target="_blank">Cat. # CY-SC013</a></span></p>
<p><span style="color: #000000;"><span style="color: #ff0000;"><strong>NEW </strong></span>SiR700-Tubulin Kit, <a title="SiR700-Tubulin Kit" href="http://www.cytoskeleton.com/cy-sc014" target="_blank">Cat. # CY-SC014</a></span></p>
<p><span style="color: #000000;"><span style="color: #ff0000;"><strong>NEW </strong></span>SiR700-DNA Kit, <a title="SiR700-DNA Kit" href="http://www.cytoskeleton.com/cy-sc015" target="_blank">Cat. # CY-SC015</a></span></p>
<p><span style="color: #000000;"><span style="color: #ff0000;"><strong>NEW </strong></span>SiR700-Lysosome Kit, <a title="SiR700-Lysosome Kit" href="http://www.cytoskeleton.com/cy-sc016" target="_blank">Cat. # CY-SC016</a></span></p>
<p><span style="color: #000000;"><span style="color: #ff0000;"><strong>NEW </strong></span>SiR-Lysosome Kit, <a title="SiR-Lysosome Kit" href="http://www.cytoskeleton.com/cy-sc012" target="_self">Cat. # CY-SC012</a></span></p>
</td>
</tr>
</tbody>
</table>]]></description>
      <pubDate>Thu, 16 Feb 2017 15:40:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Rac1 GTPase activity: Role in Lung Cancer Proliferation, Migration, and Metastasis]]></title>
      <link>https://www.cytoskeleton.com/blog/rac1-gtpase-activity-role-in-lung-cancer-proliferation-migration-and-metastasis/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title=" 	Swiss 3T3 cell stained with anti-vinculin (red), Dapi (blue nucleus) and F-actin is stained with Acti-stain&trade; 488 (green F-actin, Cat.# PHDG1)." src="https://www.cytoskeleton.com/media/wysiwyg/PHDG1_img1.jpg" alt=" 	Swiss 3T3 cell stained with anti-vinculin (red), Dapi (blue nucleus) and F-actin is stained with Acti-stain&trade; 488 (green F-actin, Cat.# PHDG1)." width="210" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;">
<div style="text-align: justify;"><span style="font-size: small;">Swiss   3T3 cell stained with  anti-vinculin (red), DAPI  (blue nucleus) and   F-actin is stained with  Acti-stain&trade; 488 (green  F-actin stress fibers, <a title="Acti-stain 488 phalloidin" href="http://www.cytoskeleton.com/phdg1" target="_blank">Cat.# PHDG1</a>).</span></div>
</div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, Jeganathan et al. examined the role of intersectin-1s (ITSN-1s) in lung cancer proliferation, migration, and metastasis. These cellular processes require actin cytoskeleton re-arrangement typically regulated by RhoA, Rac1, and/or Cdc42 GTPases. ITSN-1s is a multi-domain adaptor protein linking cell surface receptors to intracellular signaling cascades. ITSN-1s&rsquo;s expression levels are reduced in human lung cancer cells and tissues. Among many findings, the authors report that ITSN-1s down-regulates the epidermal growth factor receptor kinase substrate 8 (Eps8) via ubiquitination and degradation, which in turn decreases the Eps8 and Ras/Rac1 guanine exchange factor mSos1 complex. The Eps8/mSos1 complex activates Rac1 which mediates the subsequent actin cytoskeletal re-arrangements necessary for cancer cell migration and metastasis. Restoration of normal ITSN-1s levels decreases Rac1 activation, increases RhoA activation (leaving Cdc42 activity unaffected), and results in a cytoskeletal network unfavorable to cancer cell migration and metastasis. Cytoskeleton&rsquo;s RhoA, Rac1, and Cdc42 pull-down activation assays (Cat.# <a title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays" href="http://www.cytoskeleton.com/bk036" target="_blank">BK036</a>, <a title="Rac1 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk035" target="_blank">BK035</a>, and <a title=" Cdc42 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk034" target="_blank">BK034</a>, respectively) were essential for the quantification of RhoA, Rac1, and Cdc42 activities across different levels of ITSN-1s expression. These results suggest that ITSN-1s could serve not only as a novel therapeutic target, but also a prognostic and therapeutic response indicator for lung cancer (and maybe others).</p>
<p>&nbsp;</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a title="Jeganathan N. et al. 2016. Rac1-mediated cytoskeleton rearrangements induced by intersectin-1s deficiency promotes lung cancer cell proliferation, migration and metastasis. Mol. Cancer. 15, 59. " href="https://www.ncbi.nlm.nih.gov/labs/articles/27629044/" target="_blank">Jeganathan N. et al. 2016. Rac1-mediated cytoskeleton rearrangements induced by intersectin-1s deficiency promotes lung cancer cell proliferation, migration and metastasis. <em>Mol. Cancer. </em><strong>15</strong>,<strong> </strong>59.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays" href="http://www.cytoskeleton.com/bk036" target="_blank">RhoA Pull-Down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays (Cat. # BK036)</a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays" href="http://www.cytoskeleton.com/bk036" target="_blank">Rac1 Pull-Down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays </a><a title="Rac1 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk035" target="_blank">(Cat. # BK035)</a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays" href="http://www.cytoskeleton.com/bk036" target="_blank">Cdc42 Pull-Down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays </a><a title=" Cdc42 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk034" target="_blank">(Cat. # BK034)</a></div>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 23 Jan 2017 15:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Rho-Family GTPase Activity: Key Components of Anti-Inflammatory and Neuroprotective Pathway]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-family-gtpase-activity-key-components-of-anti-inflammatory-and-neuroprotective-pathway/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title="Rac activation in Swiss 3T3 fibroblasts. F-actin is visualized with fluorescent green phalloidin staining (Cat.# PHDG1). DAPI is the blue nuclear stain. Phalloidin staining shows F-actin-rich lamellipodia. Cells were activated with Cat.# CN04." src="https://www.cytoskeleton.com/media/wysiwyg/Rac_Ruffles_PAEC_40x_1.jpg" alt="Rac activation in Swiss 3T3 fibroblasts. F-actin is visualized with fluorescent green phalloidin staining (Cat.# PHDG1). DAPI is the blue nuclear stain. Phalloidin staining shows F-actin-rich lamellipodia. Cells were activated with Cat.# CN04." width="210" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;">
<div style="text-align: justify;">Rac   activation in Swiss 3T3 fibroblasts. F-actin is visualized with fluorescent   green phalloidin staining (<a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/phdg1" target="_blank">Cat.# PHDG1</a>). DAPI is the blue   nuclear stain. Phalloidin staining shows F-actin-rich lamellipodia. Cells   were activated with <a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/cn04" target="_blank">Cat.# CN04</a>.</div>
</div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, Rom et al. examined molecular pathways involved in leukocyte-mediated neuroinflammation given its causative role in neuronal dysfunction associated with brain injuries and diseases. Neuroinflammation involves a compromised blood-brain barrier (BBB) as leukocytes need to engage brain endothelial cells. To do so, leukocytes utilize integrin adhesion receptors for rolling, arrest, adhesion, and transendothelial migration (TEM), processes requiring Rho-family GTPase-mediated rearrangement of the actin cytoskeleton. Here, the activation of VLA-4 and LFA-1 leukocyte integrins following inhibition of PARP (poly(ADP-ribose) polymerase 1) activity in leukocytes was studied with the goal of preventing BBB breakdown. Using primary human brain microvascular endothelial cells to model the BBB, PARP inhibitors reduced leukocyte adhesion and TEM, concomitant with decreased activation of the two integrins and RhoA and Rac1 GTPases, as well as a reduced F-/G-actin ratio. Cytoskeleton&rsquo;s RhoA and Rac1 G-LISA activation assays (Cat.# <a href="http://www.cytoskeleton.com/bk124" target="_blank">BK124</a> and <a href="http://www.cytoskeleton.com/bk128" target="_blank">BK128</a>, respectively), Acti-stain 488 phalloidin (<a href="http://www.cytoskeleton.com/phdg1" target="_blank">Cat.# PHDG1</a>), and cell-permeable Rho inhibitor (<a href="http://www.cytoskeleton.com/ct04" target="_blank">Cat.# CT04</a>) and Rho/Rac/Cdc42 activator (<a href="http://www.cytoskeleton.com/cn04" target="_blank">Cat.# CN04</a>) were essential reagents, allowing for sensitive and reliable quantification of RhoA and Rac1 activation under control and experimental conditions while also measuring dynamic actin cytoskeletal changes. These results suggest novel therapies for protecting BBB integrity following brain disease and injury.</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a href="https://www.ncbi.nlm.nih.gov/labs/articles/27677851/" target="_blank">Rom S. et al. 2016. PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier. <em>J. Inflammation. </em><strong>13</strong>,<strong> </strong>254.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a href="http://www.cytoskeleton.com/bk124" target="_blank"><span style="font-size: small;">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays, Cat. # BK124<strong>&nbsp;</strong></span></a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a href="http://www.cytoskeleton.com/bk128" target="_blank"><span style="font-size: small;"><span style="font-size: small;">Rac1 G-LISA Activation Assay Kit (Colorimetric Based) 96 assays, Cat. # </span>BK128<strong>&nbsp;</strong></span></a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a href="http://www.cytoskeleton.com/cn04" target="_blank"><span style="font-size: small;"><span style="font-size: small;">Rho/Rac/Cdc42 Activator I, Cat. # </span>CN04<strong>&nbsp;</strong></span></a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a href="http://www.cytoskeleton.com/ct04" target="_blank"><span style="font-size: small;"><span style="font-size: small;">Rho Inhibitor I, Cat. # </span>CT04</span></a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span style="font-size: small;"><a href="http://www.cytoskeleton.com/phdg1" target="_blank"><span style="font-size: small;">Acti-stain 488 Phalloidin, Cat. # </span>PHDG1</a></span></div>
<ol> </ol>]]></description>
      <pubDate>Thu, 15 Dec 2016 11:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Custom Services Newsletter: Rho Family GTPases and Central Nervous System Injuries, Diseases, and Disorders]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-family-gtpases-and-central-nervous-system-injuries-diseases-and-disorders/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/rho-family-gtpases-and-central-nervous-system-injuries-diseases-and-disorders/" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/julyCSDthumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter." href="http://www.cytoskeleton.com/rho-family-gtpases-and-central-nervous-system-injuries-diseases-and-disorders/" target="_self"><strong><br />Click to view&nbsp;this newsletter.&nbsp;</strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Effective treatments for central nervous system (CNS) injuries, diseases, and disorders remain a serious challenge for preclinical research scientists and clinicians This newsletter discusses some compounds that are in clinical trials or proteins/pathways that warrant consideration as therapeutic targets.</p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/rho-family-gtpases-and-central-nervous-system-injuries-diseases-and-disorders/" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Custom Modules</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Citations</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>
<div id="_mcePaste" class="mcePaste" style="position: absolute; left: -10000px; top: 0px; width: 1px; height: 1px; overflow: hidden;">Cardiovascular disease accounts for roughly one in every three deaths in the USA with heart disease accounting for the majority of these cases1.&nbsp; The pathology of heart disease often involves the death or dysfunction of cardiomyocytes, specialized heart cells that produce the contractile, beating function of the heart.&nbsp; Many different proteins and cell machinery, such as ion channels and pumps, cytoskeletal proteins, and receptors play a significant role in regulating the contractile ability of cardiomyocytes.&nbsp; Interestingly, many of these proteins are regulated through post-translational modifications (PTMs), in part because PTMs allow for rapid, but subtle changes to a protein as part of an overall cellular response2.</div>]]></description>
      <pubDate>Mon, 05 Dec 2016 18:15:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[November/December Newsletter: Small molecule inhibitors of GEF-mediated GTPase signaling]]></title>
      <link>https://www.cytoskeleton.com/blog/novdec-newsletter-small-molecule-inhibitors-of-gef-mediated-gtpase-signaling/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/novdec-newsletter-small-molecule-inhibitors-of-gef-mediated-gtpase-signaling" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-NovDec-2016-Small-Molecule-Inhibitors-of-GEF-mediated-GTPase-Signaling.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter." href="http://www.cytoskeleton.com/novdec-newsletter-small-molecule-inhibitors-of-gef-mediated-gtpase-signaling" target="_self"><strong>Click to view&nbsp;this newsletter.&nbsp;</strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Ras and Rho-family GTPases regulate multiple cellular processes,  including development, growth, motility, intracellular trafficking, gene  expression, and the cell cycle<sup>1,2</sup>. Moreover, dysfunction of  these GTPase are correlated with several human diseases (e.g., cancer,  neurodegeneration, bacterial pathogenesis)<sup>3-5</sup>. Like all  GTPases, Ras and Rho GTPases cycle between active (GTP-bound) and  inactive (GDP-bound) states. Guanine nucleotide exchange factors (GEFs)  regulate GTPase activation, driving the exchange of GDP for GTP in  response to a variety of physiological and pathological extracellular  signals<sup>1,2</sup>. Thus, GEFs are therapeutic targets; however,  small molecule inhibitors require hydrophobic pockets for binding which  are not typically found on GEFs (or&nbsp; GTPases). Only recently have novel  binding pockets on GEFs and GTPases been discovered<sup>6,7</sup>. In  this light, the current newsletter explores small molecule inhibitors of  Ras (N-, H-, K-Ras) and Rho (RhoA, Rac1, Cdc42) GEFs that inhibit  through direct binding.</p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/novdec-newsletter-small-molecule-inhibitors-of-gef-mediated-gtpase-signaling" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Custom GEF Protein Production, G-protein Effector Proteins and Kits, G-Switch Activators and Inhibitors</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 14 Nov 2016 17:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Novel Tubulin Polymerization Inhibitor and Multidrug Resistance]]></title>
      <link>https://www.cytoskeleton.com/blog/novel-tubulin-polymerization-inhibitor-and-multidrug-resistance/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title="Crystal structure of tubulin-colchicine complex." src="https://www.cytoskeleton.com/media/wysiwyg/tubulin-colchicine-binding-complex.jpg" alt="Crystal structure of tubulin-colchicine complex." width="210" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;"><address style="text-align: justify;">Crystal structure of tubulin-stathimine-colchicine complex.<br /></address></div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, Zheng et al. identified and characterized a novel tubulin polymerization inhibitor discovered during anti-cancer compound screenings using the epithelial-mesenchymal transition (EMT)-mimetic assay. The lead compound was a nitrobenzoate molecule (2-morpholin-4-yl-5-nitro-benzoic acid 4-methylsulfanyl-benzyl ester), designated as compound IMB5046. As part of the <em>in vitro</em> and <em>in vivo</em> characterization process, <em>in vitro</em> tubulin polymerization assays with 97% tubulin/3% microtubule-associated proteins (MAPs) under cell-free conditions demonstrated that the compound inhibits tubulin polymerization, complementing findings from cell culture and mouse xenograft model studies. In addition, surface plasmon resonance (SPR) technology quantified the binding interaction of IMB5046 and tubulin, using biotinylated tubulin and streptavidin-coated sensor chips.&nbsp; SPR data demonstrated a concentration-dependent, direct interaction and an equilibrium dissociation constant (K<sub>d</sub>) of 31.9 &micro;M for IMB5046. Cytoskeleton&rsquo;s HTS-tubulin polymerization assay kit and &gt;99% pure biotinylated porcine brain tubulin (Cat.# <a title="BK004P" href="http://www.cytoskeleton.com/bk004p" target="_blank">BK004P</a> and <a title="T333P" href="http://www.cytoskeleton.com/t333p" target="_blank">T333P</a>, respectively) were essential in this study, providing the necessary research tools to measure the effect of IMB5046 on <em>in vitro</em> tubulin polymerization as well as the binding kinetics with tubulin. In combination with the other findings, a unique, anti-cancer compound with novel chemical structure and the ability to inhibit tubulin polymerization in multidrug-resistant cancer cell lines has been discovered and described.</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><span style="color: black;"><span style="color: black;"><a style="color: blue; text-decoration: underline;" href="http://www.nature.com/articles/srep31472" target="_blank">Zheng  Y.-B. et al. 2016. A novel nitrobenzoate microtubule inhibitor that  overcomes multidrug resistance exhibits antitumor activity. Sci. Rep. 6,  31472.&nbsp; </a><br /></span></span></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<p style="padding-left: 30px;"><span style="font-size: 9pt; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: black;"><a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/t333p" target="_blank">Tubulin Protein (Biotin): Porcine Brain, Cat. # T333P</a></span><br /><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk004p" target="_blank">Tubulin Polymerization Assay Biochem Kit (HTS applications, absorbance): porcine tubulin: 24 assays, Cat. # BK004P</a></p>
<ol> </ol>]]></description>
      <pubDate>Tue, 08 Nov 2016 13:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Rho GTPases and epidermal stem cell migration ]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-family-gtpase-signaling-pathways-essential-for-nitric-oxide-mediated-epidermal-stem-cell-migration/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title="Figure 1. RhoGAP activity measured as GTP hydrolysis by RhoA protein. Each reaction contained reaction buffer + GTP with the addition of RhoA alone (RhoA), RhoGAP alone (GAP), or RhoA + RhoGAP (RhoA + GAP). Reactions were incubated at 37&deg;C for 20 min. Phosphate generated by hydrolysis of GTP was measured by the addition of CytoPhos&trade; reagent and reading of absorbance at 650 nm." src="https://www.cytoskeleton.com/media/wysiwyg/G-Switch-Rho_Stress-Fibers-3T3-with-CN03-250x250.png" alt="Figure 1. RhoGAP activity measured as GTP hydrolysis by RhoA protein. Each reaction contained reaction buffer + GTP with the addition of RhoA alone (RhoA), RhoGAP alone (GAP), or RhoA + RhoGAP (RhoA + GAP). Reactions were incubated at 37&deg;C for 20 min. Phosphate generated by hydrolysis of GTP was measured by the addition of CytoPhos&trade; reagent and reading of absorbance at 650 nm." width="210" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;"><address style="text-align: justify;">Rho activation in Swiss 3T3 fibroblasts. F-actin is visualized with fluorescent green phalloidin staining (<a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/phdg1" target="_blank">Cat.# PHDG1</a>). DAPI is the blue nuclear stain. Phalloidin staining shows F-actin-rich stress fibers. Cells were activated with <a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/cn04" target="_blank">Cat.# CN04</a>.</address></div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, Zhan et al. investigated the molecular pathways underlying human epidermal stem cell (hESC) migration during wound repair to better understand the activity of these cells in the restoration of skin cell and hair follicle homeostasis during wound repair and healing. The authors discovered that nitric oxide (NO) stimulates hESC migration during wound repair and healing, and using the NO donor S-nitroso-N-acetylpenicillamine (SNAP), demonstrated that NO promotes the migration of hESCs <em>in vivo</em> and <em>in vitro</em>. Furthermore, NO-mediated hESC migration <em>in vitro</em> requires cGMP-mediated activation of RhoA and Rac1 (but not Cdc42) signaling pathways. These signaling pathways were examined given that cell migration requires dynamic cell morphology changes which necessitate the re-arrangement of a cell&rsquo;s actin cytoskeleton, which is strongly regulated by Rho-family GTPases. Cytoskeleton&rsquo;s Cdc42, Rac1, and RhoA pull-down activation assays (Cat. # <a title="Cdc42 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk034" target="_blank">BK034</a>, <a title="Rac1 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk035" target="_blank">BK035</a>, <a title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays" href="http://www.cytoskeleton.com/bk036" target="_blank">BK036</a>, respectively) were essential in this study, providing researchers with the necessary research tools to measure Rho-family GTPase activities in a sensitive and consistent manner. These results provide valuable insight into the essential role that Rho-family GTPases have in NO-mediated hESC migration during wound repair and healing to restore proper cellular homeostasis.</p>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a title="Zhan R. et al. 2016. Nitric oxide promotes epidermal stem cell migration via cGMP-Rho GTPase signaling. Sci. Rep. 6, 30687." href="http://www.ncbi.nlm.nih.gov/pubmed/25799230" target="_blank">Zhan R. et al. 2016. Nitric oxide promotes epidermal stem cell migration via cGMP-Rho GTPase signaling. <em>Sci. Rep. </em><strong>6</strong>, 30687.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<p style="padding-left: 30px;"><a title="Cdc42 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk034" target="_blank">Cdc42 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays, Cat. # BK034</a></p>
<p style="padding-left: 30px;"><a title="Rac1 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays" href="http://www.cytoskeleton.com/bk035" target="_blank">Rac1 Pull-down Activation Assay Biochem Kit (bead pull-down format) - 50 Assays, Cat. # BK035</a></p>
<p style="padding-left: 30px;"><a title="RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays" href="http://www.cytoskeleton.com/bk036" target="_blank">RhoA Pull-down Activation Assay Biochem Kit (bead pull-down format) - 80 Assays, Cat. # BK036</a></p>
<ol> </ol>]]></description>
      <pubDate>Mon, 19 Sep 2016 14:20:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[September Newsletter: FtsZ Proteins: A Novel Anti-microbial Target]]></title>
      <link>https://www.cytoskeleton.com/blog/sept-newsletter-ftsz-proteins-a-novel-anti-microbial-target/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/sept-newsletter-ftsz-proteins-a-novel-anti-microbial-target" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Sept16NewsThumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter." href="http://www.cytoskeleton.com/sept-newsletter-ftsz-proteins-a-novel-anti-microbial-target" target="_self"><strong>Click to view&nbsp;this newsletter.&nbsp;</strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The tubulin homolog FtsZ (Filamenting temperature-sensitive mutant Z) protein is an essential prokaryotic cell divison protein. FtsZ is a GTPase that polymerizes in a nucleotide-dependent manner head-to-tail to form single-stranded filaments that assemble into a contractile ring called the Z-ring. This ring forms on the inside of the cytoplasmic membrane where it marks the future site of the septum of a dividing bacterial cell and is dynamically maintained through the course of cell division by continuous and rapid turnover of FtsZ polymers. FtsZ is the first protein to localize at the division site and recruits other proteins involved in bacterial cell division. Besides serving as a scaffold for other cell division proteins, FtsZ itself may exert cytokinetic forces that lead to cell division.</p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/sept-newsletter-ftsz-proteins-a-novel-anti-microbial-target" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Tubulin Proteins, FtsZ Proteins, and Tubulin Polymerization Kits</li>
</ul>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Thu, 15 Sep 2016 16:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Spotlight: Rho GTPases and SNX9: Cancer Cell Invasion and Metastasis]]></title>
      <link>https://www.cytoskeleton.com/blog/differential-regulation-of-rho-gtpases-by-snx9-in-cancer-cell-invasion-and-metastasis/</link>
      <description><![CDATA[<table style="height: 0px; width: 0px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title="Figure 1. RhoGAP activity measured as GTP hydrolysis by RhoA protein. Each reaction contained reaction buffer + GTP with the addition of RhoA alone (RhoA), RhoGAP alone (GAP), or RhoA + RhoGAP (RhoA + GAP). Reactions were incubated at 37&deg;C for 20 min. Phosphate generated by hydrolysis of GTP was measured by the addition of CytoPhos&trade; reagent and reading of absorbance at 650 nm." src="https://www.cytoskeleton.com/media/wysiwyg/EMT-News-Diagram_1.jpg" alt="Figure 1. RhoGAP activity measured as GTP hydrolysis by RhoA protein. Each reaction contained reaction buffer + GTP with the addition of RhoA alone (RhoA), RhoGAP alone (GAP), or RhoA + RhoGAP (RhoA + GAP). Reactions were incubated at 37&deg;C for 20 min. Phosphate generated by hydrolysis of GTP was measured by the addition of CytoPhos&trade; reagent and reading of absorbance at 650 nm." width="200" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address> </address>
<div style="text-align: justify;"><em><span style="font-size: x-small;">RhoGAP activity measured as GTP hydrolysis by RhoA protein.  Each  reaction contained reaction buffer + GTP with the addition of RhoA alone  (RhoA), RhoGAP alone (GAP), or RhoA + RhoGAP (RhoA + GAP).  Reactions  were incubated at 37&deg;C for 20 min. Phosphate generated by hydrolysis of  GTP was measured by the addition of CytoPhos&trade; reagent and reading of  absorbance at 650 nm.</span></em></div>
<address> </address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"><span><span style="line-height: 115%; color: black;"><span style="line-height: 115%; color: black; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"><span style="font-size: 9pt; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: #888888;">Recently,  Bendris et al. reported a novel pathway by which the multi-functional,  multi-domain scaffold protein sorting nexin 9 (SNX9) controls breast  cancer cell invasion and metastasis. SNX9 directly inhibits RhoA  activity (and by extension, its downstream effector Rho-associated  protein kinase), while exerting no significant direct effect on Cdc42.  However, SNX9 directly activates Cdc42's downstream effector, neural  Wiskott-Aldrich syndrome protein. The authors evaluated SNX9 for guanine  nucleotide exchange factor (GEF) and GTP-activating protein (GAP)  activities. SNX9 displayed no direct GEF or GAP activity toward either  GTPase. However, SNX9 did inhibit p50GAP-stimulated Cdc42, but not RhoA,  GTPase activity. Thus, SNX9 controls the activity of RhoA and Cdc42 in a  distinct and opposite manner. These GTPases and/or their downstream  effectors control actin cytoskeletal dynamics underlying cell motility, a  process integral in cancer cell invasion and metastasis. Cytoskeleton's  RhoGAP Assay Kit (<a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk105" target="_blank">Cat. # BK105</a>)  was an essential reagent in this study, allowing researchers to  determine if SNX9 affects RhoA and Cdc42 GTPase activities by acting  either as a GAP itself or influencing the activity of p50GAP. This work  advances the understanding of how RhoA and Cdc42 signaling pathways  control the cell motility that underlies the invasive and metastatic  behavior of cancer cells. </span><br /></span></span></span> </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><span style="color: black;"><a style="color: blue; text-decoration: underline;" href="http://www.ncbi.nlm.nih.gov/pubmed/26960793" target="_blank">Bendris  N. et al. 2016. SNX9 promotes metastasis by enhancing cancer cell  invasion via differential regulation of RhoGTPases. Mol. Biol. Cell. 27,  1409-1419.&nbsp; </a><br /></span></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<p style="padding-left: 30px;"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: blue; text-decoration: underline;"><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk105" target="_blank">RhoGAP assay, 80-160 assays, Cat. # BK105</a> <br /></span></span></p>
<ol> </ol>]]></description>
      <pubDate>Thu, 01 Sep 2016 14:20:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[August Newsletter: Tyrosine phosphorylation regulates Rho family GTPase activity ]]></title>
      <link>https://www.cytoskeleton.com/blog/aug-newsletter-tyrosine-phosphorylation-regulates-rho-family-gtpase-activity/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/aug-newsletter-tyrosine-phosphorylation-regulates-rho-family-gtpase-activity" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Aug-Newsletter-2016.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/aug-newsletter-tyrosine-phosphorylation-regulates-rho-family-gtpase-activity" target="_self">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">The Ras GTPase superfamily, which includes Ras, Rho, Rab, Arf, and Ran subfamilies (among others), has been shown to regulate a wide spectrum of cellular functions. GTPases function as molecular switches, cycling between an inactive GDP-bound form and an active GTP-bound form. The Rho GTPase subfamily includes Rho, Rac, and CDC42, and is believed to be involved primarily in the regulation of cytoskeletal organization in response to extracellular growth factors...</p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/aug-newsletter-tyrosine-phosphorylation-regulates-rho-family-gtpase-activity" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Antibodies, G-Switch Activators and Inhibitors, Activation Assays, G-protein Effector Proteins and Kits, NEW Signal Seeker Kits</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Wed, 03 Aug 2016 16:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Inhibitors of hepatocyte growth factor-stimulated epithelial scattering also inhibit tubulin polymerization ]]></title>
      <link>https://www.cytoskeleton.com/blog/citation-highlight-Inhibitors-of-hepatocyte-growth-factor-stimulated-epithelial-scattering-also-inhibit-tubulin-polymerization/</link>
      <description><![CDATA[<table style="height: 300px; width: 264px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: auto; margin-right: auto; display: block;" title="Microtubules assembled from HiLyte 488&trade; labeled tubulin (Cat. # TL488M)." src="https://www.cytoskeleton.com/media/wysiwyg/TL488MMTs.gif" alt="Microtubules assembled from HiLyte 488&trade; labeled tubulin (Cat. # TL488M)." width="250" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address>
<p>Microtubules assembled from HiLyte 488&trade; labeled tubulin (<a style="color: #0000ff ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/tl488m" target="_blank">Cat. # TL488M</a>).</p>
</address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"><span><span style="line-height: 115%; color: black;"><span style="line-height: 115%; color: black;"><span style="color: black;"><span><span style="line-height: 115%; color: black; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;"> </span></span></span></span></span></span></span></span></span></span></p>
<div style="text-align: justify;">Recently, Hoj et al. further characterized compounds that were  previously identified in a phenotypic, cell-based screen for inhibitors  of hepatocyte growth factor (HGF)-mediated scattering of epithelial  cells. HGF-induced epithelial cell scattering is an<em> in vitro</em> model to study the epithelial-mesenchymal transition (EMT), a key  process in the sequential detachment, migration, and invasion of cancer  cells at sites distal to the primary tumor. Thus, one potential class of  anti-cancer compounds is HGF inhibitors or inhibitors of HGF-mediated  signaling cascades. Here, a subset of the previously identified  small-molecule compounds, those with no reported biological activity,  were characterized across a variety of<em> in vivo</em> pharmacological and<em> in vitro</em> cellular and biochemical assays, including inhibition of tubulin  polymerization using &gt;99% pure tubulin to calculate maximal rates of  polymerization and IC50 values for each compound. With &gt;99% pure  tubulin, inhibition was due to a direct interaction between tubulin and  the compounds. Cytoskeleton's fluorescent tubulin polymerization assay  kit (<a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk011p" target="_blank">Cat. # BK011P</a>)  was an essential reagent in this study to not only calculate each  compound's IC50 value, but also demonstrate that inhibition of tubulin  polymerization is a key characteristic of compounds that also inhibit  HGF-mediated epithelial cell scattering, a well-characterized and  utilized<em> in vitro</em> model of EMT.</div>
<p>&nbsp;</p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><span style="color: black;"><a style="color: blue; text-decoration: underline;" href="http://www.ncbi.nlm.nih.gov/pubmed/27245142" target="_blank">Hoj  T.H. et al. 2016. Small molecules revealed in a screen targeting  epithelial scattering are inhibitors of microtubule polymerization.J.  Biomol. Screen. doi: 10.1177/1087057116651850</a> <br /></span></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div><span style="color: blue; text-decoration: underline;">
<div style="padding-left: 30px;"><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk128" target="_blank"></a><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: blue; text-decoration: underline;"><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk011p" target="_blank">Tubulin polymerization assay using &gt;99% pure tubulin, fluorescence based (Cat.# BK011P)</a> <br /></span></span></div>
</span></div>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Thu, 14 Jul 2016 14:59:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[July Newsletter: PTMs Regulate Cytoskeletal Proteins in Heart Disease]]></title>
      <link>https://www.cytoskeleton.com/blog/july-ptms-regulate-cytoskeletal-proteins-in-heart-disease/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/july-ptms-regulate-cytoskeletal-proteins-in-heart-disease" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Cytoskeleton-Newsletter-July-2016-PTMs-Regulate-Cytoskeletal-Proteins-in-Heart-Disease.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><a title="Click to view this newsletter." href="http://www.cytoskeleton.com/july-ptms-regulate-cytoskeletal-proteins-in-heart-disease" target="_self"><strong><br />Click to view&nbsp;this newsletter.&nbsp;</strong></a></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Cardiovascular disease accounts for roughly one in every three deaths in the USA with heart disease accounting for the majority of these cases.&nbsp; The pathology of heart disease often involves the death or dysfunction of cardiomyocytes, specialized heart cells that produce the contractile, beating function of the heart.&nbsp; Many different proteins and cell machinery, such as ion channels and pumps, cytoskeletal proteins, and receptors play a significant role in regulating the contractile ability of cardiomyocytes.&nbsp;</p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/july-ptms-regulate-cytoskeletal-proteins-in-heart-disease" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New Signal Seeker Kits, Purified Actin Proteins, and Custom Proteins</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>
<div id="_mcePaste" class="mcePaste" style="position: absolute; left: -10000px; top: 0px; width: 1px; height: 1px; overflow: hidden;">Cardiovascular disease accounts for roughly one in every three deaths in the USA with heart disease accounting for the majority of these cases1.&nbsp; The pathology of heart disease often involves the death or dysfunction of cardiomyocytes, specialized heart cells that produce the contractile, beating function of the heart.&nbsp; Many different proteins and cell machinery, such as ion channels and pumps, cytoskeletal proteins, and receptors play a significant role in regulating the contractile ability of cardiomyocytes.&nbsp; Interestingly, many of these proteins are regulated through post-translational modifications (PTMs), in part because PTMs allow for rapid, but subtle changes to a protein as part of an overall cellular response2.</div>]]></description>
      <pubDate>Wed, 06 Jul 2016 16:52:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[ June Newsletter: Kinesin Motor Proteins and Neurodegeneration]]></title>
      <link>https://www.cytoskeleton.com/blog/june-newsletter-kinesin-motor-proteins-and-neurodegeneration/</link>
      <description><![CDATA[<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/june-newsletter-kinesin-motor-proteins-and-neurodegeneration" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/June-Newsletter-2016.png" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/june-newsletter-kinesin-motor-proteins-and-neurodegeneration" target="_self">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Kinesin motor proteins regulate mitosis and anterograde cargo transport as exemplified by fast axonal transport (FAT) in neurons. Neurons depend on kinesins for cell cycle regulation, especially the assembly and function of the mitotic spindle, a macromolecular structure composed primarily of microtubules (MTs) that undergo cycles of polymerization and depolymerization to properly segregate duplicate chromosomes into separate daughter cells.</p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/june-newsletter-kinesin-motor-proteins-and-neurodegeneration" target="_self"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Kinesin &amp; Dynein Proteins, Kits and Assays, and Microtubules</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Thu, 16 Jun 2016 16:52:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Highlight: Rac1: Essential for fibroblast-like synoviocyte migration, invasion, and activation]]></title>
      <link>https://www.cytoskeleton.com/blog/rac1-essential-for-fibroblast-like-synoviocyte-migration-invasion-and-activation/</link>
      <description><![CDATA[<table style="height: 300px; width: 264px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title="HeLa CCL-2 cells were grown to 70% confluency at 37&deg;C/5% CO2. Cells were untreated (lanes S1, P1, S2, P2) or treated with 3.3 mM of the tubulin polymerizing drug paclitaxel (i.e., taxol) for 60 min at 37&deg;C/5% CO2 (lanes S3, P3, S4, P4). Cells were lysed and separated into supernatant (S) and pellet (P) fractions and analyzed by western blot quantitation of tubulin protein according to the Microtubules/Tubulin In Vivo Assay Kit (Cat. # BK038) instructions. " src="https://www.cytoskeleton.com/media/wysiwyg/Rac_Ruffles_PAEC_40x_1_1.jpg" alt="HeLa CCL-2 cells were grown to 70% confluency at 37&deg;C/5% CO2. Cells were untreated (lanes S1, P1, S2, P2) or treated with 3.3 mM of the tubulin polymerizing drug paclitaxel (i.e., taxol) for 60 min at 37&deg;C/5% CO2 (lanes S3, P3, S4, P4). Cells were lysed and separated into supernatant (S) and pellet (P) fractions and analyzed by western blot quantitation of tubulin protein according to the Microtubules/Tubulin In Vivo Assay Kit (Cat. # BK038) instructions. " width="250" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address>
<p><span style="font-size: x-small;">Rac activation in Swiss 3T3 fibroblasts. F-actin is visualized with fluorescent green phalloidin staining <a href="http://www.cytoskeleton.com/phdg1" target="_blank">(Cat.# PHDG1)</a>. DAPI is the blue nuclear stain. Phalloidin staining shows F-actin-rich lamellipodia. Cells were activated with <a href="http://www.cytoskeleton.com/cn04" target="_blank">Cat.# CN04</a>.</span></p>
</address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="line-height: 115%; font-family: Arial,Helvetica,sans-serif; font-size: 9pt;">Recently,  Lao et al. studied how PIAS3, the protein inhibitor of activated signal  transducer and activator of transcription 3 (the transcription factor  STAT3) regulates the migration, invasion, and activation of  fibroblast-like synoviocytes (FLSs), a key component in the  pathophysiology of rheumatoid arthritis (RA), specifically joint  destruction. Rate of joint destruction is positively correlated with  increased FLS motility, invasion, and activity. Here, the authors  examined PIAS3-mediated regulation of FLS migration and invasion, and  expression of matrix metalloproteinases in RA. Among other findings,  PIAS3 knockdown with short hairpin RNA demonstrated that PIAS3 controls  lamellipodium formation during FLS migration through activation of Rac1  GTPase as PIAS3 knockdown reduced both the activity of Rac1 and its  downstream effector PAK1. Activation of this Rac1 pathway is integral in  actin cytoskeleton remodeling which underlies lamellipodium formation  and protrusion. Additional results strongly suggest that PIAS3-mediated  regulation of Rac1 activation involves SUMOylation (specifically SUMO-1)  of Rac1 by PIAS3, as it can act as a SUMO-E3 ligase. Cytoskeleton's  Rac1 G-LISA activation assay kit <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk128" target="_blank">(Cat. # BK128)</a> was an essential reagent in this study, providing a sensitive and  quantitative measurement of Rac1 activity following PIAS3 knockdown.  These results expand understanding of the molecular pathways regulating  FLS migration, invasion, and activation, and the subsequent joint  destruction the cells mediate in RA. </span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a style="color: blue; text-decoration: underline;" href="http://www.ncbi.nlm.nih.gov/pubmed/26667168" target="_blank">Lao  M. et al. 2016. Protein inhibitor of activated STAT3 regulates  migration, invasion, and activation of fibroblast-like synoviocytes in  rheumatoid arthritis. J. Immunol. 196, 596-606.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div><span style="color: blue; text-decoration: underline;">
<div style="padding-left: 30px;"><a style="color: blue; text-decoration: underline;" href="http://www.cytoskeleton.com/bk128" target="_blank">Rac1 G-LISA Activation Assay Kit, Colorimetric Based, (Cat. # BK128)</a>&nbsp;</div>
</span></div>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Thu, 16 Jun 2016 08:20:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citation Highlight: Microtubule Binding and Content Changes Induced by Excessive Alcohol]]></title>
      <link>https://www.cytoskeleton.com/blog/citation-highlight-microtubule-binding-and-content-changes-induced-by-excessive-alcohol/</link>
      <description><![CDATA[<table style="height: 300px; width: 264px; margin: 15px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title="HeLa CCL-2 cells were grown to 70% confluency at 37&deg;C/5% CO2. Cells were untreated (lanes S1, P1, S2, P2) or treated with 3.3 mM of the tubulin polymerizing drug paclitaxel (i.e., taxol) for 60 min at 37&deg;C/5% CO2 (lanes S3, P3, S4, P4). Cells were lysed and separated into supernatant (S) and pellet (P) fractions and analyzed by western blot quantitation of tubulin protein according to the Microtubules/Tubulin In Vivo Assay Kit (Cat. # BK038) instructions. " src="https://www.cytoskeleton.com/media/wysiwyg/may_citation_img.png" alt="HeLa CCL-2 cells were grown to 70% confluency at 37&deg;C/5% CO2. Cells were untreated (lanes S1, P1, S2, P2) or treated with 3.3 mM of the tubulin polymerizing drug paclitaxel (i.e., taxol) for 60 min at 37&deg;C/5% CO2 (lanes S3, P3, S4, P4). Cells were lysed and separated into supernatant (S) and pellet (P) fractions and analyzed by western blot quantitation of tubulin protein according to the Microtubules/Tubulin In Vivo Assay Kit (Cat. # BK038) instructions. " width="250" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address><span style="font-size: x-small;">HeLa CCL-2 cells were grown to 70% confluency at 37&deg;C/5% CO2. Cells were untreated (lanes S1, P1, S2, P2) or treated with 3.3 mM of the tubulin polymerizing drug paclitaxel (i.e., taxol) for 60 min at 37&deg;C/5% CO2 (lanes S3, P3, S4, P4). Cells were lysed and separated into supernatant (S) and pellet (P) fractions and analyzed by western blot quantitation of tubulin protein according to the Microtubules/Tubulin In Vivo Assay Kit (<a title="Microtubule/Tubulin In Vivo Assay Biochem Kit (Cat. # BK038)" href="http://www.cytoskeleton.com/bk038" target="_blank">Cat. # BK038</a>) instructions.</span></address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, Liu et al. studied how excessive alcohol consumption regulates downstream signaling cascades of mammalian target of rapamycin complex 1 (mTORC1), focusing on the Akt/glycogen synthase kinase-3&szlig; (GSK-3&szlig;)/collapsing response mediator protein-2 (CRMP-2) pathway in rodent nucleus accumbens. Excessive alcohol increases protein levels of the microtubule (MT) binding protein CRMP-2 via mTORC1-mediated translation.&nbsp; Additionally, Akt is activated, initiating a sequential cascade of GSK-3&szlig; deactivation by Akt-mediated phosphorylation and a subsequent decrease in GSK-3&szlig; -mediated phosphorylation of CRMP-2.&nbsp; Phosphorylation of CRMP-2 inhibits its binding to MTs and the alcohol-induced reduction in CRMP-2 phosphorylation increases binding between CRMP-2 and MTs, as well as MT asssembly. The authors posit that these alcohol-induced changes in MT binding and protein levels underlie the neuroadaptations (i.e., structural plasticity) that occur in the development and/or maintenance of alcohol-drinking behaviors. Cytoskeleton&rsquo;s Microtubule Binding Protein Spin-down Assay Kit (<a title="Microtubule Binding Protein Spin-Down Assay Biochem Kit (50-100 assays), (Cat. # BK029)" href="http://www.cytoskeleton.com/bk029" target="_blank">Cat. # BK029</a>) and Microtubule/Tubulin In Vivo Assay Kit (<a title="Microtubule/Tubulin In Vivo Assay Biochem Kit (30-100 assays), (Cat. # BK038)" href="http://www.cytoskeleton.com/bk038" target="_blank">Cat. # BK038</a>) were essential reagents in this study, providing quantitation of both MT binding to CRMP-2 and changes in MT content after excessive alcohol consumption. These data suggest that CRMP-2 and its functional relationship with MTs is an essential step in the alcohol-induced neuroadaptations that underlie addiction and addictive behaviors.</p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p style="padding-left: 30px;"><a title="Liu F. et al. 2016. mTORC1-dependent translation of collapsing response mediator protein-2 drives neuroadaptations underlying excessive alcohol-drinking behaviors. Mol. Psychiatry. Doi: 10.1038/mp.2016.12." href="http://www.nature.com/mp/journal/vaop/ncurrent/full/mp201612a.html" target="_blank">Liu F. et al. 2016. mTORC1-dependent translation of collapsing response mediator protein-2 drives neuroadaptations underlying excessive alcohol-drinking behaviors. <em>Mol. Psychiatry</em>. Doi: 10.1038/mp.2016.12.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="Microtubule Binding Protein Spin-DOwn Assay Biochem Kit (50-100 assays), (Cat. # BK029)" href="http://www.cytoskeleton.com/bk029" target="_blank">Microtubule Binding Protein Spin-Down Assay Biochem Kit (50-100 assays), (Cat. # BK029)</a></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="Microtubule/Tubulin In Vivo Assay Biochem Kit (30-100 assays), (Cat. # BK038)" href="http://www.cytoskeleton.com/bk038" target="_blank">Microtubule/Tubulin In Vivo Assay Biochem Kit (30-100 assays), (Cat. # BK038)</a></div>
<ol> </ol>]]></description>
      <pubDate>Tue, 19 Apr 2016 20:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[April Newsletter: Rac1 in Diabetes: The Good and Bad]]></title>
      <link>https://www.cytoskeleton.com/blog/april-newsletter-rac1-in-diabetes-the-good-and-bad/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/april-newsletter-rac1-in-diabetes-the-good-and-bad" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/April-Newsletter-2016-thumb_1.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/april-newsletter-rac1-in-diabetes-the-good-and-bad" target="_self">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Elevations in blood glucose levels are sensed in pancreatic b-cells, which respond through a complex signaling pathway involving mitochondrial-dependent glucose metabolism1. The culmination of this pathway is the mobilization of intracellular insulin-loaded vesicles that fuse with the cell membrane releasing their contents into the...</p>
<p><a title="Click to read more" href="http://www.cytoskeleton.com/april-newsletter-rac1-in-diabetes-the-good-and-bad"><strong>Click to read more</strong></a></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Rac1 Activation Assays, Antibodies, Custom GEF Screenings and New Signal Seeker Kits</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 12 Apr 2016 16:52:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[PI3K/Akt/Rac1 activated by MMP-8 and TGF-ß1 interplay in hepatocellular carcinoma]]></title>
      <link>https://www.cytoskeleton.com/blog/pi3k-akt-rac1-activated-by-mmp-8-and-tgf-b1-interplay-in-hepatocellular-carcinoma/</link>
      <description><![CDATA[<table style="height: 287px; width: 200px; margin: 10px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title=" A) Human epidermoid carcinoma A431 cells, untreated (top) or treated (bottom) with 5 M TSA (16 h). Acetylated cytoplasmic and nuclear proteins were visualized in green fluorescence.  B) Silver stain of acetyl-lysine immunoprecipitates from wild-type (WT) and muscle-specific knock-out of E1a-binding protein (mKO) mice. " src="https://www.cytoskeleton.com/media/wysiwyg/LAMELLAPODIA-02-_002_.jpg" alt=" A) Human epidermoid carcinoma A431 cells, untreated (top) or treated (bottom) with 5 M TSA (16 h). Acetylated cytoplasmic and nuclear proteins were visualized in green fluorescence.  B) Silver stain of acetyl-lysine immunoprecipitates from wild-type (WT) and muscle-specific knock-out of E1a-binding protein (mKO) mice. " width="250" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address><strong>Figure 1:</strong> Rac1 is activated in serum treated migrating Swiss 3T3 fibroblasts, as shown by staining for F-actin rich lamellipodia with rhodamine phalloidin (<a title="Rhodamine Phalloidin Cat. # PHDR1" href="http://www.cytoskeleton.com/phdr1">Cat. # PHDR1</a>).</address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span style="color: #888888;"><span style="line-height: 115%;"><span style="line-height: 115%;">Recently, Qin et al. studied the interplay between matrix metalloproteinase-8 (MMP-8) and transforming growth factor beta 1 (TGF-b1) and the effect on each protein&rsquo;s expression and activity levels in hepatocellular carcinoma (HCC) cells as HCC is responsible for most primary liver cancers.&nbsp; MMPs are integral for tumor cell metastasis and invasion while TGF-b1 drives cancer progression via epithelial-mesenchymal transition (EMT) and induction of MPP expression.&nbsp; The authors found that the proteins reciprocally activate each other, leading to increased EMTs and HCC metastasis and invasion <em>in vitro</em>. Moreover, each protein rescues the depleted expression of the other <em>in vitro</em>. In both cases, the PI3K/Akt/Rac1 signaling pathway is the primary mediator as demonstrated pharmacologically. Furthermore, overexpression of MMP-8 or TGF-b1 increases PI3K/Akt/Rac1 pathway activity whereas knockdown exerts the opposite effect.&nbsp; Cytoskeleton&rsquo;s Rac1 G-LISA activation assay kit (<a title="Rac1 G-LISA Activation Assay Kit (Colorimetric Based) 96 assays" href="http://www.cytoskeleton.com/bk128" target="_blank">Cat.# BK128</a>) was an essential reagent in this study as it provided consistent, sensitive, and quantitative measurement of Rac1 activity following manipulation of the expression and activity levels of MMP-8 and TGF-b1. Thus, Rac1 activation mediates the downstream effects of MMP-8/TGF-b1 interplay that results in increased EMT and HCC metastasis and invasion.</span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p><a title="Qin G. et al. 2016. Reciprocal activation between MMP-8 and TGF-1 stimulates EMT and malignant progression of hepatocellular carcinoma. Cancer Lett. 374, 85-95." href="http://www.ncbi.nlm.nih.gov/pubmed/26872724" target="_blank">Qin G. et al. 2016. Reciprocal activation between MMP-8 and TGF-b1 stimulates EMT and malignant progression of hepatocellular carcinoma. <em>Cancer Lett</em>. 374, 85-95.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><a title="Rac1 G-LISA Activation Assay Kit (Colorimetric Based) 96 assays" href="http://www.cytoskeleton.com/bk128" target="_blank">Rac1 G-LISA Activation Assay Kit (Colorimetric Based) 96 Assays (Cat. # BK128)</a></div>
<ol> </ol>]]></description>
      <pubDate>Thu, 31 Mar 2016 20:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Lysine Acetyltransferase p300 and Its Role in Skeletal Muscle Biology]]></title>
      <link>https://www.cytoskeleton.com/blog/lysine-acetyltransferase-p300-and-its-role-in-skeletal-muscle-biology/</link>
      <description><![CDATA[<table style="height: 287px; width: 200px; margin: 10px;" border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><img style="margin-left: 5px; margin-right: 5px;" title=" A) Human epidermoid carcinoma A431 cells, untreated (top) or treated (bottom) with 5 M TSA (16 h). Acetylated cytoplasmic and nuclear proteins were visualized in green fluorescence.  B) Silver stain of acetyl-lysine immunoprecipitates from wild-type (WT) and muscle-specific knock-out of E1a-binding protein (mKO) mice. " src="https://www.cytoskeleton.com/media/wysiwyg/march-citation-img-rev2.jpg" alt=" A) Human epidermoid carcinoma A431 cells, untreated (top) or treated (bottom) with 5 M TSA (16 h). Acetylated cytoplasmic and nuclear proteins were visualized in green fluorescence.  B) Silver stain of acetyl-lysine immunoprecipitates from wild-type (WT) and muscle-specific knock-out of E1a-binding protein (mKO) mice. " width="292" height="253" /></td>
</tr>
<tr>
<td style="text-align: justify;"><address style="text-align: justify;">A) Human epidermoid carcinoma A431 cells, untreated (top) or treated  (bottom) with 5 M TSA (16 h). Acetylated cytoplasmic and nuclear  proteins were visualized in green fluorescence. &nbsp;B) Silver stain of  acetyl-lysine immunoprecipitates from wild-type (WT) and muscle-specific  knock-out of E1a-binding protein (mKO) mice.</address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span><span style="line-height: 115%; color: black;"><span style="line-height: 115%; color: black;"><span style="color: black;"><span style="color: #666666;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="font-size: 10pt;">Recently, LaBarge et al. examined the role of the acetyltransferase E1a-binding protein (p300) in skeletal muscle function and metabolism. Reversible acetylation, a well-known post-translational modification, is considered a regulator of mitochondrial metabolism and exercise-induced adaptation in skeletal muscles. This conclusion is based primarily on data derived from studies of deacetylases and skeletal muscle physiology with a dearth of information on how lysine acetyltransferases impact the same muscle physiology. While whole-body heterozygous and homozygous p300 knockout mice have muscle defects (along with neural and cardiac) and die in embryogenesis, to date, the role of p300 in skeletal muscle function has not been studied with a muscle-specific knock-out mouse model. Here, the authors created such an <em>in vivo </em>model and found that knocking out p300 affected neither the development nor function of adult skeletal muscle. Moreover, it was also not required for mitochondrial adaptation induced by endurance exercising. Cytoskeleton&rsquo;s anti-acetyl lysine antibody (<a title="Cat. # AA01" href="http://www.cytoskeleton.com/aac01" target="_blank">Cat. # AAC01</a>) was an essential reagent in this study as it was used to confirm a functional loss of p300 in the knock-out mice. These mice had a significant reduction in total acetylation levels in skeletal muscle immunoprecipitates from knock-out, compared to wild-type, mice.</span></span></span></span><br /><br /></span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p><a style="color: blue; text-decoration: underline;" title="LaBarge S.A. et al. 2016. p300 is not required for metabolic adaptation to endurance exercise training. FASEB J. Doi: 10.1096/fj.15-281741." href="http://www.ncbi.nlm.nih.gov/pubmed/26712218" target="_blank">LaBarge S.A. et al. 2016. p300 is not required for metabolic adaptation to endurance exercise training. <em>FASEB J</em>. Doi: 10.1096/fj.15-281741.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span style="font-size: small;"><strong><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-size: 9pt; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: black;"><a style="color: #0000ff; text-decoration: underline;" title="Anti-Acetyl Lysine Monoclonal: Cat. # AAC01" href="http://www.cytoskeleton.com/aac01" target="_blank">Anti-Acetyl Lysine Monoclonal: Cat. # AAC01</a><br /></span><a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/cn04" target="_blank"></a></span></strong></span></div>
<ol> </ol>]]></description>
      <pubDate>Wed, 23 Mar 2016 20:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[SUMOylation: Functional Regulator of Cytoskeletal Proteins ]]></title>
      <link>https://www.cytoskeleton.com/blog/sumoylation-functional-regulator-of-cytoskeletal-proteins/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/sumoylation-functional-regulator-of-cytoskeletal-proteins" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/newsletter-thumbnail_1.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/sumoylation-functional-regulator-of-cytoskeletal-proteins" target="_self">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>The filamentous cytoskeleton is comprised of three distinctive polymer networks: actin filaments, intermediate filaments, and microtubules. Their interplay is responsible for cellular structure, motility, and material transport in order to maintain cellular homeostasis. Also, flexible and rapid cellular responses to external and internal stimuli are possible due...</p>
<p><strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/sumoylation-functional-regulator-of-cytoskeletal-proteins" target="_self">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New Signal Seeker Kits, Antibodies, and Reagents</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 08 Mar 2016 17:52:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Rho-family GTPases: Regulation by Opposing Tetraspanins in Dendritic Cells]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-family-gtpases-regulation-by-opposing-tetraspanins-in-dendritic-cells/</link>
      <description><![CDATA[<table style="height: 287px; width: 200px; margin: 10px;" border="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/tubulin-polymerization-inhibitor-screenings"><img style="margin-left: 5px; margin-right: 5px;" title="Rac Ruffles PAEC 40x1" src="https://www.cytoskeleton.com/media/wysiwyg/Rac_Ruffles_PAEC_40x_1_1.jpg" alt="Rac Ruffles PAEC 40x1" width="225" height="225" /></a></td>
</tr>
<tr>
<td style="text-align: justify;"><address>F-actin is visualized with fluorescent green phalloidin staining (Cat.# <a title="Acti-stain 488 phalloidin" href="http://www.cytoskeleton.com/phdg1">PHDG1</a>) and nuclear blue DNA staining with DAPI. Cells were activated with Cat.# <a title="Rho/Rac/Cdc42 Activator I" href="http://www.cytoskeleton.com/cn04" target="_blank">CN04</a>.</address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span><span style="line-height: 115%; color: black;"><span style="line-height: 115%; color: black;"><span style="color: black;"><span style="color: #666666;"><span style="line-height: 115%;"><span style="line-height: 115%;"><span style="font-size: 10pt;">Recently,  Jones et al. examined the role of Rho-family GTPases in the opposing  effects of tetraspanins CD82 and CD37 in bone marrow-derived dendritic  cell (BDMC) migration and T cell activation by antigen presentation.  Tetraspanins regulate dendritic cell motility and antigen presentation.  BMDC activation upregulates CD82, resulting in decreased cell migration  and increased T cell activation via stabilization of T cell/dendritic  cell interactions. Conversely, CD37 is downregulated and has the  opposite response. Deletion of either protein alters cell morphology and  the actin and tubulin cytoskeleton. To examine the role of RhoA, Rac1,  and Cdc42 in these changes, GTPase activities in cells from either  knock-out (CD37 or CD82) or wild-type mice were quantified. Using the  cell-permeable Rho/Rac/Cdc42 activator CN04, the authors found that CD82  negatively regulates RhoA while CD37 (but not CD82) regulates Rac1.  Both tetraspanins negatively regulate Cdc42. Cytoskeleton's cell  permeable Rho/Rac/Cdc42 activator I (<a style="color: #0000ff ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/cn04" target="_blank">Cat.# CN04</a>) and the RhoA (<a style="color: #0000ff ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk124" target="_blank">Cat.# BK124</a>), Rac1 (<a style="color: #0000ff ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk128" target="_blank">Cat.# BK128</a>), and Cdc42 (<a style="color: #0000ff ! important; text-decoration: underline ! important;" href="http://www.cytoskeleton.com/bk127" target="_blank">Cat.# BK127</a>)  G-LISA activation assays were essential reagents in this study. These  reagents provided a sensitive measure of Rho-family GTPase activity to  discover how these GTPases differentially contribute to the  tetraspanin-mediated regulation of BDMC migration and T cell activation  in the initiation of adaptive immunity.</span></span></span></span><br /><br /></span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><span style="font-size: small;"><strong>Link to citation:</strong>&nbsp;</span></div>
<p><a style="color: blue; text-decoration: underline;" title="Jones E.L. et al. 2016. Dendritic cell migration and antigen presentation are coordinated by the opposing functions of the tetraspanins CD82 and CD37. J. Immunol. Doi: 10.4049/jimmunol.1500357." href="http://www.jimmunol.org/content/early/2016/01/02/jimmunol.1500357.abstract" target="_blank">Jones E.L. et al. 2016. Dendritic cell migration and antigen presentation are coordinated by the opposing functions of the tetraspanins CD82 and CD37. J. Immunol. Doi: 10.4049/jimmunol.1500357.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong><br /></strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px; padding-left: 30px;"><span style="font-size: small;"><strong><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-size: 9pt; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: black;"><a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk124" target="_blank">RhoA G-LISA Activation Assay Kit (Colorimetric format) 96 assays: Cat. # BK124</a><br />&nbsp;<br /><a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk127" target="_blank">Cdc42 G-LISA Activation Assay Kit (Colorimetric format) 96 assays: Cat. # BK127</a><br /><br /><a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk128" target="_blank">Rac1 G-LISA Activation Assay Kit (Colorimetric Based) 96 assays: Cat. # BK128</a> </span><br /><br /><a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/cn04" target="_blank">Rho/Rac/Cdc42 Activator I: Cat. # CN04</a></span></strong></span></div>
<ol> </ol>]]></description>
      <pubDate>Mon, 08 Feb 2016 21:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Vimentin Intermediate Filaments: Regulation by Phosphorylation ]]></title>
      <link>https://www.cytoskeleton.com/blog/vimentin-intermediate-filaments-regulation-by-phosphorylation/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/vimentin-intermediate-filaments-regulation-by-phosphorylation" target="_self"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/newsletter/jan-feb-newsletter-full-thumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Click to view this newsletter" href="http://www.cytoskeleton.com/vimentin-intermediate-filaments-regulation-by-phosphorylation" target="_self">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Intermediate filaments (IFs) are one of three filament systems comprising the cytoskeleton of metazoan cells. IFs are highly dynamic structures essential for organizing the actin and tubulin filament systems and regulating cell signaling, motility, structure, and adhesion during interphase and mitosis. The function and localization of IFs are regulated ...</p>
<p><strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/vimentin-intermediate-filaments-regulation-by-phosphorylation" target="_self">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New Signal Seeker Kits, Antibodies, and Reagents</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 12 Jan 2016 17:52:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[RhoA and Cdc42 Activity Mediates Podoplanin-induced Tumor Progression]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-gtpases-and-tumor-progression/</link>
      <description><![CDATA[<table style="height: 287px; width: 200px; margin: 10px;" border="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/tubulin-polymerization-inhibitor-screenings"><img style="margin-left: 5px; margin-right: 5px;" title="Rac Ruffles PAEC 40x1" src="https://www.cytoskeleton.com/media/wysiwyg/G-Switch-Rho_Stress-Fibers-3T3-with-CN03-250x250.png" alt="Rac Ruffles PAEC 40x1" width="225" height="225" /></a></td>
</tr>
<tr>
<td style="text-align: justify;"><address>F-actin is visualized with fluorescent green phalloidin staining (Cat.# <a title="Acti-stain 488 phalloidin" href="http://www.cytoskeleton.com/phdg1">PHDG1</a>) and nuclear blue DNA staining with DAPI. Cells were activated with Cat.# <a title="RhoA / Rac1 / Cdc42 Activation Assay Combo Biochem Kit (bead pull-down format) - 3 x 10 assays" href="http://www.cytoskeleton.com/bk030">CN03</a>.</address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;"><span><span style="line-height: 115%; color: black;"><span style="line-height: 115%; color: black;"><span style="color: black;"><span style="font-size: small; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: #666666;">Recently,  Li et al. examined the signaling pathways underlying  podoplanin-mediated tumor invasion in oral squamous cell carcinoma  (OSCC) tissues and cell lines. Overexpression of podoplanin, a  transmembrane glycoprotein, characterizes multiple cancers; however, its  exact role(s) in tumor progression/invasion remain unknown. Here,  podoplanin overexpression increased tumor cell protrusions (i.e.,  invadopodia) and F-actin stress fibers in OSCC cells. Concomitantly,  RhoA activity decreased whereas Cdc42 activity increased.  Correspondingly, podoplanin knockdown reversed these activity patterns.  Rac1 activity did not change after any treatments. Additionally, RhoA  and Cdc42 engaged in cross-talk (e.g., RhoA inhibition resulted in  increased Cdc42 activity). Activated Cdc42 (but not RhoA) was also found  to co-precipitate with matrix metalloproteinase-14 (i.e., MT1-MMP) and  binding increased with podoplanin overexpression and decreased with  knockdown. Cytoskeleton&rsquo;s Acti-stain 488 phalloidin (Cat.# <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/phdg1" target="_blank">PHDG1</a>) and RhoA/Rac1/Cdc42 Activation Assay Kit (Cat.# <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk030" target="_blank">BK030</a>)  were essential reagents in this study, providing: 1. detection of  morphological changes in the actin cytoskeleton necessary for increased  cellular protrusions and stress fibers; and 2. confirmation that this  re-organization corresponded with opposing changes in RhoA and Cdc42  activity. Thus, podoplanin-mediated tumor cell protrusion and resulting  motility relies upon an activation and inhibition of Cdc42 and RhoA,  respectively, which, in turn, mediate the re-organization of the actin  cytoskeleton. </span><br /></span></span></span></span></p>
<div style="font-family: Arial, Helvetica, sans-serif;"><strong>Link to citation:</strong><span style="font-size: 10pt;">&nbsp;</span></div>
<p><a style="color: blue; text-decoration: underline;" href="http://www.ncbi.nlm.nih.gov/pubmed/25973294" target="_blank">Li  Y.-Y. et al. 2015. Podoplanin promotes the invasion of oral squamous  cell carcinoma in coordination with MT1-MPP and Rho GTPases. Am. J.  Cancer Res.5, 514-529.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;">
<ul>
<li><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">&nbsp;</span></span></span><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-size: 9pt; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: black;"><span style="font-size: 9pt; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: black;">RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit (pull-down format) 3x10 assays (Cat.# <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk030" target="_blank">BK030</a></span>)</span></span></span></span></span></li>
<li><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-size: 9pt; line-height: 115%; font-family: Arial,Helvetica,sans-serif; color: black;">Acti-stain 488 phalloidin (Cat.# <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/phdg1" target="_blank">PHDG1</a>)<br /></span></span></span></span></span></li>
</ul>
</div>
<ol> </ol>]]></description>
      <pubDate>Sun, 03 Jan 2016 21:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Rac1 Regulation ASCB 2015 Abstract]]></title>
      <link>https://www.cytoskeleton.com/blog/rac1-regulation/</link>
      <description><![CDATA[<h3><strong>Temporal regulation of phosphotyrosine-modified Rac1 in response to epidermal growth factor stimulation</strong></h3>
<table border="0" cellspacing="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><a title="Click here for a link to the pdf version." href="http://www.cytoskeleton.com/pdf-storage/news/rac1-regulation-ascb-2015.pdf"><img style="padding-left: 20px; padding-right: 20px;" title="ascb15poster" src="https://www.cytoskeleton.com/media/wysiwyg/poster-final_1.jpg" alt="ascb15poster" width="230" /></a><br /></td>
</tr>
<tr>
<td style="text-align: center;">Click <a href="http://www.cytoskeleton.com/pdf-storage/news/rac1-regulation-ascb-2015.pdf">here</a> for a link to the pdf version</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Abstract</p>
<p style="text-align: justify;">The aim of this study was to develop an assay sensitive enough to detect endogenous pY‐modified Rac1 uponstimulation by EGF. The IP assay was used in conjunction with a Rac1 activation assay to follow temporal changesin endogenous Rac1 activation and tyrosyl phosphorylation in response to EGF stimulation of HeLa and A431 cells. Rac1 activation, monitored by PAK‐binding, followed a predicted time course in which...</p>
<p style="text-align: justify;">click <a title="Click here to read more" href="http://www.cytoskeleton.com/temporal-rac1-phosphorylation" target="_self">here</a>&nbsp;to read more.</p>
<div style="font-family: Arial, Helvetica, sans-serif;"><strong>Link to citation:</strong><span style="font-size: 10pt;">&nbsp;</span></div>
<p>Law A., Hong S., Horita H. and Middleton K. 2015.&nbsp;Temporal regulation of phosphotyrosine-modified Rac1 in response to epidermal growth factor stimulation. Mol. Biol. Cell. ASCB Abstract Dec. B1230 / P2126.&nbsp;</p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;">
<ul>
<li><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">Rac1 Pulldown Activation Assay Kit </span><span style="color: #000000;">(Cat. # </span><a title="Rac1 Pulldown Assay Protocol" href="http://www.cytoskeleton.com/kits/pulldown-assays/bk035">BK035</a></span><span style="font-family: 'Arial',' Helvetica',' sans-serif';">)</span></span></li>
<li><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">Phosphotyrosine Antibody Mouse Monoclonal S7B10 (Cat. # <a title="Phosphotyrosine Antibody Mouse Monoclonal S7B10 (Cat. # APY03)" href="http://www.cytoskeleton.com/phosphotyrosine-antibody" target="_blank">APY03</a>)</span></span></span></li>
<li><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">Anti-Phosphotyrosine Affinity Beads (Cat.# <a title="Phosphotyrosine affinity beads" href="http://www.cytoskeleton.com/antibodies/ptm-antibodies/anti-phosphotyrosine-affinity-beads">APY03-beads</a>)&nbsp;</span></span></span></li>
</ul>
</div>
<ol> </ol>]]></description>
      <pubDate>Fri, 04 Dec 2015 21:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Rac1 Activity and SOD1 Aggregates ]]></title>
      <link>https://www.cytoskeleton.com/blog/rac1-activity-and-sod1-aggregates/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/tubulin-polymerization-inhibitor-screenings"><img style="margin-left: 30px; margin-right: 30px;" title="Rac Ruffles PAEC 40x1" src="https://www.cytoskeleton.com/media/wysiwyg/Rac_Ruffles_PAEC_40x_1_1.jpg" alt="Rac Ruffles PAEC 40x1" width="200" height="200" /></a></td>
</tr>
<tr>
<td style="text-align: center;"><address><span style="font-size: x-small;">Acti-stain HiLyte 488 phalloidin (Cat.# <a title="PHDG1 Acti-stain 488 phalloidin" href="http://www.cytoskeleton.com/phdg1">PHDG1</a>)</span></address><address><span style="font-size: x-small;">staining of ruffles characteristic of Rac activation </span></address><address><span style="font-size: x-small;">following treatement with a Rho/Rac/Cdc42</span></address><address><span style="font-size: x-small;">activation (Cat.#<a title="CN04 Rho/Rac/Cdc42 Activator I" href="http://www.cytoskeleton.com/cn04">CN04</a>) in porcine aortic endothelial </span></address><address><span style="font-size: x-small;">cells under 40X magnification.</span><br /></address></td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently R. Zeineddine et al. examined the molecular signaling pathways underlying cell-to-cell transmission of aggregated copper/zinc superoxide dismutase (SOD1). Misfolding, aggregation, and transmission of SOD1 is implicated in <em>in vitro</em> and <em>in vivo</em> models of Amyotrophic Lateral Sclerosis. Here, the authors examined the signaling pathways involved in macropinocytosis, a form of fluid-phase endocytosis, which provides the means by which macromolecules such as SOD1 aggregates are transmitted cell-to-cell. Macropinocytosis requires membrane ruffling, which in turn, depends upon re-arrangement of the actin cytoskeleton. Thus, the authors examined the activity of a known modulator of the actin cytoskeleton, the Rac1 GTPase, in motoneuron-like (NSC-34) cells. The authors found that exposure of NSC-34 cells to SOD1 aggregates initiates a cascade of sequential events: Rac1 activation &gt; membrane ruffling &gt; macropinocytosis &gt; build-up of SOD1 aggregates intracellularly. Cytoskeleton&rsquo;s absorbance-based Rac1 G-LISA activation assay kit (Cat. # <a title="Rac1 G-LISA Activation Assay Kit (Colorimetric Based)" href="http://www.cytoskeleton.com/bk128">BK128</a>) was an essential reagent in this study, demonstrating that SOD1 aggregates induce Rac1 activation that leads to the formation of actin-based membrane ruffles. These two events are necessary for propagation of SOD1 protein aggregates (and other disease-associated protein aggregates) via macropinocytosis. These findings suggest therapeutic strategies for treating a multitude of neurodegenerative diseases.</p>
<div style="font-family: Arial, Helvetica, sans-serif;"><strong>Link to citation:</strong><span style="font-size: 10pt;">&nbsp;</span></div>
<p>&nbsp;<a title="R. Zeineddine et al. 2015. SOD1 protein aggregates stimulate macropinocytosis in neurons to facilitate their propagation. Mol. Neurodegener. 10, 57." href="http://www.molecularneurodegeneration.com/content/10/1/57">R. Zeineddine et al. 2015. SOD1 protein aggregates stimulate macropinocytosis in neurons to facilitate their propagation. Mol. Neurodegener. 10, 57.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;">
<ul>
<li><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">&nbsp;</span></span></span><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">Rac1 G-LISA Activation Assay Kit (Colorimetric Based) </span>(Cat. # <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk128" target="_blank">BK128</a></span><span style="font-family: 'Arial',' Helvetica',' sans-serif';">)</span></span><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">&nbsp;</span></span></span></li>
</ul>
</div>
<ol> </ol>]]></description>
      <pubDate>Wed, 18 Nov 2015 21:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Anti-tumor activity of C36L1 peptide due to microtubule depolymerization]]></title>
      <link>https://www.cytoskeleton.com/blog/anti-tumor-activity-of-c36l1-due-to-microtubule-depolymerization1/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" cellpadding="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/tubulin-polymerization-inhibitor-screenings"><img style="margin-left: 30px; margin-right: 30px;" src="https://www.cytoskeleton.com/media/wysiwyg/asm23-if-1.jpg" alt="" width="200" height="200" /></a></td>
</tr>
<tr>
<td style="text-align: center;">
<p><span style="font-size: x-small;">Immunofluoresence of HeLa cell in</span><br /><span style="font-size: x-small;">&nbsp;metaphase with <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/sumo-2-3-antibody-asm23" target="_blank">ASM23</a> Ab (anti-SUMO2/3) and </span><br /><span style="font-size: x-small;"><a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/atn02" target="_blank">ATN02</a> Ab (anti-tubulin)</span></p>
</td>
</tr>
</tbody>
</table>
<p style="text-align: justify;">Recently, C.R. Figueiredo et al. examined the mechanism of action underlying the anti-tumor effects of the complementarity-determining region (CDR) C36L1 synthetic peptide derived from the V<sub>L</sub> CDR1 of the C36 Fab fragment of the anti-vaccinia immunoglobulin.&nbsp; This CDR exhibits both anti-tumor activity and functions as a microtubule destabilizing molecule.&nbsp; Here, the authors investigated whether its microtubule-destabilizing effect is responsible for its anti-tumor activity. The authors found that the peptide induces apoptotic effects on multiple cancer cells both <em>in vitro</em> and <em>in vivo</em>, inhibits tumor cell migration and invasion, and arrests cell cycle primarily in the G2M phase. These effects follow internalization of the C36L1 peptide which then selectively binds to microtubules and destabilizes the tubulin filaments. Microtubule polymerization and depolymerization dynamics were examined in living cells and under cell-free conditions. Cytoskeleton&rsquo;s fluorescent tubulin polymerization assay kit (Cat. # BK011P) was an essential reagent in this study, complementing the <em>in vivo</em> results and <em>in vitro</em> cell culture data which demonstrated conclusively that the C36L1 peptide targets microtubules in exerting its anti-tumor effects. These findings contribute to the growing and intense field of research focused on developing peptide-based cancer vaccines.</p>
<div style="font-family: Arial, Helvetica, sans-serif;"><strong>Link to citation:</strong><span style="font-size: 10pt;">&nbsp;</span></div>
<p>&nbsp;<a style="color: blue; text-decoration: underline;" href="http://www.nature.com/articles/srep14310" target="_blank">C.R.  Figueiredo et al. 2015. A novel microtubule de-stabilizing  complementarity-determining region C36L1 peptide displays anti-tumor  activity against melanoma <em>in vitro</em> and <em>in vivo</em>. <em>Sci. Rep.</em> 5, 14310.</a></p>
<div style="margin-top: 0px; margin-bottom: 0px;"><span style="font-size: small;"><strong>Products used in this citation:</strong></span></div>
<div style="margin-top: 0px; margin-bottom: 0px;">
<ul>
<li><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="font-family: 'Arial',' Helvetica',' sans-serif';"><span style="color: #323232; font-family: Arial, ' Helvetica', ' sans-serif'; font-size: 12px;">Tubulin Polymerization Assay: 99% pure porcine tubulin, fluorescence based </span>(Cat. # <a style="color: #0000ff; text-decoration: underline;" href="http://www.cytoskeleton.com/bk011p" target="_blank">BK011P</a></span><span style="font-family: 'Arial',' Helvetica',' sans-serif';">)</span></span></li>
</ul>
</div>
<ol> </ol>]]></description>
      <pubDate>Thu, 05 Nov 2015 21:19:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Dr. Alan Hall - GTPase Legacy]]></title>
      <link>https://www.cytoskeleton.com/blog/alan-hall-gtpase/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><img style="float: right;" title="Sept-2015-newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/September-2015-Newsletter-v2_Page_1.jpg" alt="GTPase news" width="168" height="220" /></td>
</tr>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/live-cell-imaging-of-actin"></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Newsletter link" href="http://www.cytoskeleton.com/alan-hall-gtpase">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Cytoskeleton, Inc. was founded in 1993 and coincidentally that was the era when the Rho family of small G-proteins was determined to be major regulators of cytoskeletal dynamics. This finding was established in a very direct way by the seminal paper authored by Drs. Anne Ridley and Alan Hall who at that time worked at the Medical Research Council in London(1). Since then, <strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/alan-hall-gtpase">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li><span style="font-size: 12px;">Related Publications</span></li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 22 Sep 2015 06:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Tubulin Polymerization Inhibitor Screening]]></title>
      <link>https://www.cytoskeleton.com/blog/tubulin-polymerization-inhibitor-screenings-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/tubulin-polymerization-inhibitor-screenings"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/thumbnail-of-newsletter.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/info-resources/tubulin-polymerization-inhibitor-screenings">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Microtubules (MTs) are comprised of a/b tubulin heterodimers which have polymerized into cylinderical structures. MTs serve as an essential component of a cell&rsquo;s cytoskeleton as they regulate and participate in a variety of cellular functions that include motility, morphology, intracellular transport, signal transduction, and cell division (Fig. 1). The cell cycle consists of the sequential G1, S, G2, and M phases with MT polymerization and depolymerization (i.e., MT dynamics) playing a key role in the normal progression of this cycle to insure proper cell division (Fig. 1). The disruption of MT dynamics, and thereby the cell cycle, leads to cell death. As such, MTs are a well-recognized and often-studied target for cancer drug discovery efforts<sup>1-4</sup>...</p>
<p><a title="Link to Newsletter" href="http://www.cytoskeleton.com/info-resources/tubulin-polymerization-inhibitor-screenings">Read more about Tubulin Polymerization Inhibitor Screening Here.</a></p>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 03 Aug 2015 20:19:22 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Post-translational Modifications - Essential for Protein Regulation]]></title>
      <link>https://www.cytoskeleton.com/blog/ptm-crosstalk-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/ptm-crosstalk-detailed"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/newsletter_image.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/ptm-crosstalk-detailed">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>To maintain homeostasis, cells need to respond to changes in the intracellular and extracellular milieu. Some of the changes have to be acted upon quickly to avoid detrimental effects that can lead to cell damage or even death. One way that cells act is through protein post-translational modifications (PTMs) which enable...&nbsp;<strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/ptm-crosstalk-detailed">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New PTMtrue Antibodies and Reagents</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 03 Aug 2015 16:52:21 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Live Cell Imaging of the Actin Cytoskeleton]]></title>
      <link>https://www.cytoskeleton.com/blog/live-cell-imaging-of-actin-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/live-cell-imaging-of-actin"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/actin-live-cell-news.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/live-cell-imaging-of-actin">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Recent advances in organic chemical synthesis have facilitated the ultimate aim of producing small cell-permeable compounds which can efficiently label the actin cytoskeleton and track its dynamic properties... <strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/live-cell-imaging-of-actin">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New Live Cell Imaging Probes</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 29 Jun 2015 15:50:39 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[SUMOylation of Mitotic Proteins: Localization and Function]]></title>
      <link>https://www.cytoskeleton.com/blog/sumoylation-of-mitotic-proteins-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/sumoylation-of-mitotic-proteins"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/june-thumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/sumoylation-of-mitotic-proteins">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Successful execution of mitosis requires exquisite regulation and interplay of a myriad of proteins. Recently, the post-translational modification (PTM) of SUMOylation has emerged as an important functional regulator of mitotic proteins1. SUMO (Small Ubiquitin-like MOdifier) proteins are covalently ligated to&nbsp;... <strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/sumoylation-of-mitotic-proteins">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Available Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 01 Jun 2015 18:57:06 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ras Cancer Therapeutics: 5 Promising Targets]]></title>
      <link>https://www.cytoskeleton.com/blog/ras-cancer-therapeutic-targets-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/ras-cancer-therapeutic-targets"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/ras-cancer-therapeutic-promising-targets.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/ras-cancer-therapeutic-targets">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>The Ras GTPase plays an important role in multiple signal transduction pathways involved in normal cell growth and differentiation as well as several forms of cancer</span><sup>1,2</sup><span>. The three isoforms of Ras, H-Ras, N-Ras, and K-Ras, were identified over 30 years ago for their oncogenic activation in human tumors</span><sup>1,2</sup><span>. &nbsp; Aberrant Ras signaling has been identified in</span>... <strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/ras-cancer-therapeutic-targets">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Available Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Thu, 30 Apr 2015 17:41:36 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[YAP1 grabs the spotlight in oncogenic Ras addiction]]></title>
      <link>https://www.cytoskeleton.com/blog/yap1-ras-oncogenic-review/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/yap1-ras-oncogenic-review-detail"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/april-thumbnail.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/yap1-ras-oncogenic-review-detail">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>YAP1 and the Hippo Pathway</span></p>
<p><span>The Hippo signal transduction pathway plays a critical role in the regulation of organ size through the coordinated modulation of cell fate(1). The core pathway memebers include two sets of serine/threonine kinases (MST1/2 and LATS1.2) that act.</span>.. <strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/yap1-ras-oncogenic-review-detail">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Available Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Wed, 25 Mar 2015 19:03:46 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Post-translational Modifications Regulate Ral GTPases]]></title>
      <link>https://www.cytoskeleton.com/blog/ral-gtpase-posttranslational-modifications-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/ral-gtpase-posttranslational-modifications"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/ral-post-translational-modifications-news-thumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/ral-gtpase-posttranslational-modifications">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span><span>RalA and RalB GTPases regulate cell motility, morphology, signaling, vesicular trafficking, and endo/exocytosis. The regulation of these functions is critical for the development and spread of cancer</span><sup>1-4</sup><span>, implicating Ral in oncogenesis and metastasis. Both isoforms are integral for Ras-mediated tumorigenesis, metastasis, and invasion</span>.</span>.. <strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/ral-gtpase-posttranslational-modifications">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Available Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 09 Mar 2015 15:47:36 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[KSP/Eg5 Inhibition in Parasites and Fungi]]></title>
      <link>https://www.cytoskeleton.com/blog/ksp-inhibitor-sites-parasites-fungi/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/ksp-eg5-in-parasites-and-fungi"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/thumbnail-of-newsletter.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/info-resources/ksp-eg5-in-parasites-and-fungi">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>The Kinesin Spindle Protein (KSP; a.k.a. Eg5 or KIF11) is a plus end-directed Kinesin-5 (a.k.a. BimC) subfamily member and has been the focus of significant drug development efforts for decades. &nbsp;Currently, KSP (or its homologs) is a target for anti-mitotics (cancer)<sup>1,2</sup>, anti-parasitics (malaria)<sup>3</sup>, and anti-fungals<sup>4</sup>. As a microtubule (MT) cross-linking enzyme, KSP plays a critical role in mitotic spindle pole separation, and its inhibition results in the formation of monoaster spindles which is thought to lead to mitotic catastrophe and apoptosis (Fig. 1). The targeting of KSP as a treatment for cancer is well-documented<sup>1,2,5,6</sup>. The purpose of this newsletter is to briefly discuss KSP homologs as a therapeutic target for parasitic and fungal diseases...</p>
<p><a title="Link to Newsletter" href="http://www.cytoskeleton.com/info-resources/ksp-eg5-in-parasites-and-fungi">Read more about KSP/Eg5 Inhibition Here.</a></p>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 02 Feb 2015 15:50:06 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Phosphorylation of RhoA as a Regulator of Signal Transduction]]></title>
      <link>https://www.cytoskeleton.com/blog/phosphorylation-rhoa-signal-transduction-review/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/blog/phosphorylation-rhoa-signal-transduction-review-detailed"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/jan-feb-newsletter-thumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/blog/phosphorylation-rhoa-signal-transduction-review-detailed">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span><span>The activity of Rho family GTPases is regulated temporally and spatially by a variety of direct post-translational modifications (PTMs) that include prenylation, ubiquitination, oxidation, nitrosylation, and phosphorylation (Fig. 1). This newsletter focuses on control of RhoA function through phosphorylation. RhoA is a target for a growing number of kinases and as such, phosphorylation is emerging as a central theme in the regulation of this family of proteins<sup>2</sup></span>.</span>.. <strong><a title="Link to newsletter" href="http://www.cytoskeleton.com/blog/phosphorylation-rhoa-signal-transduction-review-detailed">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Available Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Fri, 23 Jan 2015 20:49:42 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[GTPase Activation Assays: Detecting Different Isoforms]]></title>
      <link>https://www.cytoskeleton.com/blog/small-gtpase-activation-assay-review/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Oct News" href="http://www.cytoskeleton.com/blog/small-gtpase-activation-assay-review-detailed/"><img style="margin-left: 30px; margin-right: 30px;" title="Nov and Dec news" src="https://www.cytoskeleton.com/media/wysiwyg/dec-jan-newsletter-thumb.jpg" alt="Nov and Dec news" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/blog/small-gtpase-activation-assay-review-detailed/">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>Ras and Rho family GTPases are cytoskeletal small G-proteins that critically regulate multiple actin-dependent cell processes, including development, growth, motility, and intracellular trafficking1,2. Moreover, dysfunction of Ras and Rho family GTPases are correlated with several human diseases (e.g., cancer, neurodegeneration) and these GTPases are.</span>.. <strong><a title="Oct News" href="http://www.cytoskeleton.com/blog/small-gtpase-activation-assay-review-detailed/">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Available Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Fri, 31 Oct 2014 19:45:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Citrullination: Taking the Charge out of Arg]]></title>
      <link>https://www.cytoskeleton.com/blog/citrullination-news/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Oct News" href="http://www.cytoskeleton.com/blog/citrullination-news-detailed/"><img style="margin-left: 30px; margin-right: 30px;" title="Oct news" src="https://www.cytoskeleton.com/media/wysiwyg/october-full-thumb.jpg" alt="Oct news" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/blog/citrullination-news-detailed/">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>Protein citrullination (a.k.a. deimination) is a novel arginine-directed post-translational modification (PTM) that results in a permanent change in the targeted protein. &nbsp;Peptidylarginine deiminases (PADs) mediate the calcium-dependent deimination of the guanidino group of.</span>.. <strong><a title="Oct News" href="http://www.cytoskeleton.com/blog/citrullination-news-detailed/">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Wed, 01 Oct 2014 20:25:59 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Drugable site selection for KSP inhibitors]]></title>
      <link>https://www.cytoskeleton.com/blog/ksp-inhibitor-sites/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/blog/phosphorylation-rhoa-signal-transduction-review-detailed"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/csd-news-2014-q3.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/info-resources/ksp-inhibitor-sites">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Since the discovery of the first kinesin spindle protein (KSP, also known as Eg5, KIF11) inhibitor, monastrol, in 1999 (1), there have been a plethora of articles, 3D structures, and FDA applications based on the same binding site (review [2]). The binding site is called the allosteric monastrol binding site (AMBS) which functionally plays a significant role in transducing chemical energy to movement of the neck-linker region. Drugs that bind this site are non-competitive...</p>
<p>&nbsp;</p>
<p><a title="Link to Newsletter" href="http://www.cytoskeleton.com/info-resources/ksp-inhibitor-sites">Read more about KSP/Eg5 Inhibition Here.</a></p>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 30 Sep 2014 14:21:26 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Probing Sub-domains of Kinesin]]></title>
      <link>https://www.cytoskeleton.com/blog/probing-kinesin-sub-domains-detailed-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Sept News" href="http://www.cytoskeleton.com/blog/probing-kinesin-sub-domains-detailed"><img style="margin-left: 30px; margin-right: 30px;" title="Sept news" src="https://www.cytoskeleton.com/media/wysiwyg/SeptNewsThumb.jpg" alt="Sept news" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/blog/probing-kinesin-sub-domains-detailed">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span><span>Recent reports have highlighted a new phase of research for molecular motors. In contrast to five or more years ago, when macromolecular approaches were used</span><sup>1</sup><span>, recent research has focused on</span>.</span>.. <strong><a title="Sept News" href="http://www.cytoskeleton.com/blog/probing-kinesin-sub-domains-detailed">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 08 Sep 2014 19:14:23 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[SUMOylation: A Post-translational Modification Targeting Cytoskeletal Proteins]]></title>
      <link>https://www.cytoskeleton.com/blog/sumoylation-targeting-cytoskeletal-proteins-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Sumoylation News" href="http://www.cytoskeleton.com/blog/sumoylation-targeting-cytoskeletal-proteins-detailed"><img style="margin-left: 30px; margin-right: 30px;" title="SUMOylation targeting cytoskeletal proteins news" src="https://www.cytoskeleton.com/media/wysiwyg/AugNewsThumb.jpg" alt="SUMOylation targeting cytoskeletal proteins news" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Sumoylation news" href="http://www.cytoskeleton.com/blog/sumoylation-targeting-cytoskeletal-proteins-detailed" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>Upon translation, proteins are trafficked to their proper subcellular location so that they can perform their physiological functions. One mechanism that mediates correct protein localizationand function is post-translational modifications (PTMs). PTMs include protease cleavage, protein folding, and the attachment of molecules such as.</span>.. <strong><a title="SUMOylation News" href="http://www.cytoskeleton.com/blog/sumoylation-targeting-cytoskeletal-proteins-detailed">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Post-translational Modification Research Tools and more.&nbsp;</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 04 Aug 2014 15:07:19 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[New Inhibitors to Control Ras signaling via Sos/K-Ras Binding]]></title>
      <link>https://www.cytoskeleton.com/blog/kras-sos-inhibitor-news-brief/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Kras and Sos News" href="http://www.cytoskeleton.com/blog/kras-sos-inhibitor-news"><img style="margin-left: 30px; margin-right: 30px;" title="kras and sos news" src="https://www.cytoskeleton.com/media/wysiwyg/kras-sos-inhibitor-news.jpg" alt="kras and sos news" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Kras and Sos news" href="http://www.cytoskeleton.com/blog/kras-sos-inhibitor-news" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>K-Ras has been identified as the most important Ras protein in cancer research, accounting for over 21% of human cancers. Despite extensive research on these proteins, no effective Ras inhibitor has been identified, earning K-Ras the reputation of an undruggable protein... Here we discuss several leading concepts in the pursuit of identifying viable drug targets to control atypical Ras signaling.</span>.. <strong><a title="Kras and Sos News" href="http://www.cytoskeleton.com/blog/kras-sos-inhibitor-news">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Small GTPase Activation Assays, Activators, Inhibitors, Proteins and more.&nbsp;</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Tue, 01 Jul 2014 21:32:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[KSP/Eg5 Inhibition in Cancer: Theory and Therapy]]></title>
      <link>https://www.cytoskeleton.com/blog/ksp-eg5-cancer-inhibition/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/ksp-eg5-cancer-inhibition"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/csd-news-2014-q2.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><a href="http://www.cytoskeleton.com/info-resources/ksp-eg5-cancer-inhibition">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>&nbsp;</p>
<p>The Kinesin Spindle Protein (KSP; also known as Eg5 or KIF11) is a Kinesin-5 subfamily member and has been the focus of a significant drug development effort throughout the pharmaceutical industry for the last 15 years. KSP plays a critical role in mitotic spindle pole separation, and its inhibition results in the formation of monoaster spindles which is thought to lead to mitotic catastrophe and apoptosis1. From a therapeutic standpoint...</p>
<p><br /><a href="http://www.cytoskeleton.com/info-resources/ksp-eg5-cancer-inhibition">Read more about KSP/Eg5 Inhibition Here.</a></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 30 Jun 2014 14:30:06 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Rho GTPases and Reactive Oxygen Species: Crosstalk and Feedback]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-gtpases-ros-news/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Myosin Acetylation News" href="http://www.cytoskeleton.com/blog/rho-gtpases-ros-news-detail"><img style="margin-left: 30px; margin-right: 30px;" title="Rho GTPases and ROS" src="https://www.cytoskeleton.com/media/wysiwyg/Newsletter_Thumb.jpg" alt="Rho GTPases and ROS" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Rho &amp; ROS" href="http://www.cytoskeleton.com/blog/rho-gtpases-ros-news-detail" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Redox agents, such as reactive oxygen species (ROS) and reactive nitrogen species (RNS), are key regulators in a variety of signal transduction pathways, including integrin signaling, extracellular matrix adhesion, and inflammation1-3. &nbsp;Rho GTPases are also key regulators of many cellular processes, including cell growth, motility, and adhesion4. While redox agents and Rho GTPases operate through a wide array of... <strong><a title="Myosin Acetylation News" href="http://www.cytoskeleton.com/blog/rho-gtpases-ros-news-detail">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Small GTPase Activation Assays, Activators, and Inhibitors</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Thu, 05 Jun 2014 15:29:04 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Myosin Acetylation Modulates Sarcomere Structure and Function]]></title>
      <link>https://www.cytoskeleton.com/blog/myosin-acetylation-review/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Myosin Acetylation News" href="http://www.cytoskeleton.com/blog/myosin-acetylation-and-sarcomere-details"><img style="margin-left: 30px; margin-right: 30px;" title="Lysine Acetylation Newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/lysine-acetylation-cellular-process-regulation.jpg" alt="Lysine Acetylation Newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Myosin Acetylation News" href="http://www.cytoskeleton.com/blog/myosin-acetylation-and-sarcomere-details" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>The calcium-sensitive sarcomeric complex is the key mechanochemical transducing unit in muscle cells. It contains myosin, actin, tromomyosin, and three different troponins, one of which, troponin C, binds calcium and facilitates myosin binding to F-actin. The functional sarcomere is controlled by... <strong><a title="Myosin Acetylation News" href="http://www.cytoskeleton.com/blog/myosin-acetylation-and-sarcomere-details">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>New Acetyl Lysine Antibody (Validated in WB, IP, ChIP, IF)</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Wed, 30 Apr 2014 16:15:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Lysine Acetylation - Regulator of Diverse Cellular Processes]]></title>
      <link>https://www.cytoskeleton.com/blog/lysine-acetylation-review/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Lysine Acetylation News" href="http://www.cytoskeleton.com/blog/lysine-acetylation-review-details"><img style="margin-left: 30px; margin-right: 30px;" title="Lysine Acetylation Newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/lysine-acetylation-antibody-newsletter-thumb.jpg" alt="Lysine Acetylation Newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Lysine Acetylation News" href="http://www.cytoskeleton.com/blog/lysine-acetylation-review-details" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Lysine acetylation is a post-translational modification (PTM) crucial for regulating the function and localization of many eukaryotic proteins. &nbsp;This PTM is reversible, regulated by histone deacetylases (HDACs) and histone acetyltransferases (HATs). &nbsp;The first evidence of... <strong><a title="Lysine Acetylation News" href="http://www.cytoskeleton.com/blog/lysine-acetylation-review-details">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 24 Mar 2014 16:24:45 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Integrin-mediated redox control of beta-actin: PDI's Emergence]]></title>
      <link>https://www.cytoskeleton.com/blog/integrin-mediated-redox-control-of-beta-actin/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Integrin-mediated redox control of beta-actin" href="http://www.cytoskeleton.com/blog/integrin-mediated-redox-control-of-beta-actin-details"><img style="margin-left: 30px; margin-right: 30px;" title="Integrin-mediated redox control of beta-actin: PDI's Emergence" src="https://www.cytoskeleton.com/media/wysiwyg/14-3-Thumb.jpg" alt="Integrin-mediated redox control of beta-actin: PDI's Emergence" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Integrin-mediated redox control of beta-actin" href="http://www.cytoskeleton.com/blog/integrin-mediated-redox-control-of-beta-actin-details" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>Cell migration is an integral part of several biological processes including angiogenesis, wound healing, and immune surveillance(1). &nbsp;Integrins are &alpha;&beta; heterodimeric transmembrane receptors that link a cell's dynamic interaction with the extracellular matrix (ECM) to the cytoskeletal rearrangements that are necessary to promote cell motility (See figure 1)</span>... <strong><a title="Integrin-mediated redox control of beta-actin" href="http://www.cytoskeleton.com/blog/integrin-mediated-redox-control-of-beta-actin-details">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Fri, 21 Feb 2014 19:55:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Compound Screening, Protein Purification, Assay Development]]></title>
      <link>https://www.cytoskeleton.com/blog/custom-service-q1-news/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/custom-service-q1-news"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Custom_Services_Citations_Newsletter_Q1_2014_Page_1.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/info-resources/custom-service-q1-news">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>As Cytoskeleton&rsquo;s Custom Services Department continues to grow and expand its offerings, we wanted to take the opportunity to highlight some past research projects that benefited from work performed by Cytoskeleton&rsquo;s Custom Services scientists. &nbsp;The three main foci of Cytoskeleton&rsquo;s Custom Services are: 1) Compound Screening, 2) Assay Development, and 3) Gene Cloning and Recombinant/Native Protein Purification. &nbsp;The citations discussed below demonstrate our effectiveness in all three types of custom services...<br /><br /><a href="http://www.cytoskeleton.com/info-resources/custom-service-q1-news">Read more about these services here.</a><br /><br /><br /></p>
<ol> </ol>]]></description>
      <pubDate>Tue, 28 Jan 2014 15:57:46 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Dynein: One Motor, Multiple Neurodegenerative Diseases]]></title>
      <link>https://www.cytoskeleton.com/blog/dynein-neurodegenerative-diseases/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Dynein News" href="http://www.cytoskeleton.com/dynein-neurodegenerative-diseases"><img style="margin-left: 30px; margin-right: 30px;" title="Dynein and Neurodegenerative Diseases Newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/dynein-neurodegenerative-disease.jpg" alt="Dynein and Neurodegenerative Diseases Newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Dynein News" href="http://www.cytoskeleton.com/dynein-neurodegenerative-diseases" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Cytoplasmic dynein 1 (hereafter referred to as dynein) is a 1.6 MDa multi-protein complex that serves as the primary ATP-hydrolyzing motor responsible for retrograde axonal transport along microtubules (MTs) in eukaryotic cells (Fig. 1A). &nbsp; Additionally, dynein is essential for many other cellular processes, including mitochondrial movement, endosomal and lysosomal trafficking, transporting mis-folded proteins bound for degradation, nuclear positioning, and mitosis<sup>1-3</sup> (Fig. 2)... <strong><a title="Neurodegeneartion: Rhes, Sumoylation, and Huntington's Disease" href="http://www.cytoskeleton.com/dynein-neurodegenerative-diseases">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Dynein Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 20 Jan 2014 15:39:20 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Dynein: Hard working, but team oriented]]></title>
      <link>https://www.cytoskeleton.com/blog/dynein-news/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Dynein News" href="http://www.cytoskeleton.com/dynein-news"><img style="margin-left: 30px; margin-right: 30px;" title="Dynein newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/dynein-hard-working-team-player-thumb.jpg" alt="Dynein newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Dynein News" href="http://www.cytoskeleton.com/dynein-news" target="_blank">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>In eukaryote cells, cytoplasmic dynein complex (CDC) and kinesin-14 family members are the only two types of motors known to move cargo to the minus-end of microtubules (MTs)<sup>1</sup>. This function is critical for cell metabolism, structure, and movement. The majority of these processes utilize CDC because of its high fidelity and steady processive movement. CDC&rsquo;s wide range of roles is impressive and the roles are further defined by ancillary proteins which select cargo or an intracellular location... <strong><a title="Neurodegeneartion: Rhes, Sumoylation, and Huntington's Disease" href="http://www.cytoskeleton.com/dynein-news">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Dynein Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools and Services</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Fri, 01 Nov 2013 07:07:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[KIF7 Kinesin Motor Assay]]></title>
      <link>https://www.cytoskeleton.com/blog/kif7-kinesin-motor-assay/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Link to newsletter" href="http://www.cytoskeleton.com/info-resources/kif7-kinesin-motor-assay"><img style="margin-left: 30px; margin-right: 30px;" title="Link to newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/kif7-news-thumb.jpg" alt="Link to newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/info-resources/kif7-kinesin-motor-assay">Click to view&nbsp;this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>KIF7 is a Kinesin-4 family member that has been shown to play an important role in embryonic development and may play a role in the development of basal cell carcinomas. KIF7 functions in Hedgehog (Hh) signaling through the negative and positive regulation of the GLI family of transcription factors (i.e., GLI1, GLI2, and GLI3)<sup>1</sup>. &nbsp;While the mechanism of this regulation is still being elucidated, it appears that in the absence of an Hh ligand, KIF7 negatively regulates GLI transcription factor activity, and in the presence of Hh signaling it positively influences GLI dependent signaling; possibly through KIF7&rsquo;s Hh-dependent translocation from the base of primary cilia to the tip<sup>1</sup>. &nbsp;Mice lacking KIF7 exhibit a ...<br /><br /><a href="http://www.cytoskeleton.com/info-resources/kif7-kinesin-motor-assay">Read more about KIF7 Kinesin Motor Assay Here.</a><br /><br /></p>
<ol> </ol>]]></description>
      <pubDate>Tue, 01 Oct 2013 14:35:02 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Neurodegeneration: Rhes, SUMOylation, and Huntington's Disease]]></title>
      <link>https://www.cytoskeleton.com/blog/neurodegeneartion-rhes-sumoylation-huntingtons-disease/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Neurodegeneration: Rhes, SUMOylation, and Huntington's Disease" href="http://www.cytoskeleton.com/neurodegeneartion-rhes-sumoylation-huntingtons-disease"><img style="margin-left: 30px; margin-right: 30px;" title="Neurodegeneration newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/neurodegeneration-rhes-sumoylation-huntingtons-disease.jpg" alt="Neurodegeneration newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Neurodegeneration: Res, SUMOylation, and Huntington's Disease" href="http://www.cytoskeleton.com/neurodegeneartion-rhes-sumoylation-huntingtons-disease" target="_blank">Click to view/download a<br />PDF version of this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><span>The small G-protein Rhes (Ras Homolog Enriched in Striatum) is a 266 amino acid protein found predominantly in striatum, and to a lesser extent, the cerebral cortex (Falk et al., 1999). &nbsp;Recent research has revealed that this GTPase may be key to understanding the paradoxical finding that while many different types of cells throughout the brain and body express wild-type and mutant huntingtin protein (mHTT), striatal neurons (and to a degree, cortical neurons) have a selective vulnerability in Huntington's disease (HD) (Harrison, 2012; Harrison and LaHoste, 2013)</span>... <strong><a title="Neurodegeneartion: Rhes, Sumoylation, and Huntington's Disease" href="http://www.cytoskeleton.com/neurodegeneartion-rhes-sumoylation-huntingtons-disease">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Neurodegeneration Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Fri, 27 Sep 2013 06:01:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Monoubiquitination and Protein Regulation]]></title>
      <link>https://www.cytoskeleton.com/blog/monoubiquitination-protein-regulation/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a title="Monoubiquitination and Protein Regulation" href="http://www.cytoskeleton.com/monoubiquitination-and-protein-regulation"><img style="margin-left: 30px; margin-right: 30px;" title="monoubiquitination and regulation newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/13.9-Newsletter-Thumb.jpg" alt="monoubiquitination and regulation newsletter" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a title="Monoubiquitination and Protein Regulation" href="http://www.cytoskeleton.com/monoubiquitination-and-protein-regulation" target="_blank">Click to view/download a<br />PDF version of this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Ubiquitination is a post-translational modification (PTM) that involves the covalent attachment of an 8 kDa ubiquitin (Ub) peptide to one or more lysines of a target protein. Modification of a target protein may occur as a single Ub on a single lysine (monoubiquitination), a single Ub on multiple lysines (multiubiquitination) or as ubiquitinated chains in which lysines on the initial protein-conjugated ubiquitin are extended through sequential rounds of ubiquitination (polyubiquitination). The fact that ubiquitin contains seven lysine residues and polyubiquitination has been demonstrated to occur through... <strong><a href="http://www.cytoskeleton.com/monoubiquitination-and-protein-regulation">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Monoubiquitination Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Related Research Tools</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Sun, 01 Sep 2013 20:17:35 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ras and Rho Post-translational Modification by Prenylation]]></title>
      <link>https://www.cytoskeleton.com/blog/ras-rho-prenylation-summary/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/ras-rho-prenylation"><img style="margin-left: 30px; margin-right: 30px;" title="Ras and Rho Prenylation News" src="http://www.cytoskeleton.com/media/wysiwyg//icon/Ras-Rho-Posttranslation-Modification-Prenylation.jpg" alt="Ras and Rho Prenylation News" width="200" height="259" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/ras-rho-prenylation" target="_blank">Click to view/download a<br />PDF version of this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Ras and Rho GTPases are small G-proteins that cycle between an active GTP-bound form and inactive GDP-bound form. &nbsp;Ras proteins, known for their role in cell proliferation, and Rho proteins, known for their involvement in cell morphology, have common post-translational modifications (PTMs) that have been identified as contributors to oncogenesis<sup>1,2</sup>. &nbsp;Understanding Ras and Rho PTMs have been of interest for drug discovery groups for many years. &nbsp;Recent studies of signaling pathways mediated by the Ras and Rho PTMs prenylation and/or palmitoylation have identified potential cancer drug targets<sup>1,2</sup>... <strong><a href="http://www.cytoskeleton.com/ras-rho-prenylation">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Ras and Rho Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Ras and Rho Protein Research Tools</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Thu, 01 Aug 2013 18:53:47 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Invasion by actin-driven membrane protrusions: Cortactin in focus]]></title>
      <link>https://www.cytoskeleton.com/blog/invasion-by-actin-driven-membrane-protrusions-summary/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/pdf-storage/news/invasion-by-actin-driven-membrane-protrusions.pdf" target="_blank"><img style="margin: 0px 30px;" title="Invasion by actin-driven membrane protrusions: Cortactin in focus" src="https://www.cytoskeleton.com/media/wysiwyg/invasion-by-actin-driven-membrane-protrusions.jpg" alt="Invasion by actin-driven membrane protrusions: Cortactin in focus" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/pdf-storage/news/invasion-by-actin-driven-membrane-protrusions.pdf" target="_blank">Click to view/download a<br />PDF version of this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p><strong>Cortactin&rsquo;s multiple signaling domains</strong></p>
<p>The actin binding protein cortactin plays an important role in several cellular functions involving plasma membrane changes that are dependent on a dendritic (i.e., branched) actin network: cell motility employing lamellipodia, clathrin dependent and independent endocytosis, host-pathogen interactions, maintenance of endothelial barrier integrity, and invadopodia-mediated cell invasion<sup>1</sup>. &nbsp;Cortactin is a monomeric ~80 kDa protein that derives its name from its intracellular colocalization with cortical actin at the periphery of the cell<sup>2</sup>. &nbsp;The amino terminus of cortactin harbors a... <strong><a href="http://www.cytoskeleton.com/invasion-by-actin-driven-membrane-protrusions">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Actin Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Actin Protein Research Tools</li>
</ul>
<p>&nbsp;</p>
<ol> </ol>]]></description>
      <pubDate>Mon, 08 Jul 2013 17:27:16 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Actin Modifications and the Cytoskeleton]]></title>
      <link>https://www.cytoskeleton.com/blog/actin-modifications-and-the-cytoskeleton/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/pdf-storage/news/Actin-Modifications-Cytoskeleton.pdf" target="_blank"><img style="margin: 0px 30px;" title="Actin Modifications and the Cytoskeleton" src="https://www.cytoskeleton.com/media/wysiwyg/general/Actin-Modifications-Cytoskeleton-WebThumb.jpg" alt="Actin Modifications and the Cytoskeleton" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/pdf-storage/news/Actin-Modifications-Cytoskeleton.pdf" target="_blank">Click to view/download a<br />PDF version of this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Actin, a highly expressed and ubiquitous cytoskeletal protein, is a major substrate for at least 17 post-translational modifications (PTMs)<sup>1</sup>. &nbsp;PTMs are highly dynamic and often reversible processes where a protein&rsquo;s functional properties are altered by addition of a chemical group or another protein to its amino acid residues. &nbsp;With roles in cell growth, motility, trafficking, and division, it is imperative to ... <strong><a href="http://www.cytoskeleton.com/actin-modifications-and-the-cytoskeleton">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Actin Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Actin Protein Research Tools</li>
</ul>]]></description>
      <pubDate>Mon, 03 Jun 2013 15:09:37 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Life Inside a Microtubule]]></title>
      <link>https://www.cytoskeleton.com/blog/life-inside-a-microtubule-summary/</link>
      <description><![CDATA[<p>&nbsp;</p>
<table border="0" align="right">
<tbody>
<tr>
<td><a href="http://www.cytoskeleton.com/pdf-storage/news/Life-inside-a-microtubule.pdf"><img style="margin: 0px 30px;" title="Life inside a microtubule pdf newsletter" src="https://www.cytoskeleton.com/media/wysiwyg/Life-inside-a-microtubule2.jpg" alt="Life inside a microtubule pdf newsletter" /></a></td>
</tr>
<tr>
<td>
<p style="text-align: center;"><strong><br /><a href="http://www.cytoskeleton.com/pdf-storage/news/Life-inside-a-microtubule.pdf">Click to view/download a<br />PDF version of this newsletter.&nbsp;</a></strong></p>
</td>
</tr>
</tbody>
</table>
<p>Microtubules (MTs) are dynamic cytoskeletal structures with multiple functions in cell growth, division, and morphological change. This review focuses on the MT lumen as a possible functional entity. &nbsp;The internal environment of the MT has its own peculiar biophysical state and is largely thought to be excluded from cytoplasmic influence, except for the 2 nm<sup>2</sup> lateral pores<sup>1</sup> and two 200 nm<sup>2</sup> entrances at its ends<sup>2,3</sup>. Its biophysical state is outside the scope of this article, but it has very interesting vitreous, electromagnetic resonance, and optical properties<sup>4</sup>....&nbsp;<strong><a href="http://www.cytoskeleton.com/life-inside-a-microtubule">Click to read more</a></strong></p>
<p>&nbsp;</p>
<p><strong>Also included in this newsletter:</strong></p>
<p>&nbsp;</p>
<ul>
<li>Microtubule Related Publications</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>Microtubule Protein Research Tools</li>
</ul>]]></description>
      <pubDate>Fri, 03 May 2013 16:02:19 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Tau PTMs as Therapeutic Targets]]></title>
      <link>https://www.cytoskeleton.com/blog/tau-ptm-therapeutic-targets/</link>
      <description><![CDATA[<p>&nbsp;</p>
<p><a title="Tau in Neurodegeneration" href="http://www.cytoskeleton.com/pdf-storage/news/Tau-PTMs-and-Neurodegeneration.pdf" target="_blank"><img style="margin: 15px; float: right;" title="Tau in Neurodegeneration" src="https://www.cytoskeleton.com/media/wysiwyg/newsletter-thumbnail.jpg" alt="Tau in Neurodegeneration" width="198" /></a>This month, the focus is on Tau PTMs as Therapeutic Targets. This newsletter features the following: &nbsp; &nbsp;</p>
<p><a title="Dendritic Spines and Arf6" href="http://www.cytoskeleton.com/pdf-storage/news/Arf6-Newsletter-2013.pdf" target="_blank"> </a></p>
<p>&nbsp;</p>
<ul>
<li><strong>The Many Faces of Tau in Neurodegeneration<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Tau Related Publications</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Tau Protein Research Tools</strong></li>
</ul>
<p>&nbsp;</p>
<p><a title="Dendritic Spines and Arf6" href="http://www.cytoskeleton.com/pdf-storage/news/Arf6-Newsletter-2013.pdf" target="_blank"></a><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><em><strong><a href="http://www.cytoskeleton.com/pdf-storage/news/Tau-PTMs-and-Neurodegeneration.pdf">Click to download our April Newsletter.</a></strong></em></p>
<ul>
</ul>]]></description>
      <pubDate>Mon, 01 Apr 2013 01:01:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Idiopathic Pulmonary Fibrosis Drug Discovery using Fluorescent Fibronectin Proteins]]></title>
      <link>https://www.cytoskeleton.com/blog/pulmonary-fibrosis-fibronectin-news/</link>
      <description><![CDATA[<p>&nbsp;</p>
<p><a title="Fibrosis Fibronectin News" href="http://www.cytoskeleton.com/pdf-storage/news/IPF-Fibrillogenesis-Newsletter.pdf" target="_blank"><img style="margin: 15px; float: right;" title="Fibronectin matrix assembly" src="https://www.cytoskeleton.com/media/wysiwyg/Fibrosis-News-Image.jpg" alt="Fibronectin matrix assembly" width="198" /></a>This month, the focus is on Idiopathic Pulmonary Fibrosis drug discovery. This newsletter features the following: &nbsp; &nbsp;</p>
<p><a title="Dendritic Spines and Arf6" href="http://www.cytoskeleton.com/pdf-storage/news/Arf6-Newsletter-2013.pdf" target="_blank"> </a></p>
<p>&nbsp;</p>
<p>
<ul>
<li><strong>Idiopathic Pulmonary Fibrosis Drug Discovery using Fluorescent Fibronectin Proteins<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>ECM Related Publications</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>ECM Protein Research Tools</strong></li>
</ul>
</p>
<p>&nbsp;</p>
<p><a title="Dendritic Spines and Arf6" href="http://www.cytoskeleton.com/pdf-storage/news/Arf6-Newsletter-2013.pdf" target="_blank"></a><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><em><strong><a href="http://www.cytoskeleton.com/pdf-storage/news/IPF-Fibrillogenesis-Newsletter.pdf">Click to download our March Newsletter.</a></strong></em></p>
<ul>
</ul>]]></description>
      <pubDate>Tue, 05 Mar 2013 15:13:38 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[New Arf1 and Arf6 Activation Assays]]></title>
      <link>https://www.cytoskeleton.com/blog/new-arf1-and-arf6-assays/</link>
      <description><![CDATA[<p>&nbsp;</p>
<h3>Arf1 and Arf6<sup>&nbsp;</sup>Activation Assays and <br />GTPase Affinity Beads&nbsp;</h3>
<p>&nbsp;</p>
<p><img style="float: right; margin: 10px 20px;" title="Arf6 activation measured by G-LISA" src="https://www.cytoskeleton.com/media/wysiwyg/biochem/Arf6v2.jpg" alt="Arf6 activation measured by G-LISA" /></p>
<p>Cytoskeleton&rsquo;s Arf1 and Arf6 activation assays are in two formats: G-LISAs and pull-downs. G-LISAs use a 96 well plate coated with an effector protein that selectively binds active Arf1 or Arf6, followed by quantitation with ELISA techniques. Typical Arf6 G-LISA data are shown (right). Arf pull-downs utilize the Arf1 and Arf6 protein binding domain (PBD) of the effector protein GGA3 (Golgi-localized &gamma;-ear containing, Arf-binding protein 3), which specifically binds the GTP-bound form of Arf1 and Arf6. The GGA3-PBD is covalently conjugated to colored sepharose beads, enabling the &ldquo;pull-down&rdquo;of active Arf1-GTP and Arf6-GTP for quantification by Western blotting.&nbsp;</p>
<p>&nbsp;</p>
<p style="text-align: justify;">&nbsp;</p>
<p style="text-align: justify;"><strong>Right: </strong>Arf6 activation measured by G-LISA. &nbsp;Lysates for Arf6 G-LISA were prepared from MDCK cells that were either attached to tissue culture plates (activated) or kept in suspension for 2 hours (control). &nbsp;12.5, 6.25, and 3.1 &mu;gs of cell lysates were subjected to the G-LISA assay (Cat. # BK133). Absorbance was read at 490 nm. Data are background subtracted.</p>
<p style="text-align: justify;">&nbsp;</p>
<p><strong>New Products</strong></p>
<ul>
<li>Arf1 G-LISA Activation Assay Biochem Kit <strong>(Cat. # <a href="http://www.cytoskeleton.com/BK132">BK132</a>)</strong></li>
<li>Arf1 Activation Assay Biochem Kit (Pull-down format)<strong><strong>&nbsp;<strong>(Cat. # <a href="http://www.cytoskeleton.com/BK032-S">BK032-S</a>)</strong></strong><br /></strong></li>
<li>Arf6 G-LISA Activation Assay Biochem Kit <strong>(Cat. # <a href="http://www.cytoskeleton.com/BK133">BK133</a>)<br /></strong></li>
<li>Arf6 Activation Assay Biochem Kit (Pull-down format)<strong><strong>&nbsp;<strong>(Cat. #&nbsp;<a href="http://www.cytoskeleton.com/BK033-S">BK033-S</a>)</strong></strong></strong></li>
<li>GGA3-PBD Bead<strong>s (Cat. # <a href="http://www.cytoskeleton.com/GGA05">GGA05</a>)</strong></li>
</ul>
<p style="text-align: justify;">&nbsp;</p>
<p><strong>For more information about the Arf small G-protein&nbsp;<a href="http://www.cytoskeleton.com/about/arf">click here</a>.</strong></p>]]></description>
      <pubDate>Thu, 31 Jan 2013 00:23:30 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Dendritic Spines: Role of Arf6 in Development]]></title>
      <link>https://www.cytoskeleton.com/blog/dendritic-spines-arf6/</link>
      <description><![CDATA[<p><a title="Dendritic Spines and Arf6" href="http://www.cytoskeleton.com/pdf-storage/news/Arf6-Newsletter-2013.pdf" target="_blank"><img style="margin: 15px; float: right;" title="Arf6 and Dendritic Spines" src="https://www.cytoskeleton.com/media/wysiwyg/Arf-2013-Newsletter-3.jpg" alt="" width="198" /></a>This month, the focus is on dendritic spine and the Arf6. This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Dendritic Spines: Role of Arf6 in Development<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Arf &nbsp;Related Publications</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Arf Protein Research Tools</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="Newsletter" href="http://www.cytoskeleton.com/pdf-storage/news/Arf6-Newsletter-2013.pdf"><em><strong>Click to download our January/February Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Fri, 04 Jan 2013 16:57:24 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Small molecule modulators of myosin]]></title>
      <link>https://www.cytoskeleton.com/blog/small-molecule-modulators-of-myosin/</link>
      <description><![CDATA[<p><a title="Small molecule modulators of myosin" href="http://www.cytoskeleton.com/pdf-storage/news/Inhibiting-Myosin-Newsletter.pdf" target="_blank"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/Nov-Dec-Newsletter-Thumbnail.jpg" alt="" width="198" /></a>This month, the focus is on small molecule modulators of myosin. This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Small molecule modulators of myosin<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Myosin Publications</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Myosin Research Tools and Services</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="Newsletter" href="http://www.cytoskeleton.com/pdf-storage/news/Inhibiting-Myosin-Newsletter.pdf"><em><strong>Click to download our November/December Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Wed, 21 Nov 2012 17:31:12 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Ubiquitination and the Regulation of Rho Family Pathways]]></title>
      <link>https://www.cytoskeleton.com/blog/rho-pathways-and-ubiquitination/</link>
      <description><![CDATA[<p><a title="Ubiquitination of Rho Family Pathways" href="http://www.cytoskeleton.com/pdf-storage/news/October-Newsletter-2012.pdf" target="_blank"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/Oct-newsletter-thumbnail.jpg" alt="" width="198" /></a>This month, the focus is on Ubiquitination and the Regulation of Rho Family Pathways. This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Ubiquitination and the Regulation of Rho Family Pathways<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Rho Ubiquitination Publications</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Rho Family Research Tools</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="Rac1 and Neurodegeneration news" href="http://www.cytoskeleton.com/pdf-storage/news/October-Newsletter-2012.pdf"><em><strong>Click to download our October Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Mon, 01 Oct 2012 16:24:47 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[The Role of Rac1 GTPase in Neurodegeneration]]></title>
      <link>https://www.cytoskeleton.com/blog/rac1-gtpase-and-neurodegeneration/</link>
      <description><![CDATA[<p><a title="Polymodifications of tubulin" href="http://www.cytoskeleton.com/pdf-storage/news/Sept-Newsletter-2012.pdf" target="_blank"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/Sept-News-Image.jpg" alt="" width="198" /></a>This month, the focus is on Rac1 GTPase and Neurodegeneration. This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>The Role of Rac1 GTPase in Neurodegeneration<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Rac1 GTPase and Neurodegeneration Publications</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Rho Family Research Tools</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="Rac1 and Neurodegeneration news" href="http://www.cytoskeleton.com/pdf-storage/news/Sept-Newsletter-2012.pdf"><em><strong>Click to download our September Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Tue, 04 Sep 2012 17:29:55 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Epithelial-Mesenchymal Transition (EMT) and the Involvement of Rho Family Small G-proteins]]></title>
      <link>https://www.cytoskeleton.com/blog/emt-news/</link>
      <description><![CDATA[<p><a title="Polymodifications of tubulin" href="http://www.cytoskeleton.com/pdf-storage/news/EMT-Newsletter-web.pdf" target="_blank"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/general/EMT-Newsletter-Image.jpg" alt="" width="198" /></a>This month, the focus is on Epithelial-Mesenchymal Transition (EMT) and the Involvement of Rho Family Small G-proteins. This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Epithelial-Mesenchymal Transition (EMT) and the Involvement of Rho Family Small G-proteins<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>EMT Publication Spotlight</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Rho Family Research Tools</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="EMT and Rho news" href="http://www.cytoskeleton.com/pdf-storage/news/EMT-Newsletter-web.pdf"><em><strong>Click to download our August Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Tue, 31 Jul 2012 16:35:41 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Polymodifications of tubulin: Glutamylation and Glycylation]]></title>
      <link>https://www.cytoskeleton.com/blog/polymodificiations-of-tubulin/</link>
      <description><![CDATA[<p><a title="Polymodifications of tubulin" href="http://www.cytoskeleton.com/pdf-storage/news/Polymodification-of-Tubulin-Newsletter.pdf" target="_blank"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/general/Polymodification-of-Tubulin-Newsletter.jpg" alt="" width="198" /></a>This month, the focus is on Polymodifications of tubulin. This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Polymodifications of tubulin: Glutamylation and Glycylation</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Tubulin Publication Spotlight</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Tubulin Research Tools</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="Polymodification of tubulin news" href="http://www.cytoskeleton.com/pdf-storage/news/Polymodification-of-Tubulin-Newsletter.pdf"><em><strong>Click to download our July Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Sun, 01 Jul 2012 01:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[The Extracellular Matrix Role in Cell Adhesion]]></title>
      <link>https://www.cytoskeleton.com/blog/extracellular-matrix-role-in-cell-adhesion/</link>
      <description><![CDATA[<p><a title="ECM News" href="http://www.cytoskeleton.com/pdf-storage/news/Extracellular-Matrix-Newsletter.pdf" target="_blank"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/general/Fibronectin-Newsletter-Image.jpg" alt="" /></a>This month, the focus is on the Extracellular Matrix Role in Cell Adhesion. You'll find useful information about exciting ECM topics and products.&nbsp; This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Fibronectin Regulation of Cell Adhesion<br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Fibronectin/ECM Publication Spotlight</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>ECM Research Tools</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="ECM News" href="http://www.cytoskeleton.com/pdf-storage/news/Extracellular-Matrix-Newsletter.pdf"><em><strong>Click to download our June Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Fri, 01 Jun 2012 01:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[2nd Annual Front Range Cytoskeleton Meeting, May 14th, 2012]]></title>
      <link>https://www.cytoskeleton.com/blog/front-range-cytoskeleton-meeting-2012/</link>
      <description><![CDATA[<p><a title="May News" href="http://www.cytoskeleton.com/pdf-storage/news/Cytoskeleton-Front-Range-Meeting-2012.pdf" target="_blank"><img style="float: right; margin: 15px;" title="Front Range Cytoskeleton Meeting" src="https://www.cytoskeleton.com/media/wysiwyg/general/Cytoskeleton-Front-Range-Meeting-2012.jpg" alt="Front Range Cytoskeleton Meeting" width="198" height="256" /></a></p>
<p><strong>Where: </strong>&nbsp;University of Colorado Anschutz Medical Campus</p>
<p><strong>When:</strong> May 14th, 2012</p>
<p><strong>Speakers: </strong></p>
<ul>
<li>Jennifer DeLuca (CSU)</li>
<li>Brian Doctor (UC SOM)</li>
<li>Jay Gatlin (U. Wyoming)</li>
<li>Andreas Hoenger (UC Boulder</li>
<li>Dinah Loerke (DU)</li>
<li>Michael McMurray (UC SOM)</li>
<li>Paul Megee (UC SOM)</li>
<li>Chad Pearson (UC SOM)</li>
<li>Rytis Prekeris (UC SOM)</li>
<li>Mark Winey (UC Boulder)</li>
</ul>
<p style="text-align: left; padding-left: 30px;">&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><em><strong><a href="http://www.cytoskeleton.com/pdf-storage/news/Cytoskeleton-Front-Range-Meeting-2012.pdf">For more information, click to download the meeting flyer.</a></strong></em></p>
<ul>
</ul>]]></description>
      <pubDate>Thu, 03 May 2012 21:09:39 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Functions of the actin oxidation cycle]]></title>
      <link>https://www.cytoskeleton.com/blog/actin-oxidation-news/</link>
      <description><![CDATA[<p><a title="May News" href="http://www.cytoskeleton.com/pdf-storage/news/Actin-Oxidation-Newsletter.pdf" target="_blank"><img style="float: right; margin: 15px;" title="Actin Oxidation News" src="https://www.cytoskeleton.com/media/wysiwyg/general/Actin-Oxidation-Newsletter-Image.jpg" alt="Actin Oxidation News" width="198" height="256" /></a></p>
<p>This month's newsletter focus is on the<strong>&nbsp;actin oxidation cycle</strong>. In this issue you will find useful information on the following topics: &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Functions of the actin oxidation cycle</strong></li>
</ul>
<div>&nbsp;</div>
<ul>
<li><strong>Actin Publications</strong></li>
</ul>
<div>&nbsp;</div>
<ul>
<li><strong>Actin Research Tools</strong></li>
</ul>
<ul>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><em><strong><a href="http://www.cytoskeleton.com/pdf-storage/news/Actin-Oxidation-Newsletter.pdf">Click to download our May Newsletter.</a></strong></em></p>
<ul>
</ul>]]></description>
      <pubDate>Tue, 01 May 2012 01:01:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Trafficking: Arfs and the Cdc42/Rac connection]]></title>
      <link>https://www.cytoskeleton.com/blog/arf-protein-news/</link>
      <description><![CDATA[<p><a title="April News" href="http://www.cytoskeleton.com/pdf-storage/news/Arf-Protein-Newsletter.pdf" target="_blank"><img style="float: right; margin: 15px;" title="Arf Protein News" src="https://www.cytoskeleton.com/media/wysiwyg/general/Arf-Protein-Newsletter.jpg" alt="Arf Protein News" width="198" height="256" /></a></p>
<p>This month's newsletter focus is on <strong>Arf&nbsp;protein research</strong>. In this issue you will find useful information on the following topics: &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Trafficking: Arfs and the Cdc42/Rac connection</strong></li>
</ul>
<div>&nbsp;</div>
<ul>
<li><strong>Arf Protein Publications</strong></li>
</ul>
<div>&nbsp;</div>
<ul>
<li><strong>Arf Protein Tools</strong></li>
</ul>
<ul>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><em><strong><a href="http://www.cytoskeleton.com/pdf-storage/news/Arf-Protein-Newsletter.pdf">Click to download our April Newsletter.</a></strong></em></p>
<ul>
</ul>]]></description>
      <pubDate>Sun, 01 Apr 2012 01:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Cardiac Research Using G-LISA Technology]]></title>
      <link>https://www.cytoskeleton.com/blog/glisa-cardiac-research-news/</link>
      <description><![CDATA[<p><a title="March News" href="http://www.cytoskeleton.com/pdf-storage/news/GLISA-Cardiac-Newsletter.pdf" target="_blank"><img style="float: right; margin: 15px;" title="G-LISA Cardiac Research News" src="https://www.cytoskeleton.com/media/wysiwyg/general/GLISA-Cardiac-Newsletter.jpg" alt="G-LISA Cardiac Research News" width="198" height="256" /></a></p>
<p>This month's newsletter focus is on&nbsp;<strong>Rho protein research</strong>. In this issue you will find useful information on the following topics: &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Cardiac research using G-LISA technology: &nbsp;Studying the Rho pathway in diabetic cardiomyopathy</strong></li>
</ul>
<div>&nbsp;</div>
<ul>
<li><strong>Rho Protein Publications</strong></li>
</ul>
<div>&nbsp;</div>
<ul>
<li><strong>Rho Protein Tools</strong></li>
</ul>
<ul>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><a title="March News" href="http://www.cytoskeleton.com/pdf-storage/news/GLISA-Cardiac-Newsletter.pdf" target="_blank"><em><strong>Click to download our March Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Mon, 27 Feb 2012 00:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[FtsZ Protein News]]></title>
      <link>https://www.cytoskeleton.com/blog/ftsz-protein-news/</link>
      <description><![CDATA[<p><a title="January/February News" href="http://www.cytoskeleton.com/pdf-storage/news/FtsZ-Protein-News.pdf" target="_blank"><img style="float: right; margin: 15px;" title="FtsZ Protein News" src="https://www.cytoskeleton.com/media/wysiwyg/general/FtsZ-Protein-News.jpg" alt="FtsZ Protein News" width="198" height="256" /></a></p>
<p><span style="color: #000000;">This month's newsletter focus is on&nbsp;<strong>FtsZ Protein</strong>. In this issue you will find useful information on the following topics:</span></p>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>FtsZ: a tubulin homolog and novel antibiotic target<br /></strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>FtsZ Protein Publications</strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>FtsZ Protein Tools</strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><a title="January/February News" href="http://www.cytoskeleton.com/pdf-storage/news/FtsZ-Protein-News.pdf" target="_blank"><em><strong>Click to download our January/February Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Sun, 01 Jan 2012 20:47:20 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Neuroscience News]]></title>
      <link>https://www.cytoskeleton.com/blog/neuroscience-news/</link>
      <description><![CDATA[<p><a title="October News" href="http://www.cytoskeleton.com/pdf-storage/news/Neuroscience-Newsletter.pdf" target="_blank"><img style="float: right; margin: 15px;" src="https://www.cytoskeleton.com/media/wysiwyg/general/Neuroscience-News.jpg" alt="" width="198" height="256" /></a></p>
<p><span style="color: #000000;">This month's newsletter focus is on&nbsp;<strong>neuroscience</strong>. In this issue you will find useful information on the following topics:</span></p>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>Rho GTPase control of neurite extension<br /></strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>Neuroscience publications</strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>Neuroscience tools</strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><a title="October News" href="http://www.cytoskeleton.com/pdf-storage/news/Neuroscience-Newsletter.pdf" target="_blank"><em><strong>Click to download our November/December Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Wed, 07 Dec 2011 05:23:22 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[HDAC, Tubulin and Cortactin News]]></title>
      <link>https://www.cytoskeleton.com/blog/tubulin-news/</link>
      <description><![CDATA[<p><a title="October News" href="http://www.cytoskeleton.com/pdf-storage/news/Tubulin-Newsletter.pdf" target="_blank"><img style="float: right; margin: 15px;" src="https://www.cytoskeleton.com/media/wysiwyg/general/Tubulin-News-Letter-img.jpg" alt="" width="198" height="256" /></a></p>
<p>This month's newsletter focus is on&nbsp;<strong><span>Tubulin</span></strong>. In this issue you will find useful information on the following topics: &nbsp;</p>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>HDAC6: An update on its interaction with tubulin, HSP90      and Cortactin</strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>Tubulin publications</strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<ul>
</ul>
<ul>
<li><strong>Tubulin tools</strong></li>
</ul>
<ul>
</ul>
<p>&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><a title="October News" href="http://www.cytoskeleton.com/pdf-storage/news/Tubulin-Newsletter.pdf" target="_blank"><em><strong>Click to download our October Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Sat, 01 Oct 2011 20:45:34 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[New Small G-protein Tools]]></title>
      <link>https://www.cytoskeleton.com/blog/new-small-g-protein-tools/</link>
      <description><![CDATA[<p><a title="September News" href="http://www.cytoskeleton.com/pdf-storage/news/sept-news.pdf" target="_blank"><img style="float: right; margin: 15px;" src="https://www.cytoskeleton.com/media/wysiwyg/G-switch-news.jpg" alt="" width="198" height="256" /></a></p>
<p>We are pleased to introduce two new activators&nbsp; to our G-switch&trade; product line.&nbsp; Based on the bacterial CNF toxins, these activators selectively target either Rho (Cat. # CN03) or Rho/Rac/Cdc42 combined (Cat.# CN04). Features of these new reagents include: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Potent      activation (5 to 10 fold) of Rho family members.</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Direct      activation within 2 to 4 hours.</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Effective      in multiple cell types derived from different species.</strong></li>
</ul>
<p>&nbsp;</p>
<p style="text-align: left; padding-left: 30px;"><a title="September News" href="http://www.cytoskeleton.com/pdf-storage/news/sept-news.pdf" target="_blank"><em><strong>Click to download our September Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Thu, 01 Sep 2011 00:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Small G-protein Activation Assay News]]></title>
      <link>https://www.cytoskeleton.com/blog/small-g-protein-activation-assay-news/</link>
      <description><![CDATA[<p><a title="August News" href="http://www.cytoskeleton.com/pdf-storage/news/aug-news.pdf"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/GLISA-News-Letter-Image.jpg" alt="" /></a>This month newsletters focus is on Small G-protein Activation Assays. In this issue you will find useful information on the following topics:</p>
<p>&nbsp;</p>
<ul>
<li>
<p><strong>Measuring Active      Small G-Proteins&nbsp; <br /></strong></p>
</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>
<p><strong>Publication Spotlight</strong></p>
</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>
<p><strong> RhoA G-LISA      Activation Assay</strong></p>
</li>
</ul>
<p>&nbsp;</p>
<ul>
<li>
<p><strong>Wide variety of      G-LISA Products</strong></p>
</li>
</ul>
<p><a title="August News" href="http://www.cytoskeleton.com/pdf-storage/news/aug-news.pdf" target="_blank"><br /></a></p>
<p style="padding-left: 30px;"><a title="August News" href="http://www.cytoskeleton.com/pdf-storage/news/aug-news.pdf" target="_blank"><em><strong>Click to download our August Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Mon, 01 Aug 2011 12:00:00 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Actin News – a major player in cell bio]]></title>
      <link>https://www.cytoskeleton.com/blog/actin-news-a-major-player-in-cell-bio/</link>
      <description><![CDATA[<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf" target="_blank"><img style="margin: 15px; float: right;" src="https://www.cytoskeleton.com/media/wysiwyg/Actin-News-Letter-Image.jpg" alt="" /></a>This month, the focus is on Actin. You'll find useful information about exciting Actin topics and products.&nbsp; This months newsletter features the following: &nbsp; &nbsp;</p>
<p>&nbsp;</p>
<ul>
<li><strong>Remodeling      of the Actin Cytoskeleton&nbsp; <br /></strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Actin      Publication Spotlight</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Actin      Polymerization Kit</strong></li>
</ul>
<p>&nbsp;</p>
<ul>
<li><strong>Wide      variety of Actin Products</strong></li>
</ul>
<p><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><br /></a></p>
<p style="padding-left: 30px;"><a title="July News" href="http://www.cytoskeleton.com/pdf-storage/news/jul-news.pdf"><em><strong>Click to download our July Newsletter.</strong></em></a></p>
<ul>
</ul>]]></description>
      <pubDate>Fri, 01 Jul 2011 12:00:00 +0000</pubDate>
    </item>
  </channel>
</rss>
